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Abstract 
A multitude of plants have been used extensively for the treatment of cancers 
throughout the world.  In many parts of the world, especially in poor countries, this may 
be the only form of cancer therapy. Much research has been focused on the scientific 
evaluation of traditional anti-cancer drugs from the tropical plant; Momordica charantia 
(MC) is one of them and it has been used frequently as an anti-cancer agent. The green 
leaves, fruits, seeds and stems of M. charantia composed of many different proteins and 
steroids that are chemically active. These proteins are α and β momorcharins which 
possess anti-cancer and anti-HIV properties similar to crude water and methanol soluble 
extracts of M. charantia. This study investigated the anti cancer effect of either the 
crude water and methanol soluble extract of M. charantia, α and β and  α, β  
momorcharins based on dose-dependent, time-dependent on the viability of 1321N1, 
Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1 and L6 cell lines employing different 
concentrations of each extract or drug. In addition, the study measured the effect of 
either temozolomide or vinblastine alone or combining each with either the crude water 
soluble extract of M. charantia or α  β momorcharin measuring cell viability in the 
different cell lines. Furthermore, the  present study investigated the cellular 
mechanism(s) via which the different anti-cancer agents were able to induce cell death 
measuring the activities of caspase - 3 and caspase - 9, the release of cytochrome c and 
intracellular free calcium concentrations [Ca 
2+ 
]i. 
The results have shown that the crude water soluble extract of M. charantia can evoke 
both     time-course at (800 µg) and dose-dependent (200 µg - 800 µg) decreases in cell 
viability with maximal increases with 800 µg over a period of 24 hrs following 
incubation. Either the crude methanol soluble of M. charantia (200 µg - 800 µg), alpha 
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or beta momorcharin  (200 µM - 800 µM) had little or no effect on the viability of the 
different cell lines. In contrast, either alpha, beta momorcharin (200 µM - 800 µM), 
temozolomide (80 µM - 320 µM) or vinblastine (10 μg - 40 μg) can evoke significant (p 
< 0.05) decrease in cell viability, similar to the crude water soluble extract of M. 
charantia. The results also show that combining either temozolomide (240 µM) or 
vinblastine (40 μg) with either (800 µg) of the crude water- soluble extract of M. 
charantia or (800 µM) of alpha, beta momorcharin can result in significant decreases in 
cell viability for each cell line but these effects were neither additive or synergetic 
compared to the individual effect of temozolomide or vinblastine. The result of this 
study have also shown that either the crude water-soluble extract of M. charantia (800 
µg) or (800 µM) of alpha, beta momorcharin can elicit marked and significant (p < 
0.050 increases in the activities of caspase - 3 and caspase - 9 in all the cell lines. 
Similarly, both the crude water soluble extract of M. charantia and alpha, beta 
momorcharin can stimulate the release of cytochrome-c and elevated [Ca
2+ 
]i   in the 
different cancer cell lines compared to untreated cell lines. Together, the results of the 
study have shown that either the crude water soluble extract of M. charantia or alpha, 
beta momorcharin can exert their anti-cancer effects (cell death) on cancer cell lines by 
increasing the activities of caspase - 3 and caspase - 9 and by releasing cytochrome-c 
and elevating [Ca
2+ 
]i   in the cancer cells. These findings implicate the role of apoptosis 
and cellular Ca 
2+ 
homeostasis in cancer cell death. Moreover, they confirm the 
beneficial use of extracts of M. charantia to treat cancers. 
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Phosphate  
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PARP (Poly (ADP-ribose) polymerase)  
PBS  Phosphate Buffer Solution 
PDT  Photodynamic therapy  
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PMA  Pilomyxoid Astrocytoma 
 
PNA  p-nitroanilide  
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1. Introduction 
A multitude of plants have been identified and used for the treatment of different 
diseases throughout the world, especially in poor countries. Much research has been 
focused on the scientific evaluation of traditional drugs from the tropical plant; 
Momordica charantia (MC) has been commonly or frequently used as an anti-cancer 
agent and anti-diabetic agent and it is often described as food of medicine (Heinrich and 
Bremner, 2006). MC is commonly known as either bitter melon or bitter gourd. Bitter 
gourd grows in all tropical parts of the world and it is cultivated throughout South 
America, Asia and Africa. The plant is a slender climbing annual vine with long-stalked 
leaves and yellow, solitary male and female flowers borne in the leaf axils (Bailey et al. 
1985). It is related to squash and cucumber plants. The fruit looks like a warty gourd. 
The young fruit is emerald green, turning to orange-yellow when ripe (see figure 1.1). 
The Latin name momordica means “to-bite” referring to the jagged edges of the leaves, 
which appear as if they have been bitten. All parts of the plant, including the fruit, the 
stem and seed taste very bitter. 
In botanical terms, the plant is referred as 
a. Family: Cucurbitaceae 
b. Genus:  Momordica 
c. Species: charantia 
d. Synonyms: Momordica chinenus, Momordica elegans, Momordica indica, 
Momordica operculata, Momordica sinenuns and Silyos fauriei. 
e. Common Names: Bitter Melon, papailla, melaode sao caetano, bittergourd, 
balsam apple, balsam pear, karela, ku kua karela, kor-kuly, ku gua, para-aki, 
salsamino, Soru, Sorossis borossieb, pare, peria La at, peria. 
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Figure 1.1: Fruits of Momordica charantia 
(Adapted from Herbal secrets of the Rainforest, 2
nd
 edition 2007) 
     1.1 Tribal and herbal Medicine uses 
In the Amazon, local people grow bitter melon in their gardens for food and 
medicines (Singh et al. 2004). They add the fruit for bitter or sour flavor by 
parboiling it first with a dash of salt to remove some of the bitter taste (Basch et al. 
2003; Abhishek et al, 2004: Akhtar, 1982). It is used as leaf tea for the treatment of 
diabetes, to expel intestinal gas, to promote menstruation and as an antiviral 
treatment for measles, hepatitis and feverish conditions (Akhtar et al, 1991:Heinrich 
and Bremner. 2006). It is also used typically for sores, wounds, infections and also 
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internally and externally to treat for worms and parasites. MC is also used for the 
treatment of cancer tumours (Ahmed et al, 2004; Lee.1998). In the last few decades, 
several hundreds of studies that have been carried with MC using modern tools and 
they have credited MC with anti-diabetic, anti-viral, anti-tumour, anti-leukemic, anti-
bacterial, anthelmintics, antimutagenic, antimycobacterial, antioxidant, antiulcer, 
anti-inflammatory and hypochlolestrolemic, hypoglyceridemic, hypotensive, 
immunostimulant and insecticidal properties (Ahmed et al, 1999: Alessandra et al, 
2008: Ng et al. 1987; Raman and Lau. 1996; Basch et al. 2003). MC seems to have 
universal medicinal properties for the treatment of different diseases. Some of the 
phytochemical constituents are shown in the Table 1.1.  
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     Source 
                                            
Phytochemicals present 
 
    References 
 
 
 
 
 
 Plant   body 
Momorcharins, momordenol, momordicilin,  
momordicins,momordicinin,momordin, 
momordolol, charantin, charine,  
cryptoxanthin, cucurbitins, cucurbitacins, 
 cucurbitanes,cycloartenols,diosgenin, elaeostearic 
acids, erythrodiol, galacturonic 
acids,gentisicacid,goyaglycosides, goyasaponins 
and multiflorenol, 
 
 
 
 
Husain et al.1994; 
Xie et al. 1998;             
Yuan et al. 1999; 
Parkash et al. 2002; 
Murakami et al. 
2001. 
 
 Plant leaves 
Glycosides, saponins, alkaloids, fixed oils,  
triterpenes, proteins and steroids 
Raman  and Lau, 
1996 
 
 
   Fruit 
Momorcharins, momordicine, charantin, 
polypeptide- p insulin, ascorbigee, amino acids, 
aspartic acid serine, glutamic acid, threonine, 
glutamic acid, threonine,  alanine and  g-amino 
butyric acid. Other constituents include  pipecolic  
acid,  luteolin and  a number of fatty acids  such as 
lauric, myristic, palmitic, palmitoleic, stearic,oleic, 
linoleic, linolenic acid 
 
Lolitkar and Rao,  
1966; Yuwai et al. 
1991 
http://www.tropil 
ab.com 
 
     Seeds 
Urease, amino acids–valine, threonine methionine, 
isoleucine, leucine, phenylalanine.  
Orlovskaya et al. 
2007 
Table 1.1: Some phytochemicals and constituents of the different parts of 
Momordica   charantia. 
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1.2 Plant chemicals with their anti-cancer effect 
Since ancient times, plant and herbal preparations have been used as traditional 
medicines to treat a number of diseases. M. charantia has been a very popular source of 
traditional medicines for several aliments (Grover et al. 2001). A number of preliminary 
studies both in vitro as well as in vivo with crude extract of M. charantia have shown 
anti-cancer activity against lymphoid leukaemia, lymphoma, choriocarcinoma, 
melanoma, breast cancer, skin tumour and prostatic cancer (Licastro et al. 1980; Ng et 
al. 1994; Ganguly et al. 2000; Sun et al. 2001). An aqueous extract of M. charantia  was 
shown to inhibit the growth of prostatic adencarcinoma (Claflin et al. 1978). The 
chronic treatment with hot water extract of M. charantia inhibited uterine adenomyosis 
and mammary tumour growth in mice (Nagasawa et al. 2002; Singh et al. 1998) 
demonstrated maximal anti-carcinogenic activity in the peel of M. charantia. 
Several studies have reported that the water-soluble extract of M. charantia can exert 
anti-cancerous activity through inhibition of DNA, RNA and cellular protein synthesis      
(Licastro et al. 1980; Zhu et al. 1990; Tsao et al. 1990; Chang et al. 2008; Terenzi et al. 
1999). The fruit juice of M. charantia has been found to increase glucose up take by 
several tissues in vitro and moreover, it can increase the storage of glycogen by the liver 
(Welihinda et al. 1986). The water-soluble extract of the M. charantia can significantly 
reduce blood glucose concentrations in type-1 diabetic rats (Ahmed et al. 1999). The in 
vivo anti-cancer activity of a crude water-soluble extract M. charantia was shown to 
inhibit tumour formation in CAB/H mice which had been given i.p injections of 1.0×10 
5
 
CBA/ DI tumours cells. The extract also inhibited tumour formation in DBA/2 mice 
which following i.p injections (Catherine et al. 1983). The water-soluble crude extract is 
cytotoxic to the CBA/DI cells in culture and the toxicity is dose-dependent and requires 
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24 hrs before it becomes apparent (Catherine et al. 1983). However, the cells exposed to 
the water-soluble extract for 30 min and washed and incubated for 24 hrs also shows a 
decrease in cell viability (Ali et al, 1993: Takemoto et al. 1982). There are also 
increasing evidences that the increased consumption of M. charantia intake can reduce 
the risk of various pathological events including cancer, high blood pressure and 
diabetes (Goodwin and Brodwick, 1995; Steinmetz and Potter, 1996). 
A number of preliminary in vitro and in vivo studies with the water-soluble extract of 
M. charantia and its various purified fractions have shown anti-cancer activity against 
human bladder carcinomas and breast cancers (Amila et al, 2000; Zhu, 1990). Recent, 
subcritical water extract has become an alternative for extraction of herbal plants 
(Ayala et al. 2001). The subcritical water extract of M. charantia potentially shows 
anti-tumour, anti carcinogenic and anti-inflammatory effects (Lee et al. 2003; Horax et 
al. 2005). The dried fruit of M. charantia can be pulverized into a fine powder in a 
grinder and stored at 4°C. This powder and the extracts of the powder can be employed 
for chemotherapeutic studies (Zhu, 1990; Pitipanponga et al. 2007). Previous studies 
employed three methods of extraction, namely sub critical water extraction, solvent 
extraction and Soxhlet apparatus extraction method in order to obtain maximal activity 
from the powder (Takemoto et al. 1982; Parichat and Artiwan, 2008).  
MC contains a number of biologically active plant-based chemicals including 
triterpenes, proteins and steroids (Zhu, 1990), alkoloids, inorganic lipids and phenolic 
compounds (Grover et al. 2004). Some proteins in bitter melon including MAP-30, 
MRK29, alpha-momocharin, beta-momocharin and momordicin (see figure 1.2) and 
they have the ability to treat tumours and HIV (Yuan et al. 1999; Luetrakul. 1998). A 
steroid called charantin is found mainly in the aerial parts of MC and it has been shown 
to possess anti-diabetic properties (cakici et al. 1994).  
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Figure 1.2: Chemical structures of (A) Alpha-momorcharin, (B) Beta-momorcharin,                  
(C) Charantin and (D) Momordicin. (Adapted from Herbal secrets of the Rainforest, 
2
nd
 edition, 2007) 
The phenolic compounds extracted from MC using a solvent extraction procedure 
were reported to exhibit anti-oxidant activity (Au et al, 2000; Horax et al. 2005). 
The ripe fruit of MC has been shown to exhibit some remarkable anti-cancer effects, 
especially leukemia (Asli and Alaattin, 2007; Satish-kumar et al. 2010). 
There is much evidence that MC can be used effectively to treat cancer. MC and its 
extracts have been shown to inhibit cancer and tumour formation (Cunnick et al. 
1990). A phytochemical in MC has been clinically demonstrated to inhibit an 
enzyme named guanylate cyclase. This enzyme is thought to be linked to the 
pathogenesis and replication of psoriasis, leukemia and cancer (Herbal secrets of the 
Rainforest, 2
nd
 edition, 2007) and clinical trials have found much evidence that MC 
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can improve immune cell function in people with cancer (Cunnick et al. 1990; Yuan 
et al. 1999). Several in vivo studies have demonstrated cytostatic and anti-tumour 
activity of the entire plant of bitter melon (Ayala and Castro 2001; Cunnick et al. 
1990; Zheng et al. 1999). A previous study has reported that a water-soluble extract 
of MC can inhibit the growth of rat prostate carcinoma and moreover, a hot water 
extract of the entire plant of MC can inhibit the development of mammary tumours 
in mice (Bailey and Day 1989; Cunnick et al. 1990). Similarly, numerous in vitro 
studies have demonstrated the anti-cancerous and anti-leukemic activities of MC 
against several commercial cell lines including human leukemia, liver cancer, 
melanoma and solid sarcomas (Zheng et al. 1999). A chemical analogue of a protein 
isolated from MC was developed and named MAP-30. It was reported that MAP-30 
could inhibit prostate tumour growth. Several phytochemicals extracted from MC 
have been documented with cytotoxic activities and they include a group of 
ribosome-inactivating proteins named (α.β momocharins, momordin and 
cucurbitacin B) (Pongnikorn et al. 2003; Satish-kumar et al. 2010). Tables 1.2 and 
1.3 summarie the anti-cancer activities for the different chemical extracts of MC 
isolated from different parts of the plant and tested on different animal species with 
positive results. 
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Table 1.2: Biological and anti-cancer activities of some extracts of Momordica charantia (Adapted from Herbal secrets of the Rainforest, 2
nd
 edition, 2007) 
 
   Part- origin 
 
Activity 
Tested For 
 
Types 
Extract 
Test Model 
and route of 
administration 
 
Dosages 
 
Notes/Organism tested 
 
Results 
 
References 
 
 
Fruit (India) 
 
 
Antitumuor 
Activity 
 
 
Aqueous Ext 
 
 
Mice 
(Oral) 
 
 
Not stated 
Protected against the development 
of skin tumour or and increased life 
expectancy. 
 
 
 
Active 
 
 
      Ganguly et al. 2000 
 
 
 
 
 
Fruit (India)             
 
 
 
Antitumuor  
Activity 
 
 
 
Aqueous Ext 
 
 
 
Mice 
(Oral) 
 
 
 
Not stated 
Reduced carcinogen-induced lipid 
peroxidation in the liver and DNA 
damage in lymphocytes 
 
 
 
 
Active 
 
 
       Ganguly et al. 2000 
 
 
 
 
Fruit (India) 
 
 
Antitumuor  
Activity 
 
 
 
Aqueous Ext 
 
 
 
Mice 
(Oral) 
 
 
 
Not stated 
Activated liver enzymes glutathione-S-
transferase,   glutathione peroxidase and 
catalase which were depressed 
after carcinogen exposure 
 
 
 
Active 
 
 
       Ganguly et al. 2000 
 
 
 
Fruit( USA) 
 
 
Antitumuor 
Activity 
 
 
H2O Ext 
 
 
Mouse 
(IP) 
 
 
100.0 µg/ml 
 
 
Cells-CBA/D1. 
 
 
 
Active 
 
   
        Jilka et al.1983 
 
 
 
Fruit (USA) 
 
 
Antitumuor   
Activity 
 
 
H2O Ext 
 
 
 Mouse 
(IP) 
 
 
Not stated 
 
 
LEUK-L1210. Drug was preincubated 
with tumour cell line in vitro. 
 
 
 
Active 
 
 
        Jilka et al.1983 
 
 
Fruit (USA) 
 
 
Antitumuor  
Activity 
 
 
H2O Ext 
 
 
Mouse 
(IP) 
 
 
Not stated 
 
LEUK-P388. Drug was pre incubated 
With  tumour cell line in vitro. 
 
 
 
Active 
 
 
        Jilka et al.1983 
 
Fruit (China) 
 
 
 
Cytotoxic 
Activity 
 
Not stated 
 
Cell Culture 
 
Not stated 
 
Ca-755. 
 
Active 
 
        Yeung et al.1984 
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Table 1.3: Biological and anti-cancer activities of some extracts of (Momordica charantia) (Adapted from Herbal secrets of the Rainforest, 2
nd
 edition, 2007) 
 
Part –Origin 
 
 
Activity Tested 
For 
 
Types Extract 
 
Test Model and 
route of 
administration 
 
Dosages 
 
Notes/Organism tested 
 
Results 
       
                References 
 
Fruit (India) 
 
Carcinogenesis 
Inhibition 
 
H2O Ext 
 
External 
Mouse 
 
100.0 mcg 
 
vs. DMBA-initiated, croton oil 
promoted skin tumours. 
 
Active 
 
 
 
 
       Singh et al.1998 
 
Fruit Pulp 
(India) 
 
Carcinogenesis 
Inhibition 
 
H2O Ext 
 
External 
Mouse 
 
100.0 mcg 
 
vs. DMBA-initiated, croton oil  
promoted skin tumours. 
 
Active 
 
 
 
 
 
       Singh et al.1998 
 
Fruit Peel (India) 
 
Carcinogenesis 
Inhibition 
 
H2O Ext 
 
External 
Mouse 
 
 
100.0 µg 
 
vs. DMBA-initiated, croton oil 
promoted skin tumours. 
 
Active 
 
 
 
 
 
 
       Singh et al. 1998 
 
 
Seed (India) 
 
Carcinogenesis 
Inhibition 
 
H2O Ext 
 
External 
Mouse 
 
100.0 mcg 
 
vs. DMBA-initiated, croton oil 
promoted skin tumours. 
 
Active 
 
 
 
 
       Singh et al.  1998 
 
Fruit (Japan) 
 
Tumor Promotion 
Inhibition 
 
MEOH Ext 
 
Cell Culture 
 
200.0 mcg 
 
Virus-Epstein-barrvs. 12-o-
hexadecanoylphorbol-13-acetate-
induced epstein-barr virus  activation. 
 
 
Inactive 
 
 
 
 
       Koshimizu et al.1988 
 
Fruit (India) 
 
Cell Proliferation 
Inhibition 
 
Protein 
Fraction 
 
Cell Culture 
 
Not stated 
 
Hep2 cells. Sea urchin ova. 
 
 
Active 
 
 
 
 
      Raman and Lau,1996 
 
Fruit (USA-CA) 
 
Cytotoxic Activity 
 
H2O  Ext 
 
Cell Culture 
 
CD10= 50.0 
mcg/ml 
 
Cells-CBA/D1 
 
Active 
 
 
 
      Jilka et al.1983 
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       1.4 Anti-cancer activity 
Cancer is a term, which is used to refer to a number of conditions where the cells 
begin to grow and reproduce in an uncontrollable way. Sometimes a cancer begins 
in one part of the body and then spreads to other parts of the body. This process is 
known as metastasis (Kleihues et al. 2002; Lewandowicz et al. 2000). Cancer is a 
common condition and moreover, it is deemed as a serious health problem, both in 
the UK and across the world. It is estimated that 7.6 million people in the world 
died of cancer in 2009. In the UK cancer is responsible for 126,000 deaths per year 
(Cancer Research UK, 2007). 
Cancer occurs when the genes in a cell become abnormal and the cell divides and 
grows uncontrollably (see figure 1.3). Cell division is normal, but when this process 
is uncontrolled a mass of tissue called a growth or tumour is formed (Cancer 
Research UK, 2007). 
Malignant tumours are cancerous and also can spread widely to other parts of the 
body by entering either the blood stream or lymphatic system as well as harming 
nearby tissues and the organs. This rapid growth of cancerous cells is known as  
malignant tumour. These cells can then invade and destroy healthy tissues, 
including organs. In addition, it can harm a number of vital organs at the same time 
(Merol et al. 2006) 
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Figure 1.3: A schematic diagram showing the development of a cancer                                                              
(Adapted form bio.miami.edu, January 2006) 
Types of cancers:  
There are different types of cancers in the body. They include anal, bladder, breast, 
cervical, colon, endometrial, oesophageal, kidney, leukaemia, liver, lung, 
lymphoma, ovarian, pancreatic, penile, prostate, skin, stomach cancer and several 
others. Almost any part of the body can be infected with cancers (Roberts and 
Rudee. 1988). All the cells in the body have similar structures and share a majority 
of their functions. Cancers may be categorized based on the functions and locations 
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of the cells from which they originate (see figure 1.3). The following terms are 
commonly used to distinguish tumours of different origin. 
 Carcinoma- is a tumour, which is derived from epithelial cells that line the 
surface of our skin and organs. The digestive tract and airways are also lined 
with epithelial cells. This is the most common cancer type and represents 
about 80-90% of all cancer cases reported (Wen and Keasri. 2008).  
 Sarcoma- is a tumour, which is derived from muscle, bone, cartilage, fat 
and connective tissues.  
 Leukemia- is a cancer, which is derived from white blood cells or their 
precursors. The cells that form both white and red blood cells are located in 
the bone marrow.  
 Lymphoma- is a cancer of bone marrow and it is derived from cells that 
affect the lymphatic system.  
 Myeloma- is a cancer involving the white blood cells and it is responsible 
for the production of antibodies (B lymphocytes or B-cells).  
       1.6 Causes of cancer 
There are many causes of cancers and they include mutation of the genes that 
control cell growth, chemicals, radiations, preservatives etc (Merlo et al. 2006). 
Gene mutation is found in every cell in the body and it regulates all of its activities. 
Cancers are caused by damage to the DNA. The body is usually able to repair 
damaged DNA, but it is unable to do so in cancer cells (Goodarz et al. 2005). In 
most cases, people damage their DNA via their lifestyle habits, which include 
unbalanced diet, smoking, stress, exposure to ultraviolet radiation (UV) from the 
sun and to substances known as carcinogens in the environment. Some carcinogens 
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include benzene, asbestos, formaldehyde, which are specific for skin cancers and in 
most cases these can be prevented with care and by following health and safety 
regulations. Smoking causes the majority of lung cancers, but scientists have long 
known that tobacco contributes to a number of other forms of the disease (Roberts 
et al. 1988).  Each type of cancer is caused by different factors, which are well 
established, while others are uncertain and unknown (Goodarz et al. 2005). 
       1.7 Introduction to CNS and CNS tumours 
                                                 
            
Figure 1.4:  Diagram showing the lobes and functions of the brain 
(Adaptedfrom-http://www.cancerbackup.org.uk/Cancertype/Brain/General/Thebrain#2006) 
31 
 
The brain is the most important part of the central nervous system (CNS). It is 
divided into several lobes, the cerebellum and the brain stem (see figure 1.4). The 
different parts of the brain are associated with different functions of the body. For 
example, each lobe or area of brain has one or more specific functions such as 
vision, smell, taste, hearing and balance (see figure 1.4). Brain tumours are 
composed of cells that exhibit uninhibited growth in brain. There are nearly 100 
types of brain tumours. They are generally named after the type of cells they 
develop from.  The tumour cell arising in glial cells (supportive nerve cells in brain) 
is called glioma. Glioma can develop in any part of the brain or its nerves and 
covering tissues. They can be benign (non-cancerous, meaning that they do not 
spread elsewhere or invade surrounding tissue) or malignant (cancerous). The two 
major types of brain tumours are primary and secondary. Primary brain tumours 
start in the brain. Secondary brain tumours start in another part of the body, and 
then spread to the brain. A glioma is a primary brain tumour, accounting for 45% of 
cancers that begin in brain cells (Goodarz et al. 2005). 
Central nervous system (CNS) tumours are very common and they can cause death 
of the patients. CNS tumours are lumps of abnormal growth of cells and can be 
benign and malignant. 
CNS tumours are of two types: - 
1. Begnin tumours 
They are also called primary tumour which can grow in the brain or the spinal cord 
itself and they do not spread to other organs or tissues of the body. They are not 
usually life-threatening cancers and moreover, they grow very slowly. 
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2. Malignant tumours 
These are also called secondary tumours of the body, which usually spread to other 
parts of the body including organs and tissues. They generally tend to grow very 
fast and invade nearby tissues. 
Eventually, more than half of the CNS tumours are benign. They can cause 
substantial morbidity, but according to some literature, malignant primary brain 
tumours are life threatening and they are the leading cause of death in children and 
the third leading cause of death in adolescents and adults aged 15 to 34 yrs 
(Kimmel et al. 1987). Some common symptoms of CNS tumours in the patients 
include headache, seizures and altered mental status. The imaging technique such 
as Magnetic Resonance Imaging (MRI) scan can help to define the anatomical 
extent of the tumours. Biopsy is normally performed on most occasions for the 
conformation of diagnosis in order to treat CNS tumours. Benign tumours are 
usually curable with either surgical resection or radiation. Radiation therapy 
includes stereotactic radiation. However, the majority of patients having malignant 
brain tumours benefit from chemotherapy either at the initial diagnosis or at 
tumours recurrence. Metastases to the brain remain a frequent and morbid 
complication of solid tumours but are frequently controlled with either surgery or 
radiation therapy. Unfortunately, the mortality rate from malignant brain tumours 
remains high, despite initial disease control. Therefore, there is an urgent need in 
finding remedies from the natural sources without any side effects. In order to find 
the remedies of tumour treatment, it is necessary to identify the grade of tumour. 
Therefore, the World Health Organization (WHO) grading system was established 
in order to detect and cure the tumour at different stages by various treatment 
identified (Kimmel et al. 1987; Nelson and Cha, 2003).  
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1.7.1 The new WHO Classification of tumours affecting the central nervous                    
system 
In 1993, the WHO ratified a new wide-ranging classification of neoplasms affecting 
the CNS (WHO grade, 2007). The classification of brain tumours is based on the 
abnormal growth of a specific cell type. The tumour classification dictates the 
choice of therapy and predicts prognosis. The new WHO system is particularly 
useful in this regard with only a few notable exceptions for example, either all or 
almost all gemistocytic astrocytomas are actually anaplastic and hence named grade 
III or even IV rather than grade II has been designated by the WHO system. The 
WHO classification also provides a corresponding grading system for each type of 
tumour. In this grading system, most named tumours are of a single defined grade. 
The new WHO classification provides the standard for communication between 
different Centres in the United States and around the world. An outline of this 
classification is provided below. 
        1.7.2 Neuro-epithelial Tumours of the CNS 
Astrocytic tumours [glial tumours--categories I-V, below] may also be sub-
classified as invasive or non-invasive, although this is not formally part of the 
WHO system. The non-invasive tumour types are indicated below. Categories in 
italics are also not recognized by the new WHO classification system, but are in 
common use. 
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1. Astrocytoma (WHO grade II) 
1. Variants: protoplasmic, gemistocytic, fibrillary, mixed 
2. Anaplastic (malignant) astrocytoma (WHO grade III) 
1. Hemispheric, diencephalic,optic,brain stem,cerebellar 
3. Glioblastoma multiforme (WHO grade IV) 
1. Variants: giant cell glioblastoma, gliosarcoma. 
      1.8 Gliomas 
Gliomas are the commonest primary tumours of the brain and they comprise about 
2% of all newly diagnosed cancers every year in the UK (The National Institute for 
Health and Clinical Excellence Cancer Service Guidance, 2007). Overall, the 
incidence of malignant gliomas roughly equals that of leukemia. Gliomas form 
about 50% of all intracranial tumours in the adult, of which half are malignant 
gliomas. There are two main types of brain tumours: those that start in the brain 
(primary) and those that spread from cancer to somewhere else in the body 
(secondary). Primary brain tumours that appear to derive from cells of neuroglial 
origin are referred to as glioma (Nikkhah et al. 1992). According to the (WHO) 
grading system, gliomas are assigned a malignancy grade of I–IV based on the 
appearance of certain pathological features (Laws et al. 2003). The malignant 
transformation of astrocytes, oligodendrocytes or their cells gives rise to a tumour 
that is called a glioma (Noda et al. 2001). Gliomas account for 40-60 percent of the 
primary brain tumours. 
 There are several kinds of gliomas and they include astrocytomas, which grow 
anywhere in the brain or spinal cord. Brain stem gliomas, arise in the lowest part of 
the brain. Ependymomas develop inside the brain, in the lining of the ventricles. 
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Oligodendrogliomas, usually grow in the cerebrum (very rare, representing just 3% 
of all primary brain tumours). An advanced astrocytoma is called glioblastoma and 
it represents 23% of all primary brain tumours (Laws et al. 1993). 
        1.8.1 Epidemiology 
 Brain tumors always have been one of the most devastating diseases because they 
are so difficult to treat, much less cure. But now scientists are on track toward 
finding what may be definitive treatments for the most virulent of these tumors. 
These may be broadly classified into primary brain tumours that start in the brain 
and secondary brain tumours that spread to the brain from another site. The 
worldwide annual incidence rate of primary malignant brain tumours ranges from 
5.8 per 100,000 for males and 4.1 per 100,000 for females in developed countries 
(Jain et al. 2008). Gliomas are the most common forms of primary brain tumours 
accounting for 80% of the cases (Schwartzbaum et al. 2006; DeAngelis, 2001). 
Gliomas are essentially tumours, which arise from the glial cells present in the 
brain, which provide support and nutrition. They also produce myelin, and maintain 
homeostasis in the nervous system. The incidence of glioma in the UK is about 21 
per 100,000 (Poberskin and Chadduck, 2000). In the USA, 13,000 deaths and 
18,000 new cases of primary malignant brain tumours occur annually of which 
glioma is responsible for approximately 77% cases (Schwartzbaum et al. 2006). 
        1.8.2 Classification and Grades 
Depending on their cell of origin, gliomas are classified into three main types 
including astrocytoma, oligodendroglioma, and ependymoma. The WHO system 
further grades these, on the basis of histological degrees of malignancy with Grade 
I being the least malignant to Grade IV being the most malignant (Louis et al. 
2007). The degree of malignancy is based on either the presence or absence of 
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increased cellularity, nuclear atypia, mitosis, endothelial proliferation and necrosis. 
Grade I and Grade II tumours are considered to be low grade gliomas while Grade 
III and Grade IV are high-grade gliomas. Low-grade tumours are usually 
circumscribed and grow slowly over a period of time while high-grade tumours are 
comparatively aggressive having poor prognosis (Chandana et al. 2008). Some of 
the low-grade gliomas undergo malignant transformation to high-grade neoplasms 
with time and age. High-grade gliomas are the most common type of brain tumours 
in the adult age group and represent a major cause of morbidity and mortality in 
neurologic practice (Benjamin et al. 2003). Glioblastoma multiform (GBM) and 
anaplastic astrocytoma (AA) are the most malignant and aggressive high-grade 
glioma (WHO Grade IV and III, respectively), having a combined incidence of 5-
8/100,000 population (Avgeropoulos and Batchlor, 1999). In 2007, the WHO 
classification of tumours of the nervous system revised and added three new 
tumours (Table 1.3): angiocentric glioma (AG), pilomyxoid astrocytoma (PMA), 
and pituicytoma (Louis et al. 2007; Brat et al. 2007). 
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WHO DESIGNATION GRADE 
Astrocytic Tumours  
Pilocytic Astrocytoma I 
Pilomyxoid Astrocytoma II 
Diffuse Astrocytoma II 
Anaplastic Astrocytoma III 
Glioblastoma Multiforme IV 
Oligodendroglial Tumours  
Oligodendroglioma II 
Anaplastic oligodendroglioma III 
Ependymal Tumours  
Subependymoma I 
Ependymoma II 
Anaplastic ependymoma III 
Mixed and other common types of 
glioma 
 
Angiocentric glioma I 
Oligoastrocytoma II 
Anaplastic oligoastrocytoma III 
Table 1.3: WHO classification of Gliomas 
(Adapted from NICE cancer service guidance 2007) 
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1.8.3 Mutations leading to infiltrative astrocytic tumours 
Molecular studies have identified some of the genetic changes that underlie the 
pathologic differences among astrocytic tumours. Progression in tumour grade is 
associated with an ordered accumulation of mutations (see figure 1.5). Approximately, 
33% of low grade infiltrating astrocytomas (St. Anne/Mayo Grade 2) have mutations 
detected in the p53 gene on chromosome 17p. Anaplastic astrocytomas (Grade 3) - 
whether found in pre-existent low grade astrocytomas or detected de novo-have a 
similar incidence of p53 mutations but, in addition, show a loss of heterozygosity on 
chromosome 19q in more than 40% of cases (Louis et al. 2007). Progression from 
astrocytoma to anaplastic astrocytoma also involves mutations in other tumour 
suppressor genes including the retinoblastoma gene on chromosome 13q (see figure 
1.5). Finally, glioblastomas have the same incidence of these genetic aberrations and in 
addition 70 percent have lost heterozygosity for chromosome 10 and one third have 
amplification of the epidermal growth factor receptor gene. Many of these correlations 
have been defined largely through work at the MGH Molecular 
Neurooncology Laboratory (Brat et al. 2007). 
 
Figure1.5: Diagram showing the progression (arrows) of astrocytoma to glioblastoma                            
multiform (Adapted from stke.sciencemag.org). 
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1.9 Astrocytoma 
Astrocytes are star-shaped neuroglial cells that provide structural supports for the 
neurones and maintain electrolytes and neurotransmitter homeostasis in the brain. The 
majority of gliomas in both adults and children are astrocytomas originating from 
astrocytes (Yarbro et al. 2005). Tumours are graded to describe their degree of 
malignancy where each grade is associated with a clinically distinct prognosis (Pagano 
et al. 2004). By histological appearance, astrocytes can be characterized into two main 
types: namely fibrillary and protoplasmic (Miller et al. 2004). The distinction between 
the two is based on the shape of their cell processes and on the presence of intra 
cytoplamic fibrils. 
 Astrocytes are present in the white matter of the brain (Kettenmann et al. 1995). All 
these types of astrocytes are found in different sub-types of astrocytoma. The major 
histological subtypes of low-grade astrocytomas include pilolytic, fibrillary, 
gemistocytic and protoplasmic astrocytoma. Low-grade astrocytomas are more frequent 
in children than adults (Vinken and Bruyn. 2002). The astrocytoma accounts for the 
majority of malignant gliomas in adults and graded into four groups according to the 
WHO grade classification 2007 (See table 1.4). 
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GRADING OF ASTROCYTOMAS 
WHO grades Designation Histological Criteria 
I Pilocytic astrocytoma Rosenthal fibres + piloid cells 
II Diffuse astrocytoma Nuclear atypia 
III Anaplastic  
astrocytoma 
Cellular anaplasia, mitoses 
IV Glioblastoma Anaplasia, mitoses, vascular 
endothelial proliferation and 
necrosis 
 
Table 1.4: WHO grading of gliomas. 
In the cerebral hemispheres, astrocytomas form 25-30% of all gliomas. In the 
cerebellum, they make up 30% of the gliomas in children. In adults, grade I is 
uncommon and comprise a distinct entity called pilocytic astrocytoma which occurs 
most commonly in the cerebellum in children. Grade II astrocytomas account for 
approximately 10-15% of all astrocytic brain tumours with an incidence rate of 1.4 new 
cases / million people a year (Bigner et al. 1998). Grade II astrocytomas affect any 
region of CNS but predominately occur in the cerebrum followed by the brain stem and 
spinal cord (Reiser et al. 2007). Grade II astrocytomas are well differentiated slowly 
growing as astrocytic glioma (Louis et al. 2007). Grade II astrocytomas exhibit hyper-
cellularity and cellular plemorpheins. Microscopically, these tumours exhibit low and 
moderate cellularity. Microcystic degeneration and occasional nuclear is a typical 
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feature of these tumours. Mitotic activity is generally absent or extremely rare (Black 
and Loeffler, 2004). 
1.9.1 Grade III 
Anaplastic astrocytoma represents 10% of all intra-cerebral tumours and about 25-30% 
of all gliomas (Yarbro et al. 2005). Grade III gliomas generally appear between the 
fourth and fifth decades of life, which are more common in males than in females 
(Moore et al. 1998). Grade III astrocytomas show strong mitotic activity along with 
hyper-cellularity and anaplasia. Grade III astrocytomas may be defined as an in 
filtrating lesion with either focal or dispersed anaplasia or marked proliferative 
potential. When the tumour shows either vascular endothelial proliferation and or the 
presence of necrosis, it is graded as Grade IV glioblastomas (Sawyer et al. 1991; Reiser 
et al. 2007; Louis et al. 2001). Treatment is based on the location of the tumour and 
how far it has progressed. The treatment of Grade III requires a multidisciplinary 
approach, which includes maximal surgical debulking of the tumour followed by 
radiation therapy, with chemotherapy during or post radiotherapy (Gilbert et al. 2007). 
1.9.2 Grade IV (Glioblastomas: GMBs) 
Grade IV astrocytomas are generally referred to as malignant astrocytomas. 
Glioblastomas are the most frequent brain tumours accounting 6-075% of astrocuticory 
tumours (Ricci. 1999; Louis et al. 2007). Grade IV GMBs are highly anaplastic 
infiltrating tumours, which invade and destroy surrounding brain tissues in patient‟s age 
of 50-70 years (Morantz and Walsh, 1993). They commonly arise within the cerebral 
hemispheres, basal ganglia and thalamus (Bradley et al. 2004). Molecular biology 
studies suggest two types of glioblastomas, primary (de novo) and secondary (evolving 
from a pre-existing low grade glioma) (Louis et al. 2007). 
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Primary tumours exhibit frequent occurrence of epithelial growth factor receptor 
(EGFR) gene amplification, whereas the secondary tumours show more frequent P53 
gene mutation (Barnet. 2006; Louise, 2008). Prominent micro vascular proliferation, 
endothelial hyperplasia, tumoural haemorrhage and tissue necrosis are essential 
diagnostic features of GBMs (Barnett, 2006; Louise, 2008). 
1.10 Diagnosis of gliomas 
Early clinical diagnosis of glioma can be challenging. After a clinical suspicion the 
diagnosis is made by imaging with CT scans‟ or Magnetic Resonance Imaging (MRI). 
MRI is more sensitive than CT scan and enables the visualization that might not be 
detected by CT scan (Kaye. 2005). Recently, the role of Diffusion Tersor Imaging (DTI) 
to study the peritumoural region of glioma has been proven to be useful for diagnosis 
(Lu et al. 2004). MR Spectroscopy (MRS), diffusion and perfusion MR (DPMR), 
functional MRI (fMRI), Magnetic-Source Imaging (MSI) and Diffusion Tersos Imaging 
(DTI) have all been extremely helpful in the assessments of the nature and extent of 
gliomas and their relation with eloquent brain areas (Fan et al. 2006). 
Magnetic Resonance Spectroscopy (MRS) can reveal chemical and physiological 
changes which may occur in brain tumours and it can also help to determine the 
presence and ratio of tissue metabolites (Bernstein et al. 2007). MRS is used to grade 
gliomas before treatment. These include the study of peritumoural regions helping to 
guide biopsies, to identify radiotherapy targets, to distinguish between tumour 
recurrence and radiation necrosis and monitor patients post treatment (Butowski et al. 
2006; Fan et al. 2006). The evaluation of the tissue samples obtained from biopsies also 
plays a vital role in definitive diagnosis. Detection of tumour residue in either post 
operative or post radiotherapy MRI /CT scan can be difficult and 18-GDG-PET (18f-
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flucrodeoxyglucose positron emission tomography) has proven to be useful in this 
situation. The accuracy of 18-FDG PET is reported to be as high as 87% compared to 
60.9% for CT /MRI scan (Fan et al. 2006). 
Positron emission tomography (PET) and Single proton emission tomography (SPET) 
are additional metabolic imaging modalities, which aid in glioma diagnosis. These 
techniques involve intravenous administration of radioactive tracers, which are detected 
by scanners followed by tomographic image reconstruction (Miller et al. 2004). Recent 
application of PET involves mapping of tumour receptors for either various 
radiolabelled chemotherapeutic agents or for monoclonal antibodies (Miller et al. 2004). 
Dynamic imaging techniques, such as capillary permeability mapping, are being used in 
studies of new drugs that target specific molecular features of gliomas (Simpson et al. 
1993). 
1.10.1 Use of fluorescent dyes to detect, locate and help with treatment of brain 
tumours 
The use of fluorescent optical methods for brain tumour diagnostics was evaluated 
according to the difference of florescence spectra. Injection of 5-amainolevulinic acid 
(ALA) induces fluorescence when applied to in vivo detection of spectral signatures of 
endogenous porphyries in malignant tissues. Tsien (2010) used synthetic molecules 
called activatable cell penetrating peptides (ACCPs) and microscopic nanoparticles to 
develop probes carting fluorescent and magnetic tags (Tsien, 2010). These tags make 
tumours visible to MRI scanning and allow the tumour to „glow‟. The ACCP 
nanoparticles probe enabled to visualize areas of tumours, which are buried beneath 
other tissues. Only a single injection of the nanoparticle- based probe containing the 
fluorescent and magnetic tag examines the tumour before and after surgery techniques. 
There are many advantages to molecularly guided cancer surgery techniques. Probes 
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can be used in staging cancer, particularly in prostate cancer, and can be used in a 
variety of tumour types. In addition, probes can be used in laparoscopic and robotic 
surgery, where surgeons cannot feel the tumour (Tsien, 2010). 
1.11 Treatment of gliomas. 
The treatment of malignant gliomas includes surgery, chemotherapy and radiotherapy 
(Lonardi et al. 2005). Depending on the site of the lesion and the condition of the 
patient, surgery can include gross total excision of the tumour using image guidance or 
may be restricted to biopsy. The treatment remains challenging whilst advances in each 
of these disciplines have improved both the quality of life and survival of the patients 
(Liu et al. 2008). The main goal of the surgery is to resect the tumour completely. 
However, the in filtering nature of gliomas and their ill-defined margins make this goal 
very difficult (Wen and Kesari, 2008). Surgery is definitely the first modality in glioma 
management. Maximal resection is performed whenever possible and it has positive 
outcome in patients with both low-grade and malignant gliomas (Lamborn et al. 2004). 
A meta-analysis has concluded that for the population as a whole, the extent of resection 
is not predictive of outcome, but radical resection may be useful in a small subset of 
young patients with favorable functional status and histology, as a mean of increasing 
survival and quality of life (Quigley and Maroon, 1991). A study from the Eastern co-
operative oncology and radiation therapy group showed a positive correlation between 
survival and extent of resection. A retrospective review on three consecutive trials 
revealed a longer median survival for maximal resection of 11.3 months as compared to 
biopsy alone of 6.6 months (Chang et al. 1983). Many recent advances in surgical 
techniques have helped to achieve the aim but have not shown to make any significant 
differences in survival time (Keles and Berger, 2004). The main advances include pre-
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operative functional imaging, fusion of functional and anatomical imaging for 
preoperative neuro-navigation intra operative functional mapping and  the use of intra 
operative MRI (Rampling et al. 2004). 
Technical advances in neuro-imaging like MRI, MR spectroscopy and surgical 
technology like image guided surgery, intra operative ultrasound and, CT have 
improved and maximized tumour resection, while decreased procedure - related 
morbidity (Rampling et al. 2004). 
Magnetic Source Imaging (MSI) is useful in the surgical decision making for lesions 
adjacent to functionally important brain areas (Ganslandt et al. 2004). The integration of 
Functional Magnetic Resonance Imaging (fMRI) data into neuro-navigation is a useful 
concept to assess the risk of a new motor deficit after surgery (Nimsky et al. 2004). The 
adjuvant strategies include radiotherapy and chemotherapy, which are employed before 
tumour progression (Keles and Berger, 2004). 
1.11.1 Radiotherapy 
Radiation therapy is one of the most vital systems to treat gliomas. Standard radiation 
treatment of glioma includes whole brain irradiation of 60GY with conventional 
external beam radiotherapy following surgery in fractionated doses (Laperrier et al. 
2002). High radiation doses using standard fractionation may pose a greater risk of 
radiation injury to normal brain without any survival benefits (Ricci. 1999). Only 10% 
of patients with glioblastomas and 44% of those with Grade III gliomas will survive for 
more than 2 years following their diagnosis (Burger et al.1985). 
Radio-immunotherapy is a beneficial treatment technique as it aims at selectively 
destroying tumour cells by using radio-labelled monoclonal antibodies which target 
specific antigens expressed only by tumour cells (Westphal et al. 2003) while sparing 
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normal tissues. Diffusion tensor (DT) magnetic resonance imaging to track fibers is 
being used to help image guided tumour resection with decreased morbidity  
1.11.2 Chemotherapy  
Approximately, 45% of brain tumour patients treated with nitrosourea drugs respond 
clinically (Kornblith and Szypko, 1978). Despite treatment with surgery and 
radiotherapy, their inevitable recurrence makes high-grade gliomas the most devastating 
neoplasms, causing death. A number of randomized clinical trials have been tried to 
assess the role of chemotherapy in the improvement of survival for glioma patients 
(Lonardi et al. 2005). Various chemotherapeutic agents have been administrated before 
(neo-adjuvant), concomitantly or post radiotherapy (Stewart et al. 2001). The most 
influential randomized study was undertaken by the National Cancer Institute of 
Canada, which led to the establishment of concurrent temozolomide and radiation 
therapy (Stupp et al. 2005). The two major classes of chemotherapeutic drugs that are 
being used currently in the treatment of gliomas include the alkylating agents and 
microtubule modulations. 
1.12 Alkylating agents 
Alkylating agents were the first compounds identified to treat cancer (Espinosa et al. 
2003). These compounds react directly with electron rich atoms in biological molecules 
to form covalent bonds. The chemotherapeutic and cytotoxic effects are directly related 
to the alkylation of DNA (Goeffrey et al. 2003). Temozolomide (TMZ) is an orally 
administrated alkylating agent and has excellent penetration power into the blood brain 
barrier. TMZ is the current standard treatment for anaplastic astrocytomas. TMZ is also 
being tested in combination with spectrum of other drugs extensively in low-grade 
gliomas (Berger et al. 2007). Nitrosoureas are other commonly used drugs in the 
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salvage treatment of gliomas as they are highly lipid soluble and readily cross the blood 
brain barrier (Walker et al. 1978). The main nitrosureas employed in glioma treatment 
are nimustine, carmustine and lomustine (Espinosa et al. 2003).  
1.12.1 Alkylating antineoplastic agents 
An alkylating anti-neoplastic agent is an alkylating agent used in cancer treatment and it 
attaches an alkyl group (CnH2n+1) to DNA. The alkyl group is attached to 
the guanine base of DNA, at the number 7 nitrogen atom of the imidazole ring. 
Alkylating agents were the first compounds to be identified for the treatment of 
neoplasms (Espinosa et al. 2003). Since cancer cells, in general, proliferate faster and 
with less error correcting than healthy cells, they are more sensitive to DNA damage 
(Berger et al. 2007). The alkylating agent drugs lead to an alteration in DNA structure 
by interfering in the transcription and replication process. Alkylating agents are used to 
treat several cancers. However, at the same time, they are also toxic to normal cells 
(cytotoxic) in the body. This can lead to damage, in particular in cells that divide 
frequently, as those in the gastrointestinal tract, bone marrow and ovaries, which can 
cause loss of fertility and other complications. The primary goal of these drugs, as 
stated above, is to either kill or inhibit proliferation of abnormal cells (Berger et al. 
2007). This is best accomplished by administering the highest dose possible (one that 
does not endanger the life of the patient).  Since these agents may present with severe 
toxicity, there are several agents whose dose may be limited by their toxicity.  Since 
many of these agents act by different mechanisms, combination therapy is common.  
Additionally, since these drugs act by inhibiting cell division, the most common side 
effects are those that occur in areas of the body where cell replication occurs.  These 
side effects may represent the dose limiting toxicity or some other toxic effect may limit 
the dose of a particular anti-neoplastic. 
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Anti-neoplastics, while sharing many of the same mechanisms of action, may exhibit 
varying degrees of efficacy in different neoplasias (Bernstein et al. 2007).  This may 
represent differences in the growth cycle of the specific neoplasia or they can result 
from different uptake mechanisms that may limit the amount of drug that reaches the 
nucleus of the neoplastic cell.  Anti-neoplastic drugs enter the cell by different 
mechanisms including active transport (often at sites for amino acids or other cell 
constituents such as choline) and passive diffusion.  Changes in the uptake of the drug 
represent one form of resistance that may develop to anti-neoplastic therapy. Other 
forms of resistance include increases in glutathione production, which may serve as the 
site of drug action, reducing its effect on DNA, increased efficiency in DNA repair, 
increased metabolism of the drug and failure to express the p53 gene.  
1.12.2 Temozolomide (TMZ) 
Temozolomide (Temodal) is an alkylating agent derived from dacarbazine and first 
synthesised in 1984 (Stevens et al. 1993; Friedberg. 2001). Temozolomide (trade name: 
Temadol in Europe, Temador in the USA) is a new chemotherapy agent that has 
generated considerable interest as a treatment for glioma. Temozolomide is an 
interesting drug in part because its development (in England) was based on 
chemosensitivity assays using a wide variety of cultures of brain-tumour cells. 
Surprisingly, the other common chemotherapy agents used for brain cancer were 
developed, not on their effect in the laboratory on cultured brain tumour cells, but on 
cell cultures from other types of cancer. It is recommended for the treatment of patients 
with malignant gliomas showing recurrence or progression after standard therapy. FDA 
in the USA has approved TMZ for the treatment of glioma. It is easier to administer than 
other chemotherapeutic regimes for this indication and is given orally, once a day for 5 
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days in a 28-day cycle. It has high bioavailability and crosses the blood-brain barrier 
where it is spontaneously hydrolysed to its active form (Newlands et al.1992). It is toxic 
to cancer cells due to inhibition of tumour cell DNA replication. In a clinical trail, the 
combination of TMZ and radiotherapy showed more significant effect than radiotherapy 
alone. The 2 year survival rate was 10.4% with radiation alone and 26.5% with radiation 
and TMZ (Stupp et al. 2005). Its half-life is 1.83 hours (Newlands et al. 1992). 
1.12.3 Structure of Temozolamide (TMZ) 
Temozolomide (8-carbamoyl-3-methylimidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one) is a 
bicyclic heterocycle and is chemically classed as an imidazotetrazinone (see figure 1.6) 
(Stevens et al. 1984). The defining characteristic of this class of compound is an 
imidazole ring that is fused with a tetrazinone ring system that contains three adjacently 
bonded nitrogen atoms.                               
                                             
Figure1.6: Chemical structure of TMZ ( Taken from Stupp et al., 2005) 
(Adapted from http://www.medicinescomplete.com/mc/clarke/images/clk1564c001.gif 2009) 
 TMZ is a 3-methyl derivative of mitozolomide. It is structurally similar to dacarbazine 
(DTIC), both producing the common active metabolite (3-methyl)-triazen-1-yl-
imidazole-4-carboxamide (MTIC).              
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1.12.4 Mechanism of action of TMZ 
To the malignant cells, the main mechanism for cytotoxicity of TMZ seems to be 
methylation of DNA (see figure 1.7). The effect of the water at highly electropositive c4 
position of TMZ helps to convert it into methyldiazonium cation and AIC (Clark et al. 
1990). Methylation occurs commonly at N7 position of guanine followed by 
methylation at O3 position of adenine and O6 position of guanine. The hypothesis is 
that the MMR cannot find the correct partner opposite to O6 MG. This in turn leads to 
the long lived nicks in DNA. These nicks accumulate and persist into subsequent cell 
cycle. Thus, replication of daughter cells are inhibited and eventually G2/M phase is 
blocked this leads to apoptosis of cells (Aoki et al, 2003; Taverna et al. 2000). 
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Figure 1.7: Mechanism of action of TMZ 
(Adapted from http://theoncologist.alphamedpress.org/cgi/content/full/5/2/144/F1) 
1.12.5 Mechanism of Resistance of TMZ      
AGT, MMR pathway and PARP are the three different mechanisms of resistance to the 
TMZ. 
a) AGT (O6-alkylguanine-DNA alkyltransferase): AGT plays the major role in 
resistance to the TMZ. The alkyl group is removed from the O6 position of 
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guanine and this in turn reverses the cytotoxicity lesion of the TMZ. BNCU and 
DTIC are correlated with the AGT levels (Tisdale, 1987). 
b) MMR (miss match repair)  pathway 
The mutations in the one or more protein complexes make MMR pathway deficiency. 
Thus, cells can tolerate to the methylation and cytotoxic effects of the TMZ. This leads 
to the unrepaired O6 MG adducts produced by the TMZ causing DNA replication to 
pass the O6 MG adducts without apoptosis (Wedge et al.1996). 
c) PARP (Poly (ADP-ribose) polymerase) 
Base excision repair pathway or PARP is another mechanism of resistance. The cells 
treated with the TMZ induced an increase in PARP activity which is thought to be 
involved in the nucleotide excision repair (Wedge et al.1996). The cells deficient in the 
excision repair plays a major in the repairing of N7 methyl guanine and O3 methyl 
adenine adducts in resistance to TMZ (Tisdale et al.1985). 
1.12.6 Introduction of Vinblastine 
The Vinca alkaloids have become clinically useful since the discovery of their anti-
tumour properties in 1959 (Nederman et al.1984). Vinblastine is a chemotherapeutic 
drug that belongs to the class of microtubule depolymerising agents and binds 
specifically to tubulin, inhibiting its polymerization and the subsequent association of 
microtubules (Yang et al. 2010). Vinblastine is mainly used to treat bladder cancer and 
to a lesser extent to treat other cancers including lymphoma and Kaposls sarcoma (BNF 
58 edition, Perry book source 2007). 
 The anti tumour drug, vinblastine was analysed on the human tumour cell lines U-118 
MG (glioma) and HTh 7 (Thyroid cancer). The cells were cultured as monolayers and 
exposed to different concentrations of 0.1, 1.0, 10 μg/ml of vinblastin for 15 min, 2 hrs, 
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24 hrs, respectively. The drug was found to induce a significant delay in cell growth 
(Nederman et al.1984). 
Renal cell cancer (RCC) is characteristically unresponsive to chemotheraphy 
(Repchinsky et al. 2006). Vinblastine has been found to be one of the most consistently 
active agents, including objective responses in 7 % to 15 % of patients when 
administered as a single agent or in combination with other chemotherapeutic agents 
(Wen et al.2006, Robert and Rudee 1998). Vinblastine has some immunosuppressant 
effects. The vinca alkaloids are sometimes referred to as cycle phase specific (Stevens et 
al. 1993). 
Some recent experiments have shown that mouse L-cells exposed to vinblastine in vitro 
accumulate in mitosis and concomitantly lose their proliferative capacity (Takemoto  et 
al.1980). When such cells were exposed to vinblastine for one generation time, most of 
the cells lose their ability to produce colonies (Binet et al.1990). 
1.12.7 Structure of vinblastine 
 Vinblastine sulfate has the molecular formula of C46H58O9N4•H2SO4 and it is a dimeric 
alkaloid containing both indole and dihydroindole moieties (see figure 1.8). The 
molecular weight of vinblastine is 909.07. Vinblastine sulfate is a white to off-white 
powder and it is freely soluble in water, in methanol and slightly soluble in ethanol. It is 
insoluble in benzene, ether and naphtha. 
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Figure 1.8: Chemical structure of vinblastine (Adapted from lookchem.com) 
1.12.8 Mechanism of action of vinblastine 
The mechanism of action of the Vinca alkaloids was initially thought to involve 
depolymerization of spindle microtubules and induction of paracrystalline tubulin-
Vinca alkaloid arrays. At relatively high concentrations (micromolar), the Vinca 
alkaloids inhibit microtubule polymerization (Binet et al. 1990; Jordan and Wilson. 
1999; Kruczynski et al. 1998). However, they also have a more subtle and powerful 
action on microtubules. They inhibit their dynamics at concentrations below those 
required to inhibit polymerization (Jordan et al. 2004; Yang et al. 2010 
; Dhamodharan et al.1995). For example, low concentrations of vinblastine (8–32 nM) 
block mitosis in BSC-1 cells in association with suppression of microtubule dynamics, 
in the absence of appreciable changes in microtubule mass or spindle microtubule 
organization (Dhamodharan et al. 1995). Vinblastine inhibits chromosome congression 
at the prometaphase movement of chromosomes to the spindle equator and the 
transition from metaphase to anaphase, by binding with high affinity to microtubule 
ends and suppressing microtubule dynamics (Jordan and Wilson, 2004; Yang et al. 
2010). 
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1.13 Lung carcinoma 
Lung cancer is a disease of uncontrolled cell growth in tissues of the lung. This growth 
may lead to metastasis, which is the invasion of adjacent tissue and infiltration beyond 
the lungs.  The primary lung cancers are carcinomas, derived from epithelial cells. Lung 
cancer is the most common cause of cancer-related death rates in men and women 
(Gorlova et al. 2007). Lung cancer remains the first cancer killer in 2009, claiming over 
161,000 lives in UK, three times as many men as prostate cancer. Death rate is 39 % 
more than 2003 (Lung Cancer Alliance). 
The main types of lung cancers are:  
A. Non-small cell lung carcinomas (NSCLC) 
B. Small cell lung carcinomas (SCLC; figure 1.9) 
                       
Figure 1.9: (a) Enlarged, irregular alveolar spaces. (b) Small cell lung carcinoma       
cells (600 × 452 pixels)                      
          (Adapted from http://radiographics.rsna.org/content/22/6/1473.full 2004)                                 
A 
B 
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Figure 1.10: (a) Enlarged, irregular alveolar spaces. (b) Non-small lung carcinoma cells. 
(c) Normal Lung cells (750 × 600 pixels) 
(Adapted from http://radiographics.rsna.org/content/27/5/1777.full 2004) 
1.13.1 Non-small cell lung carcinomas (NSCLC; figure 1.10)  
NSCLC is sometimes treated with surgery, while SCLC usually responds better to 
chemotherapy and radiation (Vaporciyan et al. 2000). NSCLC are grouped together 
because their prognosis and management are similar (see figure 1.10). The three main 
sub-types are a. squamous cell lung carcinomas, b. adenocarcinomas and c. large cell 
lung carcinomas (Travis, 2002). 
1.13.2 Squamous cell lung carcinomas 
Squamous cell lung carcinomas usually start at the central bronchus and accounting for      
25 % of lung cancers (Travis, 2002). A hollow cavity and associated necrosis are 
A 
B 
C 
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commonly found at the centre of the tumours. Generally, squamous cell lung cancers 
often grow more slowly than other cancer types (Vaporciyan et al. 2000). 
1.13.3 Adenocarcinomas 
Adenocarcinomas usually originate in peripheral lung tissues and account for 40% of 
non-small cell lung cancers (Travis, 2002). Most cases of adenocarcinomas are 
associated with smoking (Subramanian et al. 2007). A subtype of adenocarcinoma, the 
bronchiole-alveolar carcinoma, is more common in female non-smokers and it may 
respond differently to treatment (Raz et al. 2006). 
1.13.4 Large cell lung carcinomas 
Large cell lung carcinomas are a heterogeneous group of indifferent malignant 
neoplasms originating from transformed epithelial cells in the lung (Blachhall et al. 
2007). Large cell lung carcinoma comprise between 5% - 10% of all lung cancers. 
Large cell lung carcinomas are differentiated from small cell carcinomas primarily by 
the larger size of the anaplastic cells, a higher cytoplasmic to nuclear size ratio 
chromatin (Blachhall et al. 2007). At the cellular level, large cell lung carcinomas have 
a higher proliferation rate (Edelman et al. 2006). Large cell lung carcinomas are more 
frequently present as a peripheral tumour as opposed to typical, which are generally 
central in location. Garcia (2007) reported that two thirds of large cell lung carcinomas 
are present in the periphery of the lung parenchyma. Patients with large cell lung 
carcinomas are less likely to present with symptoms such as cough, haemoptysis or post 
obstructive pneumonia (Etienne et al. 2002). 
 
 
58 
 
1.13.5 Small cell lung carcinomas (SCLC) 
Small cell lung carcinomas are less common (see figure 1.9). They were formerly 
referred as „oat cell‟ carcinomas (Raz et al. 2006). Small cell lung carcinomas are 
strongly associated with smoking (Barbone et al. 1997). The cancer cells contained 
dense neurosecretory granules (neuroendocrine hormones) which give the tumour an 
endocrine paraneoplastic syndrome association (Rosti et al. 2006). Small cell lung 
carcinomas are more sensitive to chemotherapy and radiation therapy. Small cell lung 
carcinomas have been distinguished into limited and extensive stage disease (Borbone 
et al. 1997).  
1.13.6 Diagnosis of lung carcinomas 
Performing a chest radiograph is the first step suggested for lung cancer (Raz et al. 
2006). Bronchoscope and CT scan may provide the necessary information. Either 
bronchoscope or CT guided biopsy is often used to identify the tumour type (Edelman 
et al. 2006). Sputum cytological examinations combined with other screening 
examinations have an important role in the early detection of lung cancer (Fan et al. 
2009). The accurate differentiation of large cell lung carcinoma from other subtitle 
requires careful review of the pathologic specimen. Large cell lung carcinomas are 
frequently diagnosed preoperatively. The diagnosis of large cell lung carcinoma was 
ascribed to these tumours. In addition, neuroendocrine differentiations must also be 
confirmed by light microscopy and subsequently distinguished from typical carcinoma, 
atypical carcinomas and absence of necrosis or mitosis rate (Travis, 2002). Large cell 
lung carcinomas can be confirmed by immune-histochemical staining for 
neuroendocrine markers such as chrommogranin, synaptophysin, neuro- specific 
enloase and neuroendocrine differentation can be determined using ultra structurally 
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using electron microscopy (Krewski et al. 2005). Positron emission tomography (PET) 
is also used to determine the disease is localized (Strand et al. 2010). 
1.13.7 Treatments of lung carcinomas 
The treatments of SCLC and NSCLC are based on the cancer specific cell types and 
how far they have invaded other tissues and organs of the body. The most common 
treatments are surgery, chemotherapy and radiation therapy (Schiller et al. 2009). 
Surgery is usually only an option in non-small cell lung carcinomas limited to one lung. 
 Treatment procedures include:- 
 Wedge resection     -   Removal of part of a lobe  
 Segmentectomy     -   Removal of an anatomic division of a particular lobe of the lung  
 Lobectomy            -   Removal of a one lobe 
 Bilobectomy          -   Removal of a two lobes 
 Pneumonectomy   -    Removal of a whole lung  
 In patients with adequate respiratory reserve, lobectomy is the preferred option (El-
Sherif et al. 2007; Fernando et al. 2005). 
a. Chemotherapy treatment 
Small cell lung carcinomas and non-small cell lung carcinomas are treated primarily 
with chemotherapy and radiation. The combination regimen depends on the tumour 
type. Non-small cell lung carcinomas are often treated with either cisplatin or 
carboplatin and in combination with gemcitabine, paclitaxel, docetaxel, etoposide, or 
vinorelbine (Clegg et al. 2002).  In small cell lung carcinomas, cisplatin and etoposide 
are most commonly used (Murray et al. 2006). Combination either with carboplatin, 
gemcitabine, paclitaxel, vinorelbine, topotecan or irinotecan is also used (Araujo et al. 
2009). Radiotherapy is often given together with either chemotherapy. For both non-
small cell lung carcinomas and small cell lung carcinomas patients are given smaller 
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doses of radiation to the chest as this may be used for symptom control (palliative 
radiotherapy). Unlike other treatments, it is possible to deliver palliative radiotherapy 
without confirming the histological diagnosis of lung cancers. Brachytherapy (localized 
radiotherapy) may be given directly inside the airway when the cancer affects a short 
section of the bronchus (Raben et al.1997). This treatment is used when it is not 
possible to operate on lung cancer due to blockage of a large airway lobe (Celebioglu et 
al. 2002). 
1.14 Skin melanomas  
The skin is the major organ of the body and it is made up of several layers including the 
epidermis and the dermis (see figure 1.11A). The main function of the skin is to protect 
the inner tissues of the body from external insults including chemicals, sun light, 
radiations, burns and others. Constant exposure to some of these external insults can 
lead to skin cancers. One such cancer is melanoma, which is the most dangerous form 
of skin cancer (Figure 1.11B). Melanomas are least common, with 10,672 new cases 
diagnosed in 2009. The statistics show that 5,697 cased were diagnosed in women and 
4,975 in men. In 2009, there were 491 deaths in the UK, around 80 % occur in people 
aged 60 years and over.  In their advanced states, they can cause serious illness and even 
death (Sabal and Tsai, 2008). 
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Skin melanomas                                
Structure of the Skin 
 
 
Figure 1.11: Diagrams showing (A) the structure of the skin and (B) the formulation of 
skin melanoma.                                                                                                                        
(Adapted from http://img.Webmed.com/ March, 2005) 
Melanomas are the most serious form of skin cancer. However, if they are recognized 
and treated early, they can be cured by almost 100%. Melanomas of the skin are one of 
the most rapidly increasing malignancies in both young and old patients because 
patient‟s body may be less able to repair damage caused by exposure to ultraviolet (UV) 
rays and intense intermittent sun exposure (Gachon et al. 2005). New methods of 
imaging and targeting therapy are widely sought. Radio- iodinated methylene blue is a 
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promising tracer showing selective uptake in human pigmented melanoma cells (Sabal 
and Tsai. 2008). At present, the examination of melanomas is usually followed by 
biopsy of suspicious lesions and is the gold standard (Sabal and Tsai, 2008).   
1.14.1 Classification of skin melanomas  
Skin melanomas classified as- 
A. Radial melanoma (about 70% of skin melanoma cases) – appears from 
dysplastic lesions. Melanoma progress takes up to 5 years and it can be detected 
by using the ABCD rule, specific for elderly ages. In early phases, melanomas 
spread in the upper layer of skin – epidermis (see figure 1.11). Later, it enters a 
vertical growth phase, after which the cancer becomes dangerous as it starts to 
invade the inner tissues (Cancer Research UK, 2007). 
B. Nodular melanoma (about 15% of cases) – This type of melanoma rises very 
rapidly and it is the most aggressive type of skin cancers and it grows vertically 
up and down. Thus, there is a danger from the beginning that the melanoma may 
spread into inner tissues of the body. This type of melanoma appears to be either 
dark black, blue, grey or red with smooth borders (Cancer Research UK, 2007). 
C. Lentigoous malignant melanoma -This type of melanoma usually appears in 
the head and the neck areas and it is bigger than 3 centimetres with a non 
symmetrical lesion. It takes a long time to progress – up to 20 years. Most cases 
usually occur in a patient of 70 over or under years of age (Cancer Research UK, 
2007). 
D. Acral lentigous melanoma – It is the most common type of melanoma for dark 
skinned people. It appears on the palms of the hands and the feet- especially 
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under the nail of the first finger. It takes a short time to progress from 3 to 36 
months and it is most common among people who are 60 years of age and over 
(Cancer Research UK, 2007). 
E. Unclassified – There are other types of carcinomas, which represent about 5% of 
cases. Generally speaking, all melanomas grow in two phases including 
horizontal-radial and vertical. In the radial phase, the lesion usually spreads in the 
epidermis and papillary dermis without metastases (see figure 1.11). In this 
period, the patient can easily cured. When the growth enters the vertical phase, 
the lesions usually spread in to deeper tissues through dermis and other deeper 
layers of skin.  In this area, they usually begin to form metastases (Jemal et al. 
2009; Rigel and Carucc,. 2003; Cockburn et al. 2009; Gachon et al. 2005). 
1.14.2 Diagnosis of Skin Melanomas 
Dermoscopy is a technique whereby the dermatologist is able to examine a lesion using 
a hand-held instrument called a dermoscope. This is equipped with a special polarizing 
light and standard magnifying optics. The lesion may or may not be placed in a fluid 
medium for better visualization. The technique allows evaluation of specific, minute 
pigment patterns, enhancing differential diagnosis (Morris et al.2008). Melafind is 
another non-invasive instrument that can assist in early diagnosis of melanomas by 
providing physicians with a recommendation for whether a suspicious lesion should be 
biopsied. It uses light of multiple wavelengths to capture images of suspicious skin 
lesions and compares the data against a database of melanomas and benign lesions 
(Vries et al. 2003).  
Siascopy spectrophotometric intracutaneous analysis system (SSIAS) is yet another 
imaging process that may allow the Physician to distinguish the difference between 
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benign moles and melanomas. Like Melafind, it employs multiple wavelength 
illumination of clinical and dermoscopic images, but requires the Physician‟s 
interpretation. In contrast, Melafind provides diagnosis in a completely automated 
system (Lipsker et al. 1999). Other non-invasive diagnostic techniques are also in 
development and they include Confocal Scanning Screening (CSS), which is used to 
check people who are unaware of signs or symptoms (Vries et al. 2003).  
Some melanomas may involve a total body examination by a Health Professional. 
Recently, various technologies have been introduced including digital photography to 
process where suspicious lesions are mapped on a whole body image (mole mapping). 
These methods identify lesions, which could be either melanomas or other forms of skin 
cancers (Vries et al. 2003). 
Treatments   
a. Radiotherapy for skin cancer  
Skin cancer can be treated with both radiotherapy and chemotherapy. Radiotherapy uses 
high energy rays to kill cancer cells. It can be used to treat skin cancers that cover a 
large area or on an area of the body that is difficult to operate on or where the cosmetic 
result may be poor. It can also be used in people who are not fit enough for surgery. 
Radiotherapy may be given after surgery to lower the risk of the cancer coming back or 
to treat skin cancers that have invaded other areas of the body (Legha et al. 1989). 
 
b. Photodynamic therapy (PDT) for skin cancer 
Photodynamic therapy or PDT is a relatively new type of treatment. It is a treatment 
with a chemical that makes the skin cells sensitive to light. When the area to be treated 
is exposed to laser light, the cells die off (Hiller et al. 2001).  PDT is an alternative 
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option to surgery. It is best used in cases where a lot of surgery is required. It is not 
suitable for deeper skin cancers because the light cannot penetrate far enough into the 
skin. PDT is not recommended for squamous cell skin cancers because there is too high 
a risk of the cancer returning. PDT is now available on the NHS for Bowen's disease, 
basal cell skin cancers and actinic keratosis (solar keratosis) (Agarwal et al. 2002). 
Chemotherapy 
Either chemotherapy tablets or injections are only used in certain circumstances for skin 
cancer. More often, chemotherapy creams are used. Either solar or actinic keratosis can 
sometimes develop into squamous cell skin cancer if it is not treated. Chemotherapy 
cream containing 5FU is a common treatment. Bowen‟s disease is also sometimes 
treated with chemotherapy cream. Chemotherapy tablets or injections are only used for 
skin cancers that have spread. This treatment is mostly used to relieve symptoms in 
cancers that cannot be cured (Legha et al.1989). 
1.15 Chemical structures of compounds of M. charantia with some commercial 
available anti-cancer drugs for comparison. 
 M.charantia has many different chemical components, which help medicinally either 
alone or when combined. Charantin has a molecular weight of 9.7 kDa and it is the 
belief that charantin is the active parent agent of M. charantia (Taylor, 2002). Figures 
1.12 and 1.13 show the chemical structures of some medicinal compounds including 
charantin (MW 548), momordicine, α momorcharin (MW 576), β momorcharin (MW 
576.), diterpene (MW 397), triterpenoids (MW 532) extracted from M.charantia 
compared to some commercially available anti-cancer drugs including vincristine (MW 
923), vinblastine (MW 909.), temozolomide (MW 194), cisplatine (MW 300) and 
pacitaxel (MW 853).  
66 
 
A. Diterpene                                                                     B.Vinblastine 
                    
C. Triterpenoids                                                             D. Vincristine 
           
E. Charantin                                                               F. Pacitaxel  
                           
Figure 1.12:  Chemical structures of (A) Diterpene, (B) Vinblastine, (C) Triterpenoids,                      
(D) Vincristine, (E) Charantin and (F) Pacitaxel.  
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A. Momordicine                                                               B.  Temozolomide 
                                               
 
C.  Alpha momorcharin                                                  D.   Cisplatin 
                                                                                                                                               
               
E.Beta-momorcharin  
 
Figure 1.13:  Chemical structures of (A) Momordicin, (B) Temozolomide, (C) Alpha 
momorcharin (D) Cisplatin and (E) Beta momorcharin.  
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1.16 Cellular and sub-cellular mechanisms associated with cell death 
1.16.1 Introduction 
There are different mechanisms via which chemotherapeutic drugs can exert their 
effects on cancer cell death. These include apoptosis involving permanent damage to the 
mitochondria leading to the release of cytochrome-c, caspase-3, caspase-9 and cellular 
calcium over load (Kerr et al. 1972). This study measured the activities of cytochrome 
c, caspase-3 and caspase- 9 as well as intracellular free calcium concentrations [Ca 
2+
 ]i  
in different treated and untreated cancer cell lines compared to L6 cell line. Thus, 
emphasis will be placed on processes which involve the metabolism of these cellular 
markers and the methods involved in their measurements. 
Apoptosis was originally described as a mechanism of controlled or programmed cell 
death (Kerr et al. 1972). Apoptosis is very common in cells and tissues with 
hematopoietic activity and in organs with high proliferative activity. Apoptosis has been 
implicated in the progression of a number of pathological conditions, including cancers, 
AIDS and autoimmune diseases (Ameisen et al. 1995). 
Apoptosis is characterized by a variety of cellular changes including loss of membrane 
phospholipid asymmetry, mitochondrial swelling and DNA cleavage (Vermes et 
al.1995; Darzynkiewicz et al.1992). The result of these changes is a form of cell death 
that avoids the normal inflammatory response associated with necrosis. 
1.16.2 Cytochrome-c and its assay 
Cytochrome-c is a small heme protein found loosely associated with the inner 
membrane of the mitochondrion. Cytochrome-c is a highly soluble protein, unlike other 
cytochromes with a solubility of about 100 g/L (Tris-acetate-phosphate medium) and is 
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an essential component of the electron transport chain. Cytochrome-c is capable of 
undergoing oxidation and reduction (Vidal et al. 2002). 
1.16.3 Role of apoptosis  
Cytochrome-c is an intermediate in apoptosis, which is a controlled form of cell death in 
the process of development or in response to infection or the induction of DNA damage 
of any apoptotic programme in cell free extracts (Chandra et al. 2002; Johnstone et al. 
2002). NADPH-cytochrome c reductase (NADPH cytochrome P450 reductase, EC 
1.6.2.4) is a flavoprotein localized in the endoplasmic reticulum (ER) of the cell. It 
transfers electrons from NADPH to several oxygenases. The most important of which is 
the cytochrome P450 family of enzymes, which are responsible for xenobiotic 
metabolism (Shen et al. 1993; Plonne et al. 1999). NADPH-cytochrome c reductase is 
widely used as an ER marker-3 and as a biomarker of ecological pollution and dietary 
lipid uptake (Vidal et al. 2002; Hochgraf et al.1997). Cytochrome-c is released by the 
mitochondria in response to pro-apoptic stimuli. Normally calcium levels are elevated 
and this in turn is preceded by the release of cytochrome-c from the mitochondria. The 
small amounts of releasable cytochrome-c lead to an interaction with the inositol 
triphosphate (IP3) receptor on the ER causing it to release calcium. The increase in 
cellular free calcium triggers a massive release of cytochrome-c which then maintains 
ER calcium release through the inositol 1, 4, 5-triphosphate receptors (IP3RS). ER 
calcium release can reach cytotoxic levels and cause calcium overloading.  
The release of cytochrome-c in turn enhances the activity of caspase-9, a cysteine 
protease. Cytochrome-c assay kit is designed to measure the NADPH cytochrome-c 
reductase activity in cell and in purified microsomes of the ER. The cytochrome-c 
measurement is based on a colorimetric assay that monitors the reduction of 
cytochrome-c by NADPH- cytochrome-c reductase in the presence of NADPH. The 
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reduction of cytochrome-c results in the formation of distinct bands in the absorption 
spectrum and the increase in absorbance at 550 nm is measured with time (Vermillion 
and Coon, 1974). 
1.16.4 Caspase-3 and its assay 
Caspases (Cysteine-requiring aspartate proteases) are a family of proteases that mediate 
cell death. It is also important to the process of apoptosis. Caspase-3 is a member of the 
CED-3 subfamily of caspase and is one of the critical enzyme of apoptosis. Caspase-3 
processes procaspase 2, 6, 7 and 9 and specifically cleaves most of caspase- related 
substrates. Many key proteins including nuclear enzyme activate poly (ADP-ribose), 
and polymerase (PARP) (Nicholson et al. 1995),
 
the inhibitor of caspase-activated 
deoxyribonuclase (ICAD) gelsolin and fodrin, which are the proteins, involved in the 
apoptosis regulation (Sakahira et al.1998). This cleavage is part of the mechanism 
leading to cell death.
 
Caspase-3 plays a central role in mediating nuclear apoptosis 
including chromatin condensation and DNA fragmentation as well as cell blebbing. The 
activity of caspase- 3 in cells and tissues of the body is either a marker or indicator of 
cell death (Porter and Janicke, 1999). 
Caspase-3 colorimetric assay is based on the hydrolysis of the peptide substrate acetyl-
Asp-Glu-Val-Asp p-nitroanilide (AC-Devo-PNA) by Caspase-3, resulting in the release 
of the p-nitroanilide (PNA) moiety. The p-nitroanilide has a high absorbance at 405 nm               
(∑mM = 10.5). The concentration of PNA released from the substrate is calculated from 
the absorbance values at 405 nm or from a calibration curve prepared with defined PNA 
solutions. 
                                                               Caspase 3 
                                     Ac-DEVD-pNA                     Ac-DEVD + pNA 
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Caspase-3 is a crucial component of the apoptotic machinery in many cell types. The 
activation of caspase-3 is a central event in the process of apoptosis (Thornbery and 
Littlewood, 1998; Wolf et al. 1999). 
 
1.16.5 Caspase – 9 and its assay 
There are four different apoptotic pathways, which are associated with cell death 
leading to the elevation in caspase-3 and caspase-9. They include. 
A. Caspase -9 and caspase-3 dependent apoptotic pathway. 
B. Caspase -9 and caspase-3 independent apoptotic pathway. 
C. Caspase -9 independent and caspase -3 dependent apoptotic pathway. 
 D. Caspase-9 dependent and caspase -3 independent apoptotic pathway (Hakem et 
al.1998). 
Caspase-9, also known as ICE –Lap6, Mch6, is an upstream proenzyme in the cascade 
of enzymatic reactions required to induce cellular apoptosis (Duan et al. 1996). During 
the release of mitochondrial cytochrome-c, and caspase-9 activated following their 
association with the protein complex of Apaf and cytochrome-c. The active caspase-9 is 
generated through protein phosphoylation events and the optimal cleavage recognition 
sequence for caspase-9 is Leu-Glu-His-Asp-7 (LEHD). The caspase-9 is associated with 
both pro-apoptotic and anti-apoptotic proteins as well as its regulatory function during 
embryonic development. This suggests that caspase-9 is a key regulatory enzyme of 
apoptosis (Thornberry et al.1997; Petty et al. 1995). The Caspase-Glo® 9 assay is a 
homogenous luminescent assay that measures caspase-9 activity. Addition of a single 
Caspase-Glo®-9 reagents in an „add-mix measure‟ formant resulting in cell lysis. This 
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is followed by caspase cleavage of the substrate and the generation of a glow type 
luminescent signal produced by the luciferase reaction. The signal generated is 
proportional to the amount of caspase activity present. Figure 1.14 shows the process 
involved in the measurement of caspase-9 in cells and tissues. 
                     
Figure 1.14: Caspase-9 cleavage of the luminogenic substrate containing the LEHD 
sequence. (Adapted from www.promega.com/automethods/ April 2004) 
1.16.6 Luminescent assay 
Luminescent assay for ATP was developed to measure cell viability. The high level of 
ATP will produce a high level of luminescence and this indicates the number of viable 
cells. A lower luminescence value is an indication of a lower level of ATP release from 
cells due to cell death or low cell viability. The assay is more sensitive and accurate. 
The colorimetric assay for ATP has simplified the sensitivity testing. The sensitivity of 
the assay is limited by the number of cells and there ATP levels. The assay is most 
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efficient from 100 to 200 cells per wells. The ATP assay is based on the principle of 
bioluminescence and measures ATP in live cell. The process involves the interaction of 
a substrate luciferin with ATP in the presence of an enzyme extracted from the firefly 
called luciferase, which produces light. Firefly, luciferase extracted from Photinus 
pyralis is a 62 KDa enzyme responsible for the yellow green bioluminescence of this 
species (Tisi et al. 2002). Firefly luciferase is high-sensitivity bio-detection. Its light 
emitting assay is fast, rapid and accurate and moreover, it can generate consistent results 
very quickly. Firefly luciferase is a single polypeptide chain that catalyzes the moo-
oxygenation of the compound of beetle luciferin (LH2) in an ATP-dependent fashion to 
give oxyluciferin (LO) (Tisi et al. 2002). The nascent LO is in the excited state that 
delays to its ground state releasing a photon (Jeffrey et al.1986). 
LH
2 
+ ATP (Mg
2+
) + O
2 
= LO + CO
2 
+ PPi + AMP + hv 
                 Figure 1.15 (Adapted from www.promega.com/automethods/ May 2009) 
The reaction (Figure 1.15) is extremely efficient with a photon emitted for nearly every 
LH2 molecule consumed, giving a quantum yield of close to 0.9 as shown in figure 1.14 
(Tisi et al. 2002). The emitted photon is measured quantitatively in a luminometer, and 
thus, the luminescence is directly proportional to the amount of ATP and hence, the 
number of live cells (Di et al.2002). 
Another ATP assay is the CellTiter-Glo™ Luminescent Cell Viability Assay 
(Promega®) which is a homogeneous method of determining the number of viable cells 
in culture based on quantification of the ATP present, which signals the presence of 
metabolically active cells. The CellTiter-Glo® Assay is designed for use with 96 and 
384 multi well-plate formats, making it ideal for automated high-through put screening, 
and cell proliferation and cytotoxicity assays. The CellTiter-Glo® Assay relies on the 
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properties of a proprietary thermo stable luciferase (Ultra-Glo™ Recombinant 
luciferase), which generates a stable glow-type. Luminescent signal improves 
performance across a wide range of assay conditions. The luciferase reaction is shown 
below in figure 1.16. 
 
 
Figure 1.16: Ultra-Glo™ Recombinant luciferase reaction 
(Adapted from www.promega.com/automethods/ May 2009) 
 
The half-life of the luminescent signal resulting from this reaction is greater than five 
hours. This extended half-life eliminates the need for reagent injectors and provides 
flexibility for continuous or batch-mode processing of multiple plates (Promega, USA). 
1.16.7 MTS   (Colorimetric cell viability assays) 
MTS assay is most popular colorimetric assay in which the compound 3-(4, 5-dimethyl 
thiazol-2yl)-5,(3-carboxymethoxyphenyl)-2(4sulfophenyl)-2H(tetrazolium) is converted 
to a coloured insoluble formazan product by mitochondrial enzymes. The end product is 
solubilised in either alcohol or detergent and the absorption measured at 490 nm 
(Lewandowicz et al. 2000; Nikkhah et al. 1992). The amount of colour produced is 
directly proportional to the number of live cells. MTS assay has been used in several 
investigations for the measurement of chemo-sensitivity testing in malignant gliomas 
(Nikkhah et al. 1992). The enzymatic reactions (see figure 1.17) are based on either the 
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oxidase and dehydrogenase reactions, which are determined either calorimetrically or 
fluorimetrically using different reagents including oxidative chromogenic dyes or 
reductive chromogenic dyes. Tetrazolium salts are one of the reductive chromogenic 
dyes employed in the measurement and it is a very sensitive detection system.  
 
           
Figure 1.17: (a) Structure of tetrazolium salt and (b) electron transfer mechanism for 
MTS assay   (Adapted from www.promega.com/automethods/ April 2007) 
 
The tetrazolium salt is generally reduced through the reaction directly with either 
NADH (nicotineamide adenine dinucleotide reduced form) or NADPH (nicotineamide 
adenine dinucleotide phosphate reduced form), which is generated, from either NAD or 
NADP by the reaction of dehydrogenase and its substrates, lactate dehydrogenase and 
lactic acid. Therefore, the tetrazolium salt is utilized for the determination of 
dehydrogenase activity (Berridge et al. 1996). The CellTiter 96 AQueous is a cell 
proliferation assay solution, which is based on a colorimetric method for the 
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determination of viable cells in proliferation or in cytotoxicity assay. The assay solution 
contains a novel tetrazolium compound [3-(4,5-dimethylthiazol-2yl)- 5- (3-
carboxymethoxyphenyl)-2–(4-sulfophenyl)-2H-tetrazolium:MTS] and an electron-
coupling reagent (phenazine ethosulfate; PES). PES has enhanced chemical stability, 
which allows it to be combined with MTS to form a stable solution. MTS tetrazolium 
compound is bio- reduced by cells into a coloured formazan product in tissue culture 
medium. Figure 1.18 below shows the MTS formazan reaction. 
 
 
 
Figure 1.18: The molecular structure of MTS and formazan 
(Adapted from www.promega.com/automethods/ April 2007) 
 
The amount of the formazan product is measured at an absorbance range of 490 nm and 
this is directly proportional to the number of living cells in culture. The MTS formazan 
product is soluble in tissue culture medium. 
1.16.8 Calcium (Ca 
2+
) 
Calcium is the most important physiological cation in cellular regulation (Koolman et 
al. 2005; Johansson et al. 2003). It is the trigger, the promoter and the regulator and 
moreover, a ubiquitous intracellular signalling molecule which controls a wide range of 
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cellular processes including secretion, membrane transport, contraction, cell 
proliferation, gene transcription and even cell death (Bootman and Berridge. 1995; 
Clapham, 2007). In un-stimulated pancreatic acinar cells, as well as in other cells, the 
free intracellular calcium concentration [Ca
2+
]i is between 50–100 nM. In order to 
maintain this low resting level, a variety of pumps and uptake systems are present in the 
plasma membrane and in intracellular organelles to buffer (Ca
2+
) (Williams et al. 1993). 
Calcium mobilisation is dependent upon intracellular calcium stores as well as 
extracellular calcium medium [Ca
2+
]o. An increase in cellular calcium originates from 
two major sources: 
a. The release of Ca2+ from intracellular stores (ER), which is rapid. Calcium 
release from the ER after IP3 generation is crucial for exocytosis. Similarly the 
release of   Ca 
2+ 
from SR is crucial in muscle contraction. 
b. The influx of Ca2+ from extracellular source with the aid of IP3 by the depletion 
of an intracellular pool (Putney, 1989; Irvine, 1989). 
Both of these mechanisms give rise to high-localised (Ca
2+
) signals. Many agonists 
can promote an influx of Ca
2+ 
from the extracellular medium by the following 
processes: 
a.   Opening of voltage-operated Ca2+ channels 
b. Phosphorylation of Ca2+ channel proteins by cAMP and cGMP. 
c. Receptor-operated Ca2+ channels in which modulation of channel activity does 
not involve cytosolic signal molecules but a direct control by receptor channel 
coupling G- proteins (Berridge and Irvine, 1989). 
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1.16.9 Calcium signalling 
The intracellular level of [Ca
2+
]i in resting cells is maintained within a normal range of 
50 -100 nM. Ca
2+ 
homeostasis is tightly controlled to prevent and overcome problems of 
cytotoxicity due to its very low diffusibility in the cytoplasm. Distributed throughout the 
cytoplasm is an extensive array of Ca
2+ 
pumps (Irigoin et al. 2009; Carafoli, 1994). 
There are two main intracellular mechanisms which increase [Ca 
2+ 
]i . They include 
a. Ca2+ release from internal stores (eg ER, SR, mitochondria) via  intracellular 
calcium channels, activated via the ryanodine receptors (RYRs), and the inositol 
1, 4, 5- triphosphate receptor   (IP3 R). 
b. Ca 2+ entry from the outside [Ca2+]o through a variety of channels such as the 
VOCs, ROCs or store- operated channels (SOCs). 
Cytosolic Ca
2+ 
homeostasis in resting cells is achieved by balancing the leak of Ca
2+ 
 
(entering from the outside of from the stores) by the constant removal of Ca 
2+ 
 using 
pumps either on the plasma membrane or on the internal stores. These pumps ensure 
that cytoplasmic [Ca
2+
]i  remains low and that the stores are loaded with signal Ca
2+
. In 
most cells, it is the internal stores (eg ER, SR, mitochondria) which provide most of the 
signal calcium (Streb et al. 1983). Activation of the IP3 Rs is also regulated by cytosolic 
(Ca
2+
) concentrations. Intact and internally per-fused cells have evidently shown that an 
increase in [Ca
2+
]i  can inhibit IP3 -evoked Ca
2+ 
 release (Wakui et al. 1990; Parker and 
Ivorra. 1990)
   
where opening of the IP3R is enhanced by low concentration of Ca
2+
. 
This is crucial in the generation of complex patterns of Ca
2+ 
signals seen in many cells 
(Bootman and Lipp, 2001). Unlike the RYR, where Ca
2+ 
can act as the sole trigger for 
its activation, IP3 Rs usually requires the simultaneous presence of Ca
2+ 
and IP3 
(Berridge, 1987).   
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1.16.10 Calcium over load and cell death 
Many studies have demonstrated mitochondrial Ca
2+ 
overload as the link between 
complement deposition and the observed changes in mitochondrial physiology and the 
triggering of programmed cell death  (PCD) (Irigoin et al. 2009).  The mitochondrial 
Ca
2+ 
overload is responsible for the increased O(2)(*-) production (Jimenez and 
Hernandez-Cruz, 2001). If cytosolic Ca
2+ 
rise is not accompanied by the accumulation 
of the cation in the mitochondrion and consequent production of O(2)(*-), cells usually 
die by necrosis instead of PCD. For example, membrane attack complex assembly 
(MACA) on the parasit in cell surface allows Ca
2+ 
entry in the cell and its accumulation 
in the mitochondrion can lead to O2 production. This in turn constitutes a PCD signal 
(Jimenez  and Hernandez-Cruz, 2001). 
Based mainly on in vitro observations, one currently popular model consistent with 
excitotoxic apoptosis, proposes that mitochondrial Ca
2+ 
overload triggers an injury 
response, possibly through a mitochondrial permeability transition (MPT) that leads to 
the loss of permeabilization of the inner mitochondrial membrane, swelling of the 
matrix and outer membrane rupture, followed by the release of apoptogenic proteins 
(Bernardi et al. 2001). Such mechanisms present a paradox, in that the destruction of 
mitochondria impairs the ATP supplies that are essential for activation of energy- 
dependent apoptotic pathways (Gogvadze et al. 2004). It has also been suggested that 
only a subpopulation of mitochondria undergoes a permeability transition and releases 
apoptogens, whereas the remaining, undamaged mitochondria respire normally and 
produce ATP (Simpson et al. 2002; Kabir et al. 1999; Jimenez and Hernandez-Cruz , 
2001). 
Loss of Ca
2+ 
homeostasis, often in the form of cytoplasmic increases, leads to cell 
injury. Depending upon the cell type and the intensity of Ca
2+ 
toxicity, the ensuing 
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pathology can be either reversible or irreversible (Gogvadze et al. 2004). Although 
multiple destructive processes are activated by Ca
2+
, lethal outcomes are determined 
largely by Ca
2+
 induced mitochondrial permeability transition (Johansson et al. 2003; 
Goldstein et al. 2000). This form of damage is primarily dependent upon mitochondrial 
Ca
2+ 
accumulation, which is regulated by the mitochondrial membrane potential 
(Gogvadze et al. 2004). Retention of the mitochondrial membrane potential during Ca
2+ 
favours mitochondrial Ca
2+ 
uptake and overload, resulting in mitochondrial permeability 
transition and cell death. In contrast, dissipation of mitochondrial membrane potential 
reduces mitochondrial Ca
2+ 
uptake, retards mitochondrial permeability transition, and 
delays death, even in cells with large Ca
2+ 
increases. The rates of mitochondrial 
membrane potential dissipation and mitochondrial Ca
2+ 
uptake may determine cellular 
sensitivity to Ca
2+ 
toxicity under pathological conditions, including ischemic injury 
(Gogvadze et al. 2001). 
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1.17 Working hypothesis 
Is it possible to use naturally occurring plant-based medicines to treat cancer? Are they 
effective enough to kill the cancer cells compared to commercially available anti-cancer 
drugs? Is it possible to use a higher dose of the plant-based medicines with a low to 
moderate dose of the commercially available anti-cancer drug in order to obtain 
maximal and effective treatment without adverse side effects to the body? By what 
cellular and sub cellular mechanism(s) do these anti-cancer compounds exert their 
effects on cell death?  
1.18 Aims 
The main aim of this study was to investigate the effects of extracts and isolated 
compounds of M. charantia as well as commercially available drugs vinblastine and 
temozolomide on cancer cell viability and to determine their modes and cellular 
mechanism(s) of action as chemotherapeutic agents in cancer therapy. 
1.18.1 Objectives 
1) To isolate crude water and methanol soluble extracts of M. charantia using 
different extraction, analytic and biochemical methods. 
2) To use a tissue culture technique to measure the cytostatic and anti-tumour 
activity by in vitro study employing in the cell culture medium. 
3) To determine the time-course effects of the crude water-soluble extract of 
M. charantia on cancer cell viability. 
4) To investigate the dose-dependent toxic effects of the extracts and isolated 
and purified compounds (alpha momocharin, beta momocaharin, alpha, beta 
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momocharin) of M. charantia, and vinblastine and temozolomide on cancer 
cell viability. 
5) To investigate the combined effects of the crude water-soluble extract of M. 
charantia and alpha, beta momocharin with either temozolomide or 
vinblastine. 
6) To investigate the modes and  cellular and molecular mechanisms of action 
of each the crude water-soluble extract of M. charantia and alpha, beta 
momocharin  in inducing cell death measuring caspase-3 and caspase-9 
activities, cytochrome-c  release and cytosolic calcium. 
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Materials and Methods 
2.1 Materials 
2.1.1 Consumables required for tissue culture 
1. Cell lines: 
1321N1 (ECACC, UK), Gos-3 (DSM2, Germany), U87-MG (ECACC, UK), L6, 
WERI-Rb1 (ECACC, UK), SK-Mel (DSM2, Germany), Corl-23 (ECACC, UK) 
2. Chemicals and Reagents: 
1.  Ethanol, methanol and isopropanol, hexane (Fisher Scientific, UK). 
2.  Cell titer-Glo luminescent cell viability Assay kit (Promega, UK). 
3.  MTS assay (Promega, UK). 
4.  Fura-2 (AM) (Sigma, UK). 
5.  Caspase-3 assay kit (Sigma, UK). 
6.  Cytochrome-c assay kit (Sigma, UK). 
7.  Caspase-9 assay kit (Promega, USA). 
3. Drugs 
1. Crude water and methanol soluble extracts of M.charantia. 
2. α and β momocharin (IMAM Pharmaceuticals, China) 
3. α momocharin (IMAM Pharmaceuticals, China) 
4. β momocharin (IMAM Pharmaceuticals, China) 
5. Temozolomide (Sigma, UK) 
6. Vinblastine (Sigma, UK) 
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2.1.2 Media and supplements required for the cell culture 
DMEM (Doulbeco‟s Modified Eagle‟s Medium), MEM (Minimal Essential Medium), 
RPMI-1640 (Roswell Park Memorial Institute), Foetal bovine serum (FBS), Trypsin,                      
L-Glutamine, Non-essential amino acid (NEAA) and Sodium pyruvate (all the products 
bought from Lonza, UK). 
2.1.3 Equipment and Materials used in the study 
 
New Brunswick Scientific (CO281R) - Water jacketed CO2 incubator, Water bath , 
Laminar flow hood, Inverted phase contrast microscopes, Weighing balance, Tecan 
plate reader, Refrigerator, Freezer (-20°C), Deep Freezer (-80°C), Centrifuge machine, 
Electrical aspirator, Vortex mixture, 2, 20, 200 and 1000 μl micro pipettes and pipette 
tips, Motorized Pipette Controller,  75 cm
2
/25 cm
2 
Culture flasks,  sterile forceps, 
aluminium foil, 5 and 10 ml disposable plastic pipettes, 15 ml and 50 ml centrifuge 
tubes, Cryovials, “Mr. Frosty” freezing container and liquid nitrogen, DMSO, clear 96-
well white plates, 0.22 μm  and 0.44 μm sterile filters, syringes, pasteur pipettes, 
Universal bottles, funnel 5 ml Volumetric flask, sterile spatula and clear bottom white 
96 well plates (Nunc or Grenier). 
2.1.4 Composition of medium for cell lines 
i. 1321N1 Dulbecco‟s Modified Eagle Medium (DMEM-500 ml), 10% Foetal 
bovine serum (FBS-50 ml), 2 mM L-glutamine (5 ml). 
ii. U-87 MG Minimal Essential Medium (MEM-500 ml), 10% Foetal bovine serum 
(FBS-50 ml), 2 mM L-glutamine (5 ml),1% Non Essential Amino Acids 
(NEAA- 5 ml), 1 mM Sodium Pyruvate (5 ml). 
iii. Gos-3 Dulbecco‟s Modified Eagle Medium (DMEM-500 ml), 10% Foetal 
bovine serum (FBS- 50 ml), 4 mM L-glutamine (10 ml). 
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iv. L6 muscle cell line Dulbecco‟s Modified Eagle Medium (DMEM-500 ml), 10% 
Foetal bovine serum (FBS-50 ml), 4 mM L-glutamine (10 ml). 
v. Sk Mel Minimal Essential Medium (MEM-500 ml), 10% Foetal bovine serum 
(FBS-50 ml), 1mM Sodium Pyruvate (5 ml), 1% Non Essential Amino Acids 
(NEAA- 5 ml). 
vi. Corl-23 RPMI-1640 (Roswell Park Memorial Institute), 2 mM L-glutamine (5 
ml). 10% Foetal bovine serum (FBS-50 ml). 
vii. Weri-Rb-1 RPMI-1640 (Roswell Park Memorial Institute), 2 mM L-glutamine 
(5 ml). 10% Foetal bovine serum (FBS-50 ml). 
2.1.5 Ethical consent 
Ethical and health and safety consents were granted by the Ethics Committee of the 
School of Pharmacy and Biomedical Sciences at University of Central Lancashire 
(UCLAN).  
2.2 Methods 
2.2.1 Extraction of crude water-soluble extract of M. charantia  
The unripe green fruits of M. charantia were obtained from the local market and 
subsequently cleaned and cut into small pieces (Karunanayake et al.1984). 
Approximately one kilogram of chopped green fruit was liquidized in distilled water for 
5-10 min using a blender. The juice was then kept in a hot water bath for 2 hrs at the 
temperature of 67°C. The fruit juice was centrifuged at 5000 RPM (Beckman, UK) for 
30 min. The suspension was removed and filtered through Whatmann filter paper (No: 4 
Whatmann, UK). The filtered green sample was then transferred to the 1000 ml round 
bottom rotating flask. The flask was then connected to the Rota evaporator machine 
through a clamp. The rotating flask was then heated by partial emersion in a hot water 
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bath at a temperature of 40°C. A typical 120 rpm speed was used for the flask rotation. 
The rota evaporated sample was then scrapped using spatula and dried overnight in an 
oven at 43°C. This crude water-soluble extract (powder) was stored at 2°C for further 
use. 
2.2.2 Extraction of crude methanol soluble extract of M. charantia 
The unripe green fruits of M.charantia were obtained from the local market and cleaned 
and cut into small pieces (Karunanayake et al.1984) and oven dried at 50°C about 48 
hrs until it reached a constant weight. The dried sample was then pulverized with a 
grinder into fine homogenous powder, which was stored at 2°C until used. An amount 
40 gm of the fine ground sample was extracted with 300 ml of methanol in a flask 
placed in an ultrasonic bath, containing water and the temperature was maintained at 
65°C for 90 min. The sample was cooled to room temperature and centrifuged at 2000 
rpm for 20 min. The suspension was removed and double filtered through Whatmann 
filter paper (No: 4 Whatmann, UK). The filtered sample was then transferred to the 500 
ml round bottom rotating flask. The flask was then connected to the Rota evaporator 
machine through a clamp. The rotating flask was then heated by partial emersion in a 
hot water bath at a temperature of 50 °C. A typical 100 rpm speed was used for the flask 
rotation. The Rota evaporated sample was then scrapped using spatula and stored at 2°C 
until used. 
2.2.3 Extraction method for either of alpha or beta momorcharin 
In this study alpha, beta or alpha beta momorcharin was purchased as a purified 
compound from IMAM International Group Pharmaceutical Company in China. 
According to the literature, the Company extracted, isolated and purified each 
compound using the following procedure. The whole fruit of bitter gourd was ground 
and homogenized in 2 mM sodium phosphate buffer, pH 7.5. The resulting slurry was 
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then stirred for 3 hrs to extract the crude proteins (Feng et al. 1996). The insoluble 
component from crude proteins was removed by the filtration and centrifugation at 
30,000 x g for 1 hour at 48°C. By using 2 mM sodium phosphate buffer, pH 7.5, the 
crude protein solution was dialysed. The dialysed protein sample was applied to DEAE 
Sepharose column equilibrated with 2 mM sodium phosphate buffer at pH 7.5. The 
unbound proteins was then applied to Mono-S column which was equilibrated by 2 mM 
sodium phosphate buffer at pH 7.5 and eluted by 0.5 m of NaCl  (Fong et al.1996). 
The fraction corresponding to either alpha and beta or alpha, beta momorcharin, which 
was confirmed the N-glycoside activity RNA, was concentrated and dialysed against 20 
mM Tris-HCl buffer, pH 7.8. The chromatography was performed on Bio Logic 
DuoFlow system (BioRad, Hercules, CA) at 48°C. The purity of alpha and beta or 
alpha, beta momorcharin was examined by SDS-PAGE and gel filtration 
chromatography. The concentration of alpha momorcharin was determined by 
spectrophotometrically using optical absorbance at A280 nm. 
2.2.4 Extraction method of beta momorcharin 
The whole fruit of bitter gourd was ground and homogenized in 2 mM sodium 
phosphate buffer, pH 7.5. The resulting slurry was then stirred for 3 hrs to extract the 
crude proteins (Fong et al. 1996). The insoluble components from crude proteins was 
removed by the filtration and centrifugation at 30,000 x g for 1 hour at 48°C. By using 2 
mM sodium phosphate buffer, pH 7.5 the crude protein solution was dialysed. The 
dialysed protein sample was applied to DEAE Sepharose column equilibrated with 2 
mM sodium phosphate buffer at pH 7.5. The unbound protein was then applied to 
Mono-S column, which was equilibrated by 2 mM sodium phosphate buffer at pH 7.5 
(Fong et al. 1996). 
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The fraction corresponding to beta momorcharin, which was confirmed by the N-
glycoside activity RNA was concentrated and dialysed against 20 Mm Tris-
hydrochloride buffer, pH 7.8. The chromatography was performed on BioLogic 
DuoFlow system (BioRad, Hercules, CA) at 48°C. The purity of beta momorcharin was 
examined by SDS-PAGE and gel filtration chromatography. The concentration of beta 
momorcharin was determined spectrophotometrically using A280 nm. 
2.3 Cell culture 
2.3.1 Passaging of the Cancer cell lines and Control cell line 
The culture medium, phosphate buffer solution (PBS), and trypsin (sterile) were 
removed from the fridge at 4
o
C and subsequently placed in the water bath at 37
o
C for 30 
min in order to equilibrate. The Laminar flow hood was turned on for 15 min, prior to 
start of the experiment, in order to purge the air inside the cabinet and to reach the 
maximum cleanliness. 
 The different cancer and normal cell lines were incubated at 37°C incubator in an 
atmosphere of 5% CO2 in air. The cells were examined under the inverted contrast 
microscope to note the both confluence and general health of the cells.  The flask was 
passaged when the cells had reached 70-80% confluence. 
The medium was aspirated from the cultured flask and was washed with sterile PBS (5 
ml if 75 cm
2
 flask and 2 ml if 25 cm
2
 flask) in order to remove any traces of serum from 
the cells. This prevented the serum from inactivating the trypsin which was used to 
detach adherent cells from the cell clump. Trypsin solution (2 ml if 75 cm
2
 flask or 1 ml 
if 25 cm
2
 flask) was pipetted in the flask and incubated at 37°C in an incubator in an 
atmosphere of 5% CO2 in air for 3-5 mins until the cells began to detach. The 
detachment was confirmed by observing at intervals under an inverted microscope. The 
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cells were left in the trypsin solution for the correct length of time. If the cells were left 
for a longer period of time then this would lead to damage of the cells. A volume of 3 
ml complete growth medium was then added to the flask to inactivate the trypsin and 
the cells were pipetted up and down to break up any large cell aggregates. The cell 
suspension was transferred from flask into 15 ml centrifuge tube and centrifuged at 
1000 rpm for 5 min. Following centrifugation, the supernatant was aspirated and the 
cells were pellet at the bottom of the centrifuge tube. Based upon the cell pellet density 
volumes of 1 ml to 3 ml fresh medium were suspended in the centrifuge tube. The cell 
pellet was flicked properly in the medium containing 20 μl of trypsinised cell 
suspension and 80 μl of tryphan blue (used to detect dead cells in the cell suspension 1:5 
ratio). The contents were mixed well together and a haemocytometer test was performed 
using 1 ml of cell suspensions. This process helped to assess the total number of the cell 
suspension present in the centrifuge tube and which was required to make 1 or 2 flasks 
and to do 96 well plates. Thereafter, the cells were frozen in liquid nitrogen depending 
on the number of cells present per ml. The cell suspension was divided in either one or 
several flasks (depending on the cell density) and fresh growth medium (10 ml to 12 ml 
if 75 cm
2
 flask and 5 ml if 25 cm
2
 flask) was added to the flasks. These were then 
placed in a 5% CO
2 
incubator to continue cell growth.  
2.3.2 Cell Counting Method  
A volume of 20 μl of cell suspension and 80 μl of tryphan blue (1:5 ratio) were pipetted 
into a microcentrifuge tube and mixed together. A coverslip was gently pushed over the 
chambers of a haemocytometer and 20 μl of cell suspension was slowly pipetted against 
each short side of the coverslip so that the suspension could spread into each chamber. 
The haemocytometer was placed onto the stage of an inverted phase contrast 
microscope and focused on the central 25 squares of one chamber. The numbers of cells 
91 
 
in these squares were counted. These steps were repeated for the other chambers. The 
average number of cells in the centre grid (1 mm
2
) of each chamber was calculated. This 
number was multiplied by 10
4 
to obtain the number of cells per 1 ml of suspension. The 
total number of cells was calculated by multiplying the number of cells per 1 ml by the 
total volume of the cell suspension. 
2.3.3 Cryopreservation of cells 
The cell suspension obtained during passaging was divided into stocks and they were 
either stored for long periods or cryopreserved. This involved slowly freezing the cells 
down in culture medium supplemented with a cryoprotectant, which helped to protect 
the cells from rupture due to formation of ice crystals. The most commonly used 
cryoprotectant employed in this study was dimethyl sulphoxide (DMSO). The cell 
suspension of 900 μl was mixed with 100 μl of DMSO. Together, they contained 
approximately 1 million cells, which were subsequently frozen at -80
o
C. The cell 
populations normally survived the freezing process with high cell viability. This was 
done by the use of a freezing medium that consisted of the normal culture medium 
supplemented with 10% DMSO. However, it was common practice to increase the 
proportion of serum in the medium up to 90%. The most important principle of 
cryopreservation involved the cells being frozen down slowly at a rate of 1-3
o
C and 
thawed out quickly in a 37
o
C water bath. The vial container was also frozen in a bath of 
isopropyl alcohol called “Mr. Frosty”, which mediated a 1oC/min cooling of the 
cryovials in a -80
o
C freezer prior to storage at a temperature below -135
o
C in either 
vapour or liquid phase nitrogen. The isopropyl alcohol could only be used 5 times 
before it needed replacing.  
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2.4 Cell Viability Experiments   
2.4.1 Preparation and application of crude water-soluble and methanol soluble  
extracts of M. charantia on the cancer and L6 cell lines. 
An amount of 30 mg of the crude water-soluble extract of M. charantia was initially 
dissolved in 500 µl of phosphate buffer by continuous stirring and with the brief use of 
a sonicator water bath. This was made up to 5 ml by adding 4.5 ml of the cell medium. 
The water-soluble crude extract stock solution was transferred to a 10 ml syringe and 
sterile filtered using 0.22 µm filters into other sterile 10 ml Universal bottles. These 
stock solutions were stored in a sealed tube in the fridge until required. Once removed 
from the fridge, the prepared crude water-soluble extract of M. charantia solutions were 
gently warmed in water bath at 37°C in order to ensure that the water-soluble and 
methanol soluble crude extract was mixed complete in solution, before aliquoting. 
Volumes of 34 μl, 68 μl, 102 μl, 136 μl contained 200 µg, 400 µg, 600 µg, and 800 µg 
of the crude water-soluble extract of M. charantia respectively. Different concentration 
of either water or methanol soluble crude extract in cell medium was transferred in 
triplicate using a Gilson pipette to 96 well plates to give a final volume of 200 μl to the 
treated cell wells. An equivalent volume of 200 μl of the medium was added to the 
control (untreated) well with cells. In this study, both time course and dose-dependent 
experiments were performed. The time-course experiments were done over a period of 
48 hours, where the dose dependent experiments were done during incubation period of 
24 hrs. 
2.4.2 Time-course experiments 
Cell suspensions of either 1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1 or L6 
obtained during passaging were diluted (1:10 ratio). The required volumes of cell 
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suspensions and fresh medium volumes were calculated based on the number of wells to 
be plated. The dilution was done such that 200 μl of each suspension contained 2500 
cells. After seeding the cells, the plates (transparent 96 well plates) were incubated for 
6, 12, 18, 24 and 48 hrs at 37°C in a 5% CO
2 
incubator. After each time period the 
media from 96 well plates were tipped out completely on sterile tissue paper. The drug 
stock solution was transferred to a 10 ml syringe and sterile filtered using 0.22 µm 
filters into another sterile 15 ml centrifuge tube. A volume of 100 μl of cell medium 
(sterile filtered) contains 800 μg of crude water-soluble extract of M. charantia was then 
added to the 96 well plates. The 96-well plates were incubated for 6, 12, 18, 24 and 48 
hours at 37°C in a 5% CO
2 
incubator. In another series of control experiments, the 
different cancer cell lines were incubated in 96 well plates for the same period but in the 
absence of any extract of M. charantia. Following every 6 hrs of incubation, the plate 
for either test and control was removed from incubator for 30 min. MTS procedure was 
carried out in the transparent 96 well plates (Griner, UK). A volume of 20 µl of MTS 
assay sample was added to wells containing both treated and untreated cells. The ratio 
resulted in a final concentration of 317 µg/ml MTS assay in the assay wells. Each plate 
was then placed in the incubator at 37°C in a 5 % CO2 atmosphere for 90-120 min. The 
absorbance‟s was measured at a 492 nm wavelength, and 30 sec of shaking time and 30 
sec for the settling time in the plate reader. The absorbances of the crude extract alone at 
different time points in the medium were also measured as background sequence. These 
values were subtracted from the test values at the different time points. The same was 
also done for the dose-dependent experiments or a combination of extracts with drug. 
2.4.3 Dose - dependent experiments 
In this series of experiments, the experimental procedure was the same except that the 
test cells were incubated with different concentrations of each extract for 24 hrs. Initial 
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experiments established maximum cell viability at 24 hrs of incubation with the crude 
water-soluble extract of M. charantia. 
 Cell suspensions of either 1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1 or 
L6 obtained during passaging were diluted (1:10 ratio). The required volume of cell 
suspension and fresh medium volume were calculated based on number of wells to be 
plated. The dilution was done such that 200 μl of the suspension contained 2500 cells. 
After  seeding the cells, the plates (transparent 96 well plates) were incubated for 24 hrs 
at 37°C in a 5% CO
2 
incubator. Control 96 well plates were incubated for 24 hrs in the 
absence of extracts. After 24 hrs the media from 96 well plates were tipped out 
completely on sterile tissue paper. The drug stock solution was transferred to a 10 ml 
syringe and sterile filtered using 0.22 µm filters into another sterile 15 ml centrifuge 
tube. These stock solutions were stored in a sealed tube in the fridge until required. A 
volume of 100 μl of cell medium (sterile filtered) contained extract concentrations of 
200 μg, 400 μg, 600 μg, 800 μg in the 96 well plates. After the supplement of the crude 
extract, the 96-well plate was again incubated for 24 hrs at 37°C in a 5% CO
2 
incubator. 
Following 24 hrs of incubation, each plate was removed from incubator for 30 min. 
MTS procedure was carried out in the transparent 96 well plates (Griner, UK). A 
volume of 20 µl of MTS assay sample was added to wells containing both treated and 
untreated cells. The ratio resulted in a final concentration of 317 µg/ml MTS assay in 
the assay wells. The plate was then placed in the incubator at 37°C in 5 % CO2 
atmosphere for 90-120 min. The absorbance was measured at a 492 nm wavelength by 
initial 30 sec of shaking time and 30 sec of settling time of the plate in the plate reader. 
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2.4.4 Preparation and application of either alpha or beta momorcharin and alpha, 
beta momorcharin on the cancer and L6 cell lines. 
Amounts of 14.51 mg, 29.25 mg, 43.53 mg, 58.50 mg, and 72.57 mg of either alpha or 
beta momorcharin and alpha, beta momorcharins (9.7 kDa) were weighed out separately 
in 5 ml universal vials and initially dissolved in 500 µl of phosphate buffer by 
continuous stirring and with the brief use of a sonicator water bath. These were then 
made up to 5 ml by adding 4.5 ml of the cell medium to give concentrations 200 µM, 
400 µM, 600 µM, 800 µM, 1000 µM, respectively. The drug (extract) stock solution 
was transferred to a 10 ml syringe and sterile filtered using 0.22 µm filters into another 
sterile 10 ml Universal bottles. These stock solutions were stored in a sealed tube in the 
fridge until required. Once removed from the fridge the prepared drug (extract) 
solutions were gently warmed in water bath at 37°C in order to ensure that the alpha, 
beta momorcharins or alpha and beta momorcharin was in a complete solution, before 
aliquoting. Volumes of 40 μl, 80 μl, 120 μl, 160 μl, 200 μl contained 200 µM, 400 µM, 
600 µM, 800 µM, 1000 µM, respectively. Different concentrations of either alpha beta 
momorcharins and alpha, beta momorcharin were transferred in triplicate using a Gilson 
pipette to 96 wells plate and the volume made to 200 μl by adding the cell media to both 
treated and control cell wells. Both control (untreated) and treated with (either alpha, 
beta and alpha, beta momorcharin) 96 well plates were incubated for 24 hrs. After the 
incubation period cell viability was measured as described above. 
2.4.5 Dose dependent effects of either TEM or vinblastine on cancer cell line 
viability 
In this series of experiments, different cancer cell lines (1231N1, Gos-3, U87-MG, Weri 
Rd-1, Corl-23, Sk Mel) and healthy L6 muscle cell line were incubated with the 
different concentrations of either TEM (80 - 320 µM) or vinblastine (10 - 40 μg) for 24 
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hours. Control cell lines were also incubated for the same period of time but without any 
TEM or vinblastine. At the end of the incubation period, cell viability of each cell line 
was measured using the MTS assay as described below. 
2.5 Combined effects of either temozolomide or vinblastine with the crude water- 
soluble extract of   M. charantia or alpha, beta momorcharin 
Since both the commercial anti-cancer drugs and either the crude water-soluble extract 
of M. charantia or alpha, beta momorcharin could elicit significant decreases in cell 
viability, it was decided to investigate the combined effects of these anti-cancer agents 
(drug + extract) on cell viability. Different cancer cell lines (1231N1, Gos-3, U87-MG, 
Weri Rd-1,Corl-23, Sk Mel) and healthy L6 muscle cell line were incubated with either 
temozolomide (240 µM) and the water-soluble extract of M. charantia ( 800 µg) or 
temozolomide (240 µM) and (800 µM) of the alpha, beta momorcharin for 24 hours. 
Similarly, each cell was incubated with either vinblastine (30 µg) and the water-soluble 
extract of M. charantia (800 µg) or vinblastine (30 µg) and (800 µM) of the alpha, beta 
momorcharin for 24 hours. Control cell lines were also incubated for the same time but 
without any drug or extract. At the end of the incubation period, cell viability of each 
cell line was measured using the MTS assay. 
2.5.1 Measurement of caspase-3 assay  
The six different cancer cells lines were incubated with either 800 µg crude water-
soluble extract of M. charantia or 800 µM alpha, beta momorcharin. The induced 
apoptosis cell suspension contained roughly 10
7
 cells. A sample of non-induced cells for 
a zero-time (control) also contained 10
7
 cells. The induced and non-induced cells were 
incubated for 24 hrs at 37°C in 5 % CO2 atmosphere. The induced cells and the control 
cells were transferred to 15 ml centrifuge tube and centrifugation at 600 x g for 5 min at 
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4 °C. The supernatant was removed by gentle aspiration for both induced and control 
cell suspensions. The cells were then pelleted and washed once with 1 ml of phosphate 
buffer solution (PBS) and centrifuged at 5000 rpm for 5 min and the supernatant was 
completely removed by gentle aspiration. The centrifuged cell pellets were then treated 
with 1 X lysis buffer at a concentration of 100 μl per 107 cells, and the cells were 
incubated on a ice for 15-20 min. The lysed cells were centrifuged at 16,000 to 20,000 x 
g for 10 to 15 min at 4 °C and the supernatants were transferred to new 1 ml tube and 
subsequently frozen in liquid nitrogen and stored in aliquots at -70°C for further use 
(see table 2.1 for reaction scheme). All the values were expressed as μmol/min/ml. 
2.5.2 Determination of protein concentration by Bradford assay 
 The protein concentration of each sample was measured based on the method of 
Bradford (Bradford, 1976). Bovine serum albumin (BSA) stock solution was diluted 
with double distilled water concentrations of 2 µg/ml, 3 µg/ml, 4 µg/ml, 5 µg/ml, 6 
µg/ml, 7 µg/ml, 8 µg/ml, 9 µg/ml and 10 µg/ml for the standard solutions. In flat bottom 
transparent 96 well plates volumes of 20 µl of dye reagent and 80 µl of either BSA or 
protein sample  added. The mixtures were rota mixed for 30-40 sec and kept in an 
incubator for 10 min. The absorbance of each standard was measured at 595 nm 
wavelength recorded and generated as a standard curve. The protein concentration for 
each sample was determined by extrapolating the intersection of the standard curve at a 
point corresponding 2 to 10 µg/ml. All values were expressed as µg/ml. 
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  Test  Samples 
 
 
Cell lysate 
 
 
Caspase-3 
5µg/ml 
 
 
1x Assay 
buffer 
Caspase-3 
inhibitor 
Ac-DEVD-
CHO 
200 µM 
Caspase-3 
substrate 
Ac-DEVD-
pNA 
2mM 
 
Reagent     blank 
 
 
    ----- 
 
----- 
 
 
90µl 
 
----- 
 
10 µl 
 
Non-induced 
cells 
 
 
5 µl 
 
----- 
 
 
85 µl 
 
----- 
 
10 µl 
 
Non-induced 
cells + inhibitor 
 
 
 
5 µl 
 
----- 
 
 
 
75 µl 
 
 
10 µl 
 
 
10 µl 
 
Induced cells 
 
 
5 µl 
 
----- 
 
 
85 µl 
 
----- 
 
10 µl 
 
Induced cells + 
inhibitor 
 
 
5 µl 
 
 
----- 
 
  
 75 µl 
 
10 µl 
 
10 µl 
 
Caspase -3 
positive control 
 
 
 
----- 
 
 
 
 
5 µl 
 
 
 
85 µl 
 
 
----- 
 
 
10 µl 
 
Caspase -3 
positive control + 
inhibitor 
 
 
 
 
      ----- 
 
 
5 µl 
 
 
 
75 µl 
 
 
10 µl 
 
 
10 µl 
                  
                   Table 2.1: Reaction scheme for 96 well plate microassay method.    
(Adapted from www.Sigmaaldrich.com, April 2006) 
2.5.3 Calibration curve of P-nitroaniline (PNA) 
A series of p-nitroaniline solutions was prepared at a concentration range of 10 to 200 
µM by diluting the p-nitroaniline stock solution in the 1 X Assay Buffer (see table 2.2 
for reaction scheme). A volume 100 µl in duplicate was added into 96 well plates, 
including 100 µl of assay buffer as a blank. The absorbance was measured at 405 nm. 
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The calibration curve was plotted using absorbance values versus the concentrations of 
the p-nitroaniline solutions.      
μM p-Nitoaniline μmol p-Nitroaniline 
10 0.001 
20 0.002 
50 0.005 
100 0.01 
200 0.02 
                 Table 2.2: Reaction scheme for calibration curve of p-nitroaniline 
Calculation. 
 Caspase 3 activity was calculated in μmol pNA released per min per ml of cell lysate or 
Positive control based on the formula: 
 
 
 
 
Where: 
v - Volume of sample in ml, d - Dilution factor, t - Reaction time in minutes. 
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2.5.4 Measurement of Caspase -9 activity 
 
Figure 2.1: Schematic diagram of the Caspase-Glo® 9 Assay protocol 
(Adapted from www.promega.com/automethods/2004) 
The six different cancer cells lines and L6 cell line were incubated with either 800 µg 
crude water-soluble extract of M. charantia or 800 µM alpha, beta momorcharin. The 
induced apoptosis cell suspension contained roughly 10
7
cells. A sample of non-induced 
cells for a zero-time control also contained 10
7
cells. The induced and non-induced cells 
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were incubated for 24 hrs at 37°C in 5 % CO2 atmosphere. Prior to starting the assay the 
prepared sample of Caspase-Glo® 9 reagents was equilibrated to room temperature. 
After 24 hr prior to the experiment, each plate (96 well plates GRE 96 fb) was removed 
from the incubator for 30 min to equilibrate to room temperature (see the figure 2.1 for 
protocol). A volume of 100 μl of Caspase-Glo® 9 assay reagent was added to each well 
of a white walled 96 well plate containing 100 μl of blank and treated cells in the 
culture medium. The plate was then covered with the aluminium foil. The covered plate 
was then mixed gently by using a plate shaker at 300-500 rpm for 2 min. The plate was 
then incubated at room temperature for 30 min. The Caspase-Glo® 9 assay was carried 
in the absence of light. The Luminescence was measured on a Techan Plate reader with 
the appropriate settings for the plate. The software used for the Luminescence assay was 
XFLUORHGENIOSPRO version V 4.53. The plate type used from the software was 
specified as GRE 96 fb Pdf. The temperature was stated to be 20 - 23°C. All the values 
were expressed as μmol/min/ml. 
2.5.5 Measurement of cytochrome-c release 
The six different cancer cells lines and L6 cell line were incubated with either 800 µg 
crude water-soluble extract of M. charantia or 800 µM alpha, beta momorcharin. The 
induced apoptosis cell suspension contained roughly 10
7
 cells. A sample of non-induced 
cells for a zero-time control also contained 10
7
 cells. The induced and non-induced cells 
were incubated for 24 hrs at 37°C in 5 % CO2 atmosphere. The induced cells and the 
control cells were transferred to 15 ml centrifuge tube and centrifugation at 1000 x g for 
5 min at 4 °C. The supernatant was removed by gentle aspiration of both induced and 
control. The cell pellets were then washed once with 1 ml of PBS. The microsomal 
pellet was subsequently obtained by centrifuging at 12,000 x g supernatant for 1 hour at 
100,000 x g and the supernatant was removed completely by gentle aspiration. The 
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centrifuged cell pellets were then treated with 1 X lysis buffer at a concentration of 100 
μl per 107 cells, and the cells were incubated on ice for 15-20 min. The lysed cells were 
centrifuged at 16,000 to 20,000 x g for 10 to 15 min at 4°C and the supernatants were 
transferred to new 1 ml tube and subsequently frozen in liquid nitrogen and stored in 
aliquots at -70°C for further use. Table 2.3 showed the experimental protocol for the 
cytochrome-c assay. A volume of 950 µl of the working solution (9 mg of cytochrome-c 
to 20 ml of assay buffer to get a concentration of 0.45 mg/ml, 36 mM) was made up by 
adding 9 mg of cytochrome-c to 20 ml of the assay buffer in a 1 ml cuvette. A volume 
of 50 µl of the test sample was added to 1 ml cuvette containing the working solution. 
For the sample, which had interference from cytochrome-c oxidase activity, a volume of 
20 µl of cytochrome-c oxidase inhibitor solution was used for the positive control 
reaction. The positive control was obtained by diluting an aliquot of the cytochrome-c 
reductase (NADPH) 10-fold with the enzyme dilution buffer.  Each set of reactions 
required a total of 75 ml of the diluted positive control. A volume of 100 µl NADPH 
solutions was added to start the reaction. The blank reaction was measured by the value 
given by the reagents alone without enzyme present. 
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Test 
samples 
Working 
Solution 
Enzyme 
Dilution 
Buffer 
Sample or 
Positive 
Control 
NADPH 
Solution O.85 
mg/ml 
Inhibitor 
solution 
 
Blank 
 
 
950 µl 
 
50 µl 
 
----- 
 
    100 µl 
 
----- 
Unknown 
sample 
 
 
950 µl 
 
50 - X µl 
 
X µl 
 
    100 µl 
 
----- 
Unknown 
sample with 
interference 
 
 
950 µl 
 
30- X µl 
 
X µl 
 
    100 µl 
 
20 µl 
Positive 
control 
(10-fold 
dilution) 
 
 
950 µl 
 
25 µl 
 
25 µl 
 
    100 µl 
 
----- 
Positive 
control 
(10-fold 
dilution) 
 
 
950 µl 
 
----- 
 
50 µl 
    
    100 µl 
 
----- 
 
             Table 2.3: Reaction scheme outline to measure cytochrome–c activity 
(Adapted from www.Sigmaaldrich.com, June 2009) 
X= Volume of unknown sample 
Calculation: 
 
Unit definition: One unit could reduce 1.0 µmole of oxidized cytochrome-c in the 
presence of 100 µM, NADPH per minute at pH 7.8 at 25°C 
 
  
 
ΔA550/min = ΔAsample - ΔAblank 
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dil = the dilution factor of the original enzyme sample 
Enzvol = volume of the enzyme sample (ml) 
21.1 = extinction coefficient (EmM) for reduced cytochrome c 
1.1 = Reaction volume (ml) 
The reaction time is longer than 1 minute; divide the ΔA550 by the reaction time to 
obtain 
ΔA550 / min. All the values for cytochrome -c were expressed as units/ml. 
2.5.6 Measurement of intracellular free calcium [Ca
2+
]i using a fluorescence micro 
plate reader. 
Measurement of [Ca
2+
]i was performed as previously described in the literature 
(Robinson et al.2004). The measurement of [Ca
2+
]i was performed by seeding a density 
of 10,000 cells/well in black 96 well plates (Griner, UK) in 100 µl of growth medium. 
At sub confluence, the cell culture medium was then replaced with FBS free medium 
for 24 hr in order to synchronize cells into a non-proliferation stage. The cell were then 
loaded with  25 µM Fura-2  acetoxylmethyl ester (AM) in cell medium at 37°C for 30 
min followed by 30 min at temperature to minimize dye leakage and sequestration into 
intracellular organelles. After loading, the cells were washed 2-3 times with 200 µl of 
Hank‟s Buffered Salt Solution (HBSS) to remove excess fluorescent dye. The cells were 
then treated with either crude water-soluble extract of M. charantia (800 µg) or with 
800 µM of alpha, beta momorcharin for different durations (0 min - 420 min) in a 
calcium free medium. The cells were washed twice with 200 µl HBSS and then a 
volume of 100 µl HBSS /wells was added to each well. The same procedure was carried 
out for the untreated cells. The intensity of the fluorescence‟s of Fura-2 AM was 
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measured at emission wavelengths of 340 nm. The relative changes in calcium 
concentration using Fura-2 AM were determined by calculations of 
                                    [[Ca 
2+ 
]i = Kd β (f – f min) / (f max – f).         
Kd, the Ca-Fura-2 dissociation constant, β the fluorescence intensity ratio, excited at 380 
nm without and with Ca; f min and f max (Robinson et al., 2004). All values were 
expressed as ratio units of the Fura-2 AM fluorescent intensity. 
2.6 Statistical Analysis 
All control and test data collected from the different experiments were analysed using 
Statistical Package for Social Sciences (SPSS) version 17, Student‟s – t test and 
ANOVA test. Data obtained were expressed as mean ± standard deviation (S.D). Each 
experiment was repeated for 4-6 times in duplicate (6 for cell viability and 4 for cell 
signalling) to ensure the accuracy of results. A value of (p < 0.05) was taken as 
significant. 
 
 
 
 
 
 
 
 
 
106 
 
 
 
 
Chapter Three 
 
Effects of different extracts of the fruit 
Momordica charantia, alpha beta 
momorcharin and commercial anti-
cancer drugs on cancer cell line 
viability in vitro 
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3. Introduction 
The present study investigated the anti-cancer effects of two extracts (the crude water-
soluble extract and methanol soluble) of the fruit of M. charantia, and three isolated 
and purified proteins from M. charantia (α momorcharin, β momorcharin and α,β 
momorcharin) and two commercially available anti-cancer drugs namely vinblastine 
and temozolomide, either alone or in combination on different cancer cell lines in vitro 
measuring cell viability compared to healthy L6 skeletal muscle cell line. 
3.1 Methods 
As described in Chapter 2, section 2.4. 
3.2 Results  
3.2.1 Morphology of untreated and treated cell lines 
Figure 3.1 shows confocal images of the morphology of (A) untreated, (B) treated 
1321N1 cell line with 800 µg of the crude water-soluble extract of M. charantia and (C) 
treated 1321N1 cell line with 800 µM of the α,β momorcharin. 1 × 10 6 cells/mL cells 
were treated for 24 hours. The results in figure 3.1A show the normal structure of 
numerous 1321N1 cells growing in the medium. In contrast, figure 3.1B/C shows the 
same cells line following 24 hours of incubation with either crude water-soluble extract 
of M. charantia or with α, β momorcharin. However, in this case, the numbers of cells 
have markedly decreased and structurally, they look different from untreated cells 
(figure 3.1A). They have lost their neuronal-like structures and they seem to have a 
donought shape. 
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Figure 3.1: Confocal images, at 40X magnification, showing the morphology of (A) 
untreated (B) treated 1321N1 cell line with either 800 µg of the crude water-soluble 
extract of M. charantia or treated with 800 µM of the α, β momorcharin (C). Cells were 
treated for 24 hr. Micrographs are typical of 6 such different experiments and they were 
assessed for cell viability. Note the black arrows indicate membrane blebbing of 
individual cells under going apoptosis and cells detached from the surface and from one 
another, decrease in cell viability, the donought-like structure and the loss of neuronal 
like glands following treatment with the crude water-soluble extract of M.charantia or 
with α, β momorcharin  
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Figure 3.2 Figure 3.2 shows confocal images of the morphology of (A) untreated and 
treated Gos-3 cell line with 800 µg of the crude water-soluble extract of M. charantia 
(B)  treated Gos-3 cell line with 800 µM of the α, β momorcharin (C). The result in 
figure 3.2A shows the normal structure of numerous Gos-3 cells growing in the 
medium. In contrast, figure 3.2B/C shows the same cell line following 24 hours of 
incubation with either M. charantia or α, β momorcharin, respectively but in this case 
the treated cells seem to decrease in number. In addition the treated cells seem to shrink 
and they developed a round shape and they have lost their neuronal-like structure.  
Figure 3.3 shows confocal images of the morphology of (A) untreated and treated U87-
MG cell line with either 800 µg of the crude water-soluble extract of M. charantia (B) 
or treated or with 800 µM of the α, β momorcharin (C). The results in figure 3.3A show 
the normal structure of numerous U87-MG cells growing in the medium. In contrast, 
figure 3.3B/C shows the same cell line following 24 hours of incubation with either     
M. charantia or with α, β momorcharin, respectively. Here, the numbers of cells have 
decreased markedly and structurally, they look different from untreated cells. Typically, 
they seem to have a donought like (ring) structure and they have lost their neuronal-like 
features. 
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Figure 3.2: Confocal images at 40X magnification showing the morphology of (A) 
untreated (B) treated Gos-3 cell line with either 800 µg of the crude water-soluble 
extract of M. charantia or treated with either 800 µM of the α, β momorcharin (C). 
Cells were treated for 24 hrs. Micrographs are typical of six such different experiments 
and they were assessed for cell viability. Note the black arrows indicate decrease in 
cellular density, condensation, fragmentation, the number and structure of the treated 
cells in B and C compared to untreated cells in A. 
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Figure 3.3: Confocal images at 40X magnification showing the morphology of (A) 
untreated (B) treated U87-MG cell line with either 800 µg of the crude water-soluble 
extract of M. charantia or  treated with 800 µM of the α, β momorcharin (C). Cells were 
treated for 24 hrs. Micrographs are typical of six such different experiments and they 
were assessed for cell viability. Note the black arrows indicate decrease in cellular 
density, condensation, fragmentation, the number and structure of the treated cells in B 
and C compared to untreated cells in A. 
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Figure 3.4 shows confocal images of the morphology of (A) untreated and treated Sk-
Mel cell line with either 800 µg of the crude water-soluble extract of M. charantia (B)  
or with 800 µM of the α, β momorcharin (C). The results in figure 3.4A show the 
normal structure of numerous Sk-Mel cells growing in the medium. In contrast, figure 
3.4B/C shows the same cell line following 24 hours of incubation with either               
M. charantia or with α,β momorcharin, respectively. Here, the numbers of cells have 
decreased significantly compared to control and structurally, they look different from 
untreated cells. They seem to clump together which is typical of apoptosis or cell death. 
 
Figure 3.5 shows confocal images of the morphology of (A) untreated and treated Corl-
23  cell line with either 800 µg of the crude water-soluble extract of M. charantia (B) or 
with 800 µM of the α, β momorcharin (C). The results in figure 3.5A show the normal 
structure of numerous Corl-23 cells growing in the medium. In contrast, figure 3.5B/C 
shows the same cell line following 24 hours of incubation with either M. charantia or 
with α, β momorcharin, respectively. Here, the numbers of cells seem to decrease and 
structurally, they look smaller and they seem to separate from one another.  
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Figure 3.4: Confocal images, at 40X magnification, showing the morphology of (A) 
untreated (B) treated Sk-Mel cell line with either 800 µg of the crude water-soluble 
extract of M. charantia or with 800 µM of the α,β momorcharin (C). Cells were treated 
for 24 hrs. Micrographs are typical of six such different experiments and they were 
assessed for cell viability. Note the black arrows indicate membrane blebbing of 
individual cells under going apoptosis and cells detached from the surface and from one 
another, decrease in cell viability the reduction in number and structural difference in 
treated (B/C) compared to untreated (A) cells. 
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Figure 3.5: Confocal images, at 40X magnification, showing the morphology of (A) 
untreated (B) treated Corl-23 cell line with either 800 µg of the crude water-soluble 
extract of M. charantia or  with 800 µM of the α, β momorcharin (C). Cells were treated 
for 24 hrs. Micrographs are typical of six such different experiments and they were 
assessed for cell viability. Note the black arrows indicate decrease in the number of 
treated cells, cellular density, condensation, fragmentation and blebbing of and their 
structural difference (B/C) compared to untreated cells (A).  
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Figure 3.6 shows confocal images of the morphology of (A) untreated and treated 
WeriRb-1 cell line with either 800 µg of the crude water-soluble extract of M. charantia 
(B) or with 800 µM of the α, β momorcharin (C). The results in the figure 3.6A show 
the normal structure of numerous WeriRb-1 cells growing in the medium. In contrast, 
figure 3.6B/C shows the same cell line following 24 hours of incubation with either    
M. charantia or with α, β momorcharin, respectively. Here, the number of cells seems 
to decrease and structurally, they look different from untreated cells. Several cells seem 
to clump together which is typical of cell death during apoptosis. 
 
Figure 3.7 shows confocal images of the morphology of (A) untreated and treated L6 
skeletal muscle cell line with either 800 µg of the crude water-soluble extract of M. 
charantia (B) or with 800 µM of the α, β momorcharin (C). The results in the figure 
3.7A show the normal structure of numerous L6 cells growing in the medium. 
Similarly, figure 3.7B/C shows the same cell line following 24 hours of incubation with 
either M. charantia or with α, β momorcharin, respectively. Here, the number of cells 
seemed to be the same and with the similar structure.  
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Figure 3.6: Confocal images, at 40X magnification, showing the morphology of (A) 
untreated (B)  treated Weri Rb-1 cell line with either 800 µg of the crude water-soluble 
extract of M. Charantia or with 800 µM of the α,β momorcharin (C). Cells were treated 
for 24 hrs. Micrographs are typical of six such different experiments and they were 
assessed for cell viability. Note the the black arrows indicate decrease in number and 
the clumping to the treated cells (B/C) compared to untreated cells (A).  
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Figure 3.7: Confocal images, at 40X magnification, showing the morphology of (A) 
untreated (B) treated L6 muscle cell line with either 800 µg of the crude water-soluble 
extract of M. charantia  or with 800 µM of the α, β momorcharin (C). Cells were treated 
for 24 hr. Micrographs are typical of 4-6 such different experiments and they were 
assessed for cell viability. Note that back arrows indicate the cells growing normaly 
attached to the surface of the flask in both untreated and treated cells look similar. 
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3.2.2 Time-course effects of the crude water-soluble extract of M. charantia on cell 
viability 
Figure 3.8 shows the time-course effects of 800 μg  of the crude water-soluble extract of 
M. charantia on the viability of different cancer cell lines (1231N1, Gos-3, U87-MG, 
Weri Rd-1, Corl-23, Sk Mel) and healthy L6 muscle cell line. Each cell line was 
incubated with the extract for 6, 12, 18, 24 and 48 hours. Also shown in the figure 3.8 is 
healthy L6 skeletal muscle cell line incubated with both extracts for the same time for 
comparison. All the cells were treated for up to 48 hours. The results show that in all six 
different cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1), the 
crude water-soluble extract of M. charantia can evoke marked and significant (p < 0.05) 
decreases in the cell viability (cell death) compared to untreated cells. From these initial 
time- course experiments, it was established that cell viability (cell death) decreased to 
its maximal level after 24 hours of incubation with the crude water-soluble extract of M. 
charantia. No further sygnificant effect on cell viability was observed at 48 hours of 
incubation compared to 24 hrs. The incubation time of 24 hours was employed in all the 
dose dependent experiments of this study. The results also presented in figure 3.8 also 
show that the crude water-soluble extract of M. charantia had little or no effect on the 
death of the healthy L6 skeletal muscle cell line. 
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Figure 3.8: The time-course effects of 800 µg of crude water-soluble extract of M. charantia on the viability of six different cancer cell lines (1321N1, 
Gos-3, U87- MG, Sk Mel-2, Corl -23, Weri Rb-1) and on healthy L6 muscle cell line for comparison. Cell lines incubated at the same time point 
without any extract are also shown in the figure for comparison. Solid straight line shows the 100 % values for each time point. Cell viability for each 
time point was expressed as percentage of the respective control (no extract, but only cells in medium) at each time point of incubation. Each cell line 
was incubated with the crude water-soluble extract of M. charantia for up to 48 hrs. All Data are mean ± SD, n = 6 different experiments in duplicate; * 
p < 0.05 for all test samples compared to control (100 %). 
120 
 
3.3.3 Dose-dependent effects of the crude water and methanol soluble extracts of   
M. charantia, α momorcharin, β momorcharin and α, β momorcharin on cell 
viability.  
Figure 3.9 shows the effects of different concentrations (200 - 800 μg) of the crude 
water-soluble extract of M. charantia on the viability of the six different cancer cell 
lines and on healthy L6 skeletal muscle cell line employed in this study. Also shown 
in the figure 3.9 are the untreated six different cancer cell lines and healthy L6 
skeletal muscle cell line for comparison. All the cells were treated with the crude 
water-soluble extract of M. charantia for 24 hours. Control (untreated) cell lines 
were also incubated for 24 hrs but without any extract. The results show that in all 
six different cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-
1), the crude water-soluble extract of M. charantia evoked  marked and significant (p 
< 0.05) decreases in the cell viability (cell death) compared to untreated cells (100% 
viability). These effects of the crude extract were dose-dependent with maximal cell 
death occurring with 600 μg and which was not significantly p > 0.05 different from 
800 μg. In contrast, the crude water-soluble extract of M. charantia had a little or no 
effect on the death of healthy L6 skeletal muscle cell line for comparison. The result 
also show that the crude extract was more effective in killing 1321N1, Sk Mel and 
Corl-23 cell lines compared to its effect on Gos-3 and U87-MG cell lines. 
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Figure 3.9: Bar charts showing the effects of different concentrations (200 - 800 µg) of  the crude water-soluble extract of M. charantia on the 
viability of six different cancer cell lines (1321N1, Gos-3, U87- MG, Sk Mel-2, Corl -23, Weri Rb-1) and healthy L6 muscle cell line for 
comparison. The untreated (no crude extract) cell line for each (first bar chart) is also shown as 100% in the figure for comparison. Each cell line 
was incubated with the  crude water-soluble extract of M. charantia for 24 hrs. Data are mean ± SD, n = 6 different experiments in duplicate; (* 
p<0.05) for untreated (100 % viability) compared to the treated cells for the different concentrations. Note the pronounced anti-cancer effects of 
the crude water-soluble extract of M. charantia on 1321N1, SkMel and Corl-23 compared to the other cancer cell lines.
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Figure 3.10 shows the effect of different concentrations (200 - 800 μg) of the crude 
methanol soluble extract of M. charantia on the viability of the six different cancer cell 
lines and healthy L6 muscle cell lines for comparison. All the cells were treated for 24 
hours with the crude methanol soluble extract of M. charantia. Control cell lines were 
also incubated for 24 hrs but without any extract. The results show that in all six 
different cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl-23, Weri Rb-1), the 
crude methanol soluble extract of M. charantia can evoke only a very small decrease in 
cell viability, but the decrease was not significantly different from the viability (100%) 
of control cells lines except for 1321N1 in which high doses of 600 μg and 800 μg 
evoked a small, but significant (p < 0.05) decrease in cell viability compared to  the 
control. Similarly, administration of crude methanol soluble extract of M. charantia to 
healthy L6 cell lines did not have any sygnificant effect on the cell viability. The cell 
viability was not significantly different (p > 0.05) from the untreated cell lines 
compared to the treated cell lines using the methanol extract. 
 
  
. 
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Figure 3.10: Bar charts showing the effects of different concentrations (200 - 800 µg) of  the crude methanol soluble extract of M. charantia on 
the viability of six different cancer cell lines (1321N1, Gos-3, U87- MG, Sk Mel-2, Corl -23, Weri Rb-1) and healthy L6 muscle cell line for 
comparison. The untreated (no methanol extract) cell line for each (first bar chart) is also shown as 100% in the figure for comparison. Each cell 
line was incubated with crude methanol soluble extract of M. charantia for 24 hrs. Similarly, each control cell line was incubated in the medium 
alone for 24 hrs. Data are mean ± SD, n= 6 different experiments in duplicate; * p > 0.05 for untreated (100 % viability) compared to the treated 
cells for the different concentrations except for 1321N1 in which * p < 0.05 for 600 μg and 800 μg compared to control.
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Figure 3.11 shows the effect of different concentrations (200 - 800 μM) of                     
α, β momorcharin on the viability of six different cancer cell lines and healthy L6 
muscle cell lines for comparison. All the cells were treated for 24 hours. Control cell 
lines were also incubated for 24 hrs but without any α, β momorcharin. The results 
show that in all six different cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl -
23, Weri Rb-1)  α, β momorcharin  evoked marked and significant  (p < 0.05)  decreases 
in the cell viability (cell death) compared to untreated cells (100% viability). These 
effects of α, β momorcharin were also dose-dependent with maximal cell death 
occurring at 800 μM of α, β momorcharin. In contrast, α, β momorcharin had little or no 
effect on the death of healthy L6 skeletal muscle cell line. The results presented in 
Figure 3.11 are more or less similar to the results obtained with the crude water-soluble 
extract of M. charantia (see figure 3.9). Again α, β momorcharin was more effective in 
killing Sk Mel and Corl -23 cell lines compared to Gos-3 and U87-MG and 1321N1 cell 
lines. 
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Figure 3.11: Bar charts showing the effects of different concentrations (200 - 800 µg) of α, β momorcharin on the viability of six different cancer 
cell lines (1321N1, Gos-3, U87- MG, Sk Mel, Corl -23, Weri Rb-1) and healthy L6 muscle cell line for comparison. The untreated (no α, β 
momorcharin) cell line for each (first bar chart) is also shown as 100% in the figure for comparison. Each cell line was incubated with α, β 
momorcharin for 24 hrs. Each control cell line was also incubated for 24 hrs but with no α, β momorcharin. Data are mean ± SD, n = 6 different 
experiments in duplicate; * p < 0.05 for untreated (100 % viability) compared to the treated cells for the different concentrations. Note the 
pronounced effect of α, β momorcharin on Sk Mel and Corl -23 cell lines compared to other cell lines.
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Figure 3.12 shows the effect of different concentrations (200 - 800 μM) of α  
momorcharin on the viability of the six different cancer cell lines and healthy L6 muscle 
cell line for comparison. All the cells were treated for 24 hours. Control cell lines were 
also incubated for 24 hrs but without any α momorcharin The results show that in all six 
different cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1),             
α momorcharin was less effective in killing the cells compared to either the crude water-
soluble extract of M. charantia (Figure 3.9) or α,β momorcharin (figure F.11). Similarly, 
administration of α momorcharin to healthy L6 cell line did not have any effect on the 
cell viability. However, α momorcharin had little or no effect on 1321N1 cell line, but it 
was slightly more effective on the other five cancer cell lines especially at high 
concentrations. In some cases, the cell viability (cell death) reached significant (p < 0.05) 
level compared to untreated cells.   
Figure 3.13 shows the effect of different concentrations (200 - 800 μM) of β 
momorcharin on the viability of the six different cancer cell lines and healthy L6 muscle 
cell line for comparison. All the cells were treated for 24 hours. Each control cell lines 
was also incubated for 24 hrs but with no β momorcharin. The results show that in all six 
different cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, and Corl 23, Weri Rb-1) 
low doses of β momorcharin had little or no effect on 1321N1, Gos-3 and U87- MG cell 
lines. However, at high concentrations of 600 μM and 800 μM, β momorcharin evoked 
small, but significant (p < 0.05) dose-dependent decreases in cell viability compared to 
control. Similarly, in Sk Mel, Corl -23 and Weri Rb-1, β momorcharin evoked significant 
(p < 0.05) dose dependent decrease in cell viability for all concentrations tested compared 
to control cell lines. These effects of β momorcharin were more pronounced than α 
momorcharin (see figure 3.12) but less effective compared to either the crude water-
soluble extract of M.charantia (see figure 3.9) and α, β momorcharin (see figure 3.11). 
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Figure 3.12: Bar charts showing the effects of different concentrations (200 - 800 µM) of α momorcharin on the viability of the six different 
cancer cell lines (1321N1, Gos-3, U87- MG, Sk Mel, Corl- 23, Weri Rb-1) and healthy L6 muscle cell line for comparison. The untreated (no α 
momorcharin) cell line for each (first bar chart) is also shown as 100% in the figure for comparison. Each cell line was incubated with α 
momorcharin for 24 hrs. Each control cell lines were also incubated for 24 hrs but with no α momorcharin. Data are mean ± SD, n = 6 different 
experiments in duplicate; * p<0.05 for untreated (100 % viability) compared to the treated cells for the different concentrations. Note that α 
momorcharin is less effective in killing the cancer cell lines.
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Figure 3.13: Bar charts showing the effects of different concentrations (200 - 800 µM) of β momorcharin on the viability of six different cancer 
cell lines (1321N1, Gos-3, U87- MG, Sk Mel, Corl 23, Weri Rb-1) and healthy L6 muscle cell line for comparison. The untreated (no β 
momorcharin) cell line for each (first bar chart) is also shown as 100% in the figure for comparison. Each cell line was incubated with β 
momorcharin for 24 hrs. Each control cell lines was also incubated for 24 hrs but with no β momorcharin. Data are mean ± SD, n = 6 different 
experiments in duplicate; * p<0.05 for untreated (100 % viability) compared to the treated cells for the different concentrations. Note that β 
momorcharin was slightly more effective as an anti-cancer agent in Sk Mel cell line compared to the other cell line
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3.3.4 Dose-dependent effects of vinblastine and temozolomide on cell viability 
Figure 3.14 shows the effects of different concentrations (10 - 40 μg) of vinblastine on 
the viability of the six different cancer cell lines and on healthy L6 skeletal muscle cell 
line employed in this study. Also shown in the figure 3.14 are the untreated six 
different cancer cell lines and healthy L6 skeletal muscle cell line for comparison. All 
the cells were treated with vinblastine for 24 hours. Each control cell lines were also 
incubated for 24 hrs but with no vinblastine. The results show that in all six different 
cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1), vinblastine 
can evoke marked and significant (p < 0.05) decreases in the cell viability (cell death) 
compared to untreated cells (100% viability). These effects of the vinblastine were 
dose-dependent with maximal cell death occurring with 40 μg. Similarly, vinblastine 
significantly (p < 0.05) decreased the viability of healthy L6 skeletal muscle cell line 
compared to untreated L6 cell line but mainly at a high doses. The results also show 
that vinblastine was more effective in killing 1321N1, Gos-3, Sk Mel and Corl -23 cell 
lines. It has less effective on U87-MG cell line, which seems to be more resistant to 
the drug. The surprised finding in this study was that vinblastine could also kill 
healthy L6 skeletal muscle cell compared to the crude water-soluble extract of M. 
charantia (see figure 3.9) and α, β momorcharin (see figure 3.11) which had no 
detectable effect on the viability of L6 cell line. 
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Figure 3.14: Bar charts showing the effects of different concentrations (10 - 40 μg) of vinblastine on the viability of six different cancer cell lines 
(1321N1, Gos-3, U87- MG, Sk Mel-2, Corl -23, Weri Rb-1) and healthy L6 muscle cell line. The untreated (no vinblastine) cell lines for each 
(first bar chart) is also shown as 100% in the figure for comparison. Each cell line was incubated for 24 hours either with or without vinblastine. 
Data are mean ± SD, n = 6 different experiments in duplicate; * p < 0.05 for untreated (100 % viability) compared to the treated cells for the 
different concentrations. Note that vinblastine was more potent on viability of Gos-3 and Corl-23 compared to the others. Moreover, it was more 
effective at 40 μg. The drug also killed healthy L6 muscle skeletal muscle cell lines at high concentrations.
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Figure 3.15 shows the effects of different concentrations (80 - 320 μM) of 
temozolomide on the viability of the six different cancer cell lines and on healthy L6 
skeletal muscle cell line employed in this study. Also shown in the figure 3.15 are the 
untreated six different cancer cell lines and healthy L6 skeletal muscle cell line for 
comparison. All the cells were incubated for 24 hours either with or without 
temozolomide. The results show that in all six different cancer cell lines (1321N1, Gos-
3, U87-MG, Sk Mel, Corl -23 and Weri Rb-1)  temozolomide evoked  marked and 
significant  (p < 0.05)  decreases in the cell viability (cell death) compared to untreated 
cells (100% viability). These effects of the temozolomide were dose-dependent with 
maximal cell death occurring with 320 μM. Similarly, temozolomide evoked a 
significant (p < 0.05) decrease in viability of healthy L6 skeletal muscle cell line but 
this was less compared to the cancer cell lines. Nevertheless, the values reach 
significant levels (p < 0.05) compared to control (untreated) L6 cells. This effect of 
temozolomide on L6 muscle cells was dose-dependent.  The result also show that the 
temozolomide was more effective in killing 1321N1, Gos-3, Sk Mel, Weri Rb-1 and 
Corl -23 cell lines. It was less effective on and U87-MG cell line. Comparing the effects 
of temozolomide with vinblastine (see figure 3.14). The results clearly show that 
vinblastine was more effective than temozolomide in killing cancer cells. 
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Figure 3.15: Bar charts showing the effects of different concentrations (80 - 320 μM) of temozolomide (TEM) on the viability of six different 
cancer cell lines (1321N1, Gos-3, U87- MG, Sk Mel, Corl 23 and Weri Rb-1) and healthy L6 muscle cell linen for comparison. The untreated 
(no temozolomide) cell lines for each (first bar chart) is also shown as 100% in the figure for comparison. Each cell line was incubated for 24 
hours either with or without temozolomide. Data are mean ± SD, n = 6 different experiments in duplicate; * p < 0.05 for untreated (100 % 
viability) compared to the treated cells for the different concentrations. Note that temozolomide was more effective in killing Corl-23 cell line 
compared to the others. Temozolomide also killed healthy L6 skeletal muscle cell line, but it was less effective compared to cancer cell lines.
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3.3.5 Combined effects of crude water-soluble extract of M. charantia with either 
vinblastine or temozolomide  
Figure 3.16 shows the effect of either vinblastine (40 μg) alone or the crude water-
soluble extract of M. charantia (800 µg, a high dose) alone or a combination of 
vinblastine (40 μg) with the crude extract soluble extract of M. charantia (800 µg) on 
the viability of the six different cancer cell lines and on healthy L6 skeletal muscle cell 
line employed in this study. Also shown in the figure 3.16 are the untreated six different 
cancer cell lines and healthy L6 skeletal muscle cell line for comparison. All the cells 
were treated with either vinblastine or the crude water-soluble extract of M. charantia or 
combined drugs (drug + crude extract) for 24 hours. Control cell lines were also 
incubated for the same time. The results show that in all six different cancer cell lines 
(1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1) either vinblastine, or crude 
water-soluble extract of M. Charantia  can evoke  marked and significant  p < 0.05 
decreases in the cell viability (cell death) compared to untreated cells (100% viability). 
However, when vinblastine was combined with the crude water-soluble extract of         
M. charantia, there was a further decrease in cell viability. These values were 
significantly (p < 0.05) different compared to either untreated cells (100%) or cell 
treated with either vinblastine or crude water-soluble extract of M. charantia. 
Similarly, vinblastine combined with the crude water-soluble extract of M. charantia 
evoked significant (p < 0.05) decrease in the death of healthy L6 skeletal muscle cell 
line. The results also show that combined drugs (drug + crude extract) were more 
effective in killing 1321N1, Gos-3, Sk Mel, Weri Rb-1 and Corl -23 cell lines. It was 
less effective on U87-MG cell lines. 
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Figure 3.16: Bar charts showing the effect of either of 40 μg vinblastine alone or 800 µg 
of crude water-soluble extract of M. charantia alone or a combination of vinblastine (40 
μg) and the crude extract soluble extract of M. charantia (800 µg) on the viability of six 
different cancer cell lines (1321N1, Gos-3, U87- MG, Sk Mel-2, Corl -23, Weri Rb-1) 
and health L6 muscle cell line for comparison. The untreated (no vinblastine, crude 
extract, combined drugs) cell line for each (first bar chart) is also shown as 100% in the 
figure for comparison. Each cell line (with or without drug) was incubated for 24 hrs. 
Data are mean ± SD, n = 6 different experiments in duplicate; *p < 0.05 for untreated 
(100 % viability) compared to the treated cells for the different concentrations. Also ** 
p < 0.05 for the combined effect of vinblastine + crude extract soluble extract of M. 
charantia compared to the individual effect. 
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Figure 3.17 shows the effect of either 40 μg of the vinblastine, 800 µM of α,β 
momorcharin alone or combining α,β momorcharin (800 µM) with vinblastine (40 μg) 
on the viability of  the six different cancer cell lines and on healthy L6 skeletal muscle 
cell line employed in this study. Also shown in the figure 3.17 are the untreated six 
different cancer cell lines and healthy L6 skeletal muscle cell line for comparison (100 
% viability). All the cells were treated with either vinblastine, α,β momorcharin or 
combined drugs (vinblastine + α,β momorcharin) for 24 hours. Control cell lines were 
also incubated for the same time of 24 hours. The results show that in all six different 
cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl -23 and Weri Rb-1) either 
vinblastine, αβ momorcharin or combined drugs (vinblastine + α,β momorcharin) can 
evoke marked and significant (p < 0.05) decreases in the cell viability (cell death) 
compared to untreated cells (100% viability). In all the cell lines vinblastine was more 
effective on cell viability compared to α β momorcharin alone. Moreover, the results 
also show that when vinblastine was combined with α, β momorcharin they were 
slightly more effective in killing 1321N1, U87-MG, Sk Mel and Corl -23 cell lines.  In 
contrast, they were less effective on Gos-3 cell line. The result also show that either 
vinblastine or a combination of vinblastine with α, β momorcharin can elicit a 
significant decrease of L6 skeletal muscle cell line compared to untreated cells or 
treated with α β momorcharin alone. 
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Figure 3.17: Bar charts showing effect of either 40 μg of the vinblastine alone or 800 
µM α,β momorcharin alone or  combining α,β momorcharin (800 µM) with vinblastine 
(40 μg) on the viability of six different cancer cell lines (1321N1, Gos-3, U87- MG, Sk 
Mel, Corl -23 and Weri Rb-1) and healthy L6 muscle cell line for comparison. The 
untreated (no vinblastine, α,β momorcharin, or combined drugs) cell line for each (first 
bar chart) is also shown as 100% in the figure for comparison. Each cell line was 
incubated for 24 hrs either with or without drugs. Data are mean ± SD, n = 6 different 
experiments in duplicate; * p < 0.05 for untreated (100 % viability) compared to the 
treated cells for the different concentrations. Similarly, ** p < 0.05 for the combined 
effect of vinblastine + α,β momorcharin compared with either vinblastine or α,β 
momorcharin alone. Note that vinblastine or combination of vinblastine with α β 
momorcharin can also decrease the viability of healthy L6 skeletal muscle cell line. 
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Figure 3.18 shows the effects of 240 μM of the temozolomide alone, 800 µg of crude 
water-soluble extract of M. charantia alone or a combination crude extract soluble 
extract of M. charantia (800 µg) with temozolomide (240 μM)) on the viability of the 
six different cancer cell lines and on healthy L6 skeletal muscle cell line employed in 
this study. Also shown in figure 3.18 are the untreated six different cancer cell lines and 
healthy L6 skeletal muscle cell line for comparison. All the cells were treated with 
either temozolomide alone, crude water-soluble extract of M. charantia alone or a 
combination of both (temozolomide + crude extract) for 24 hours. Control cell lines 
were also incubated for the same time of 24 hours. The results show that in all six 
different cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1) 
either temozolomide, the crude water-soluble extract of M. charantia or combined drugs 
(temozolomide + crude extract) can evoke  marked and significant p < 0.05 decreases in 
the cell viability (cell death) compared to untreated cells (100% viability). Similarly, 
temozolomide alone, but neither the crude extract soluble extract of M. charantia nor a 
combination of both, can evoke a significant (p < 0.05) decrease in the viability of 
healthy L6 skeletal muscle cell line compared to untreated cell. The results also show 
that a combination of temozolomide with the crude extract was more effective in killing 
1321N1, Gos-3, Sk Mel and Corl -23 cell lines. They are less effective on Weri Rb-1 
U87-MG cell lines. 
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Figure 3.18: Bar charts showing effect of either temozolomide 240 μM, or the crude 
water-soluble extract of M. charantia 800 µg and a combination of the crude extract 
soluble extract of M. charantia (800 µg) with temozolomide (240 μM) on the viability 
of six different cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-
1) and healthy L6 muscle cell line for comparison. The untreated (no temozolomide or 
crude extract) cell line for each (first bar chart) is also shown as 100 % in the figure for 
comparison. Each treated and untreated cell line was incubated with for 24 hrs. Data are 
mean ± SD, n = 6 different experiments in duplicate; * p < 0.05 for untreated (100 % 
viability) compared to the treated cells either with temozolomide or with the crude 
water-soluble extract of M. charantia or when they were combined; ** p <0.05 for the 
combined effect of temozolomide and the crude water-soluble extract of M. charantia 
compared to each alone. 
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Figure 3.19 shows the effect of either temozolomide 240 μM alone, or  α,β 
momorcharin 800 µM alone or a combination of α,β momorcharin (800 µM) with  
temozolomide (240 μM) on the viability of the six different cancer cell lines and on 
healthy L6 skeletal muscle cell line employed in this study. Also shown in figure 3.19 
are the untreated (no temozolomide or α, β momorcharin) six different cancer cell lines 
and healthy L6 skeletal muscle cell line for comparison. All the cells were treated with 
either temozolomide, α,β momorcharin or a combination of temozolomide with α,β 
momorcharin for 24 hours. Control cell lines were also incubated for the same time. The 
result shows that in all six different cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, 
Corl -23, Weri Rb-1)  either temozolomide, α,β momorcharin or a combination of 
temozolomide with α,β momorcharin can evoke  marked and significant (p < 0.05) 
decreases in the cell viability (cell death) compared to untreated cells (100% viability). 
Similarly, either temozolomide or a combination of temozolomide with α,β 
momorcharin can evoke significant (p < 0.05) decreases in the viability of healthy L6 
skeletal muscle cell lines. The results also show that a combination of temozolomide 
with α,β momorcharin was slightly more effective in killing 1321N1, Gos-3, Weri Rb-1, 
Sk Mel and Corl-23 cell lines compared to either temozolomide or α,β momorcharin 
alone. However, temozolomide with α,β momorcharin seem to be more effective on 
U87-MG cell line. 
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Figure 3.19: Bar charts showing effect of  of the temozolomide 240 μM alone or of α,β 
momorcharin 800 µM alone or a combination of  α,β momorcharin (800 µM)  and  
temozolomide (240 μM) on the viability of six different cancer cell lines (1321N1, Gos-
3, U87- MG, Sk Mel, Corl -23, Weri Rb-1) and healthy L6  muscle cell line for 
comparison. The untreated (no temozolomide, α,β momorcharin, or combined α,β 
momorcharin 800 µM  and  temozolomide 240 μM) cell line for each (first bar chart) is 
also shown as 100% in the figure for comparison. Each treated or untreated cell line was 
incubated for 24 hrs. Data are mean ± SD, n = 6 different experiments in duplicate; * p 
< 0.05 for untreated (100 % viability) compared to the treated cells for the different 
concentrations. Note that the combined effect of temozolamide with α,β momorcharin 
was more or less the same as α,β momorcharin alone, except for 1321N1, U87-MG, 
WeriRb-1 and Sk Mel cells lines, where there was only a small decrease in cell 
viability; ** p < 0.05 for either temozolomide or  α,β momorcharin compared to the 
combination of  both. 
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 3.4 Discussion  
A number of preliminary studies have shown anti-cancer activity of M. charantia 
against lymphoid, leukaemia, lymphoma, choriocarcinoma, melanoma, breast, skin and 
prostatic cancers (Licastro et al.1980; Ng et al.1994; Sun et al. 2001). Maximal anti-
carcinogenic activity was demonstrated following chronic treatment with the hot water 
extract of   M. charantia in uterine adenomyosis and mammary tumour growth in mice 
(Nagasawa et al. 2002; Singh et al.1998). 
 The beneficial anti-cancer effects of the crude water-soluble extract of M. charantia 
have been reported previously by several other investigators (Ganguly et al. 2000; Jilka 
et al.1983; Singh et al.1998; Raman and Lau, 1996; Takemoto et al.1982; Yeung et al. 
1988). Moreover, a number of preliminary studies have been conducted using the crude 
preparation of M. charantia. In all these studies, the chemical profile of the extract was 
not reported in the investigations. Nevertheless, some studies have demonstrated 
marked biological activities of several compounds including charantin, MAP 30, 
momordicin, alpha, beta momorcharin extracted from M. charantia (Grover et al. 
2004). 
 In other studies, alpha, beta and alpha, beta momorcharins have been isolated and 
purified from M. charantia and they were tested on viability of different cancer cell line. 
The crude water-soluble extract of M. Charantia was found to be cytotoxic to CBA/D 
cells in culture and the toxicity was dose dependent. However, the cells exposed to the 
water-soluble extract for 30 min and washed and incubated for 24 hrs also show a 
decrease in cell viability (Takemoto et al.1982). The results of this study have also 
shown that alpha, beta momorcharin can  produce similar anti-cancer effects on the 
viability of each cell line compared to the crude water-soluble extract of M. charantia. 
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However, either alpha or beta momorcharin, the two different and distinct proteins 
extracted from M. charantia  (compared to alpha, beta momorcharins) was less effective 
in killing the different cancer cell lines employed in this study compared to alpha, beta 
momorcharin or the crude water-soluble extract of M. charantia alone. 
It has been previously reported that alpha, beta momorcharin, a type-1 ribosome 
inactivating protein (RIP), isolated and purified form M. charantia possesses a number 
of anti-cancer activities including inhibition of tumour growth and anti-HIV (Leung et 
al.1987). Similarly, it was also reported that either individual alpha momorcharin or 
beta momorcharin had excellent cytotoxicity of tumour cells (Xiong et al. 2010). These 
later findings contrast with the result for either alpha or beta momorcharin obtained in 
this study. 
Second, the present study also investigated the possibility of combining a high dose of 
the extract of M. charantia or alpha, beta momorcharin with a low to moderate dose of 
commercially available anti-cancer drugs, vinblastine and temozolomide on the viability 
of each cell line. The rationale was that the commercially available anti-cancer drug in 
high concentration not only kill cancer cells, but also healthy cells in the body 
(Nagasawa et al. 2002). If a low to moderate dose of either temozolomide or vinblastine 
can be combined with a high dose of the crude water-soluble extract of M. charantia to 
produce maximal anti-cancer effect, without killing healthy cells, then they should be 
safer in treating cancer.  
The results of the present study have shown that either vinblastine or temozolomide can 
significantly decrease the viability of 1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri 
Rb-1 cancer cell lines. Both anti-cancer drugs also decreased the viability of healthy L6 
skeletal muscle cell line. The effect of each drug was dose–dependent with maximal 
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effect occurring at 40 μg for vinblastine and 360 μM for temozolomide (Friedberg et al. 
2001). The results of this study also show that combining a moderate to a high dose of 
either vinblastine or temozolomide with a high dose of either the crude water-soluble 
extract of M. charantia or with alpha, beta momorcharin only produce a small, but 
significant decrease in the viability of each cancer cell line compared to the effect of 
either temozolomide, vinblastine, the crude water-soluble extract of M. charantia or 
alpha, beta momorcharin alone. This small decrease in cell viability of each cell line 
was significant, but it was neither additive nor synergetic compared to the separate 
effect of each. This was a rather surprising result in this study.  Nevertheless, plant-
based medicines have been shown to exert little or no effects on the cancer cells and 
tissues when they combine with drugs like, cisplatin, temozolomide, vinblastine or 5-
fluorouracil (Omar, 2007). These commercially available drugs not only kill the cancer 
cells but also kill normal cells. This also depends on the type of cancer and 
concentrations of the drugs employed by the physician (Hong Jie, 2005). However, 
further search must find a safer plant based-medicine to treat cancer. 
The question, which now arises, is: How do these different extracts exert their effect on 
cell death? The morphological data for this study have clearly shown marked changes in 
structure of each cancer cell line comparing treated with untreated cell lines for 24 hrs 
with either the crude water-soluble extract of M. charantia or alpha, beta momorcharin. 
The morphology of each glioma cell line seemed to alter, losing their normal structures 
following incubation with either the crude water-soluble extract of M. charantia or with 
alpha, beta momorcharin. Moreover, each cell line seems to aggregate forming clumps 
of cells following treatment for 24 hrs. In some cases, they seem to possess a donought-
like structure similar to red blood cells. These abnormal structural features are typical of 
either cell necrosis or apoptosis (Kerr et al. 1972). These data for the morphology study 
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presented in figures 3.1 - 3.6 of this study clearly show that either the crude water-
soluble extract of M. charantia or alpha, beta momorcharin can induce marked 
structural changes in each cancer cell line leading to morphology of the dead cells or a 
decrease in cell viability. In contrast, they had little or no effects in the cell viability of 
healthy L6 skeletal muscle cell line. Like this study, pervious workers have also 
demonstrated successfully that either the crude water-soluble extract of M. charantia or 
alpha, beta momorcharin can also kill different cancer cells (Chang et al. 1983,Terenzi 
et al. 1999).  
Previous studies (Ahmad, 1999; Cummings et al. 2004) have investigated the 
synergistic effect of the crude water-soluble extract of M. charantia with insulin 
measuring titrated glucose uptake in L6 skeletal muscle cell lines, It was shown that 
high doses (100 - 200 µg) of the crude water-soluble extract inhibited the effect of 
insulin on glucose uptake. The higher the dose of the crude water-soluble extract, the 
lower was the glucose uptake into skeletal muscle cell line. However, when a low dose 
of insulin was combined with a low dose (5 µg - 10 µg) of the crude water-soluble 
extract  of M. Charantia,  there was a synergistic increase in glucose uptake into L6 
skeletal muscle cell line (Ahmad, 1999). The present study only employed a very high 
dose of the crude water-soluble extract of M. charantia and a moderate to high dose of 
either temozolomide or vinblastine to investigate their combined effects on cancer cell 
viability. It is worthy to investigate low doses of both the extract and the commercial 
anti-cancer drug on the viability of each cell line. 
In this study, the methanol soluble extract of M. charantia failed to elicit any decrease 
in the viability of each cancer cell line except for a small decrease in the viability of 
1321N1 cell line, but only at high concentrations. This may due to the fact that the 
methanol extraction denatures the active ingredient. Similarly, either alpha or beta 
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momorcharin was less effective in decreasing cell viability (cell death) compared to the 
effect of  either alpha, beta momorcharin alone or the crude water-soluble extract of M. 
charantia  alone. Again, it is possible that both the alpha and beta moieties are required 
on the momocharin protein to make it more active or potent as an anti-cancer drug. On 
examination of the effect of either the crude water-soluble extract of M. charantia or 
alpha, beta momorcharin, the data show that each possesses more or less similar 
potency for each concentration employed in this study. Together, the results have 
clearly indicated that the active ingredient(s) of the crude water-soluble extract of M. 
charantia is possibly alpha, beta momorcharin. Further studies are required to isolate 
the active components of the crude water-soluble extract and then purify and 
characterize its chemical properties, structures and anti-cancer effects. 
3.5 Conclusion 
In conclusion, the results of this study have clearly demonstrated that either the crude 
water-soluble extract of M. charantia or the isolated and purified protein of                   
M. charantia, namely alpha, beta momorcharin can evoke significant decreases in 
cancer cell viability (an increase in cell death) without killing healthy cell line like L6 
skeletal muscle cell line. These effects were both time and dose-dependent with 
maximal effect occurring after 24 hrs at a dose of 800 µg for the crude water-soluble 
extract of M. charantia or 800 µM for alpha, beta momorcharin. Either temozolomide 
or vinblastine with maximal effect of 360 µM and 40 µg respectively can also elicit 
dose-dependent decreases in cancer cell viability. Combining either temozolomide or 
vinblastine with either the crude water-soluble extract of M. charantia or alpha, beta 
momorcharin had no additive or synergetic effect on the viability of each cell line 
compared to the effect of either alone. It is concluded that extracts of M. charantia 
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possess anti-cancer properties since they can induce cell death. However, further 
experiments are required to investigate the mechanism(s) whereby these extracts can 
induce cell death. These results are presented in the next chapter of this study. 
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Chapter Four 
 
 
 
Cellular mechanisms associated with 
decreased cancer cell viability 
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4. Introduction 
Chapter three of this study describes the anti-cancer effects of both the crude extract of 
M.charantia and alpha beta momocharin. This chapter of the study was specifically 
designed to investigate the cellular mechanisms whereby either the crude water-soluble 
extract of M. charantia or alpha, beta momorcharin can induce cell death measuring 
activities of caspase-3 and caspase-9, the release of cytochrome-c and elevation in 
intracellular free calcium concentrations in the different cancer cell lines.  
4.1 Methods 
 As described in chapter 2, section 2.5. 
4.2 Results     
4.2.1 Measurements of caspase-3 and caspase-9 activities in untreated and treated 
cells 
Figure 4.1 shows caspase -3 activity in (A) cancer and L6 cell lines treated with 800 μg 
of the crude water-soluble extract of M. charantia for 24 hours and (B) cell lines 
incubated alone with medium but without any crude extract for the same duration of 24 
hrs. The results show that caspase -3 activity decreased significantly (p < 0.05) in both 
treated and untreated cell lines compared to control caspase -3 activity without any cells 
(assay kit control). The decrease was much more pronounced in untreated cells 
compared to treated cells. Comparing cells treated with the crude water-soluble extract 
of M. charantia to untreated (no extract), the results (treated – untreated cell lines) also 
show a significant (p < 0.05) increase in caspase -3 activity. The results also show a 
significant (p < 0.05) increase in caspase -3 activity in healthy L6 skeletal muscle cell 
line compared to untreated cell lines.  
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Figure 4.2 shows the percentage difference (treated – untreated cells lines) in caspase -3 
activity in all six different cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl- 23 
and Weri Rb-1) and healthy L6 muscle cell line following incubation with 800 μg of the 
crude water-soluble extract of M. charantia.  The caspase-3 activity in each control, 
untreated cell line was expressed as 100 % and the value for the respective treated cell 
line was expressed as a percentage increase of the control (untreated) value. The 
difference (treated minus untreated activity) in the activity of caspase-3 is plotted for 
each cell line in Figure 4.2. The data are obtained from figure 4.1 and they show 
significant (p < 0.05) increases in caspase-3 activity in all the cell lines. The results 
show that caspase-3 activity was much more pronounced in Gos-3 cell line compared to 
the other cell lines. 
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Figure 4.1: Bar charts showing caspase-3 activity in six different cancer cell lines 
(1321N1, Gos-3, U87-MG, Sk Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle 
cell line incubated with 800 μg of the crude water-soluble extract of M. charantia for 24 
hours (A) and cell lines incubated alone in the medium without any crude extract for the 
same duration of 24 hrs (B). Assay kit control caspase-3 activity is shown in the figure 
for comparison. Data are mean ± SD, n = 4 different experiments in duplicate. Note that 
caspase-3 activity increased significantly (* p < 0.05) in treated cells compared to 
untreated cells. However, caspase-3 activity in both treated and untreated cells 
significantly (* p < 0.05) decreased compared to control caspase -3 value. This decrease 
was much more pronounced in the untreated cells compared to treated cells. 
151 
 
 
Figure 4.2: Bar charts showing the percentage difference (treated – untreated cell lines) 
or increase  in caspase-3 activity in six different cancer cell lines (1321N1, Gos-3, U87-
MG, Sk Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle cell line incubated with 
800 μg of the crude water-soluble extract of M. charantia for 24 hours. Caspase-3 
activity for each untreated cell line incubated alone in the medium without any crude 
extract for the same duration of 24 hrs was taken as 100 %.  The caspase-3 activity for 
each reated cell line was expressed as a percentage increase of untreated control value 
(100 %). Data are taken from figure 4.1 and they represent mean ± SD, n = 4 different 
experiments in duplicate. The results show significant  (* p < 0.05) increases in caspase 
-3 activity for all the cell lines even in L6 cell line when treated with crude water-
soluble extract of M. Charantia  compared to untreated cell lines. 
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Figure 4.3 shows caspase-9 activity in (A) cell lines treated with 800 μg of the crude 
water-soluble extract of M. charantia for 24 hours and (B) the same cell lines incubated 
alone with medium but without any crude extract for the same duration of 24 hrs. The 
results show that the crude extract can elicit significant (p < 0.05) increases  in caspase -
9 activity in 1321N1, Gos-3, U87-MG, Sk Mel, Corl-23, Weri Rb-1 cancer cell lines 
compared to untreated cell line for each. There was little or no significantly increase in 
caspase-9 activity in either Sk Mel or L6 healthy skeletal muscle cell lines compared to 
the respective untreated cell lines.  
 
Figure 4.4 shows the percentage difference (treated – untreated cell lines) or increase   
in caspase-9 activity in all six different cancer cell lines (1321N1, Gos-3, U87-MG, Sk 
Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle cell line. The Caspase - 9 activity 
for each untreated cell line was taken as 100 %. This value was substracted from the 
treated cells caspase-9 activity with 800 μg of the crude water-soluble extract of M. 
charantia. The results show marked and significant increase in caspase-9 activity in all 
the cell lines, even in L6 cell line stimulated with the crude water soluble extract of M. 
Charantia. More caspase-9 activity was seen in 1321N1, U87-MG, and Weri Rb-1 
compared to the other cell lines. 
 
153 
 
 
Figure 4.3: Bar charts showing caspase-9 activity in the  six different cancer cell lines 
(1321N1, Gos-3, U87-MG, Sk Mel, Corl- 23, Weri Rb-1) and healthy L6 muscle cell 
line following incubation with 800 µg crude water-soluble extract of M. charantia for 
24 hrs (A). The caspase-9 activity for the untreated cell lines (no extract) incubated in 
the medium alone for 24 hrs is also shown in the figure for comparison (B). Data are 
mean ± SD, n = 4 different experiments in duplicate. The results show that caspase-9 
activity increased significantly (* p < 0.05) in treated (A) 1321N1, Gos-3, U87-MG, 
Corl- 23 and Weri Rb-1 cell lines compared to their respective untreated control (B). 
The crude water-soluble extract of M. charantia had little or no significant effect on 
caspase -9 activity in Sk Mel skin cancer and L6 skeletal cell lines. 
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Figure 4.4: Bar charts showing the percentage difference  (treated -  untreated cell lines) 
in caspase-9 activity in six different cancer cell lines (1321N1, Gos-3, U87-MG, Sk 
Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle cell line incubated with 800 μg of 
the crude water-soluble extract of M. charantia for 24 hours. Caspase-9 activity for each 
untreated cell line was taken as 100 % and this caspase -9 activity for each treated cell 
line was expressed as percentage increase. This was then substracted from the untreated 
(100 % control value). Data are mean ± SD, n = 4 different experiments in duplicate. 
The results show marked and significant increases in caspase-9 activity in all the cell 
lines, even in L6 cell line stimulated with the crude water soluble extract of M. 
Charantia compared to untreated control. 
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4.2.2 Measurement of cytochrome – c activity in untreated and treated cell lines 
Figure 4.5 shows the activity of cytochrome-c in (A) cell lines incubated with 800 μg of 
the crude water-soluble extract of M. charantia for 24 hours and (B) cell lines incubated 
alone with medium, but without any crude extract for the same duration of 24 hrs. The 
control response of cytochrome-c is also shown in the figure for comparison. The 
results show that the crude water-soluble extract of M. charantia can evoke significant 
(p < 0.05)  increases in cytochrome-c activity in all the cell lines (1321N1, Gos-3, U87-
MG, Sk Mel, Corl -23, Weri Rb-1 and L6) compared to untreated cell lines. The 
increase in cytochrome-c activity in 1321N1, Gos-3, U87-MG, Corl-23 and Weri Rb-1 
cancer cell lines were much more pronounced compared to control cytochrome-c 
activity with Sk Mel and L6 cell lines.  
Figure 4.6 shows the percentage difference (treated - untreated cell lines) or increase in 
cytochrome-c activity in all six different cancer cell lines (1321N1, Gos-3, U87-MG, Sk 
Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle cell line treated with 800 μg of the 
crude water-soluble extract of M. charantia. Cytochrome - c activity in each untreated 
cell line was taken as 100 %. The cytochrome-c activity for each treated cell line was 
expressed as a percentage of the respective control and then substracted from the 
untreated control value. The results in figure 4.6 show marked and significant (p < 0.01) 
increases in cytochrome – c activity in all the cell lines including L6. However, 
cytochrome – c activity was much more pronounced in 1321N1, Gos-3, U87-MG, Corl- 
23 and Weri Rb-1 compared to L6 and Sk Mel cell lines. 
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Figure 4.5: Bar charts showing cytochrome-c activity in (A) six different cancer cell 
lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl- 23, Weri Rb-1) and healthy L6 muscle 
cell line following incubation with 800 µg crude water-soluble extract of M. charantia 
for 24 hrs. The cytochrome-c activity (B) for the untreated (no extract) cell lines is also 
shown for comparison. Similarly, the control background cytochrome-c activity in the 
absence of any cells is also shown in the figure. Data are mean ± SD, n = 4 different 
experiments in duplicate. Note the siginificantn (* p < 0.05) increases in  cytochrome-c 
activity in treated cells compared to untreated cells. For 1321N1, Gos-3, U87-MG, Sk 
Mel, Corl- 23 and Weri Rb-1 cancer cell lines, cytochrome-c activity was  significantly 
(* p < 0.05) higher compared to the assay kit control activity. In Sk Mel and L6 skeletal 
muscle cell lines, cytochrome-c activity increased significantly (* p < 0.05) for treated 
compared to untreated cells but these values were either the same (Sk Mel cell line) or 
less (L6 cell line) than the assay kit control cytochrome-c activity. 
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Figure 4.6: Bar charts showing the percentage difference (treated – untreated cell lines) 
in cytochrome-c activity in six different cancer cell lines (1321N1, Gos-3, U87-MG, Sk 
Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle cell line incubated with 800 μg of 
the crude water-soluble extract of M. charantia for 24 hours. Cytochrome – c activity in 
each cell line was taken as 100 %. The value for each treated cell line was expressed as 
a percentage of control and the value was substracted from the 100 % untreated control 
value and expressed as a percentage increase in cytochrome-c activity. Data are taken 
from Figure 4.6 and they are expresses as mean ± SD, n = 4 different experiments in 
duplicate.  Note that cytochrome-c activity increased significantly (* p < 0.05) in all cell 
lines including L6 compared to the untreated control value. 
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 4.2.3 Time-course measurements of intracellular free [Ca 
2+
]i  in untreated and 
treated cells 
In this study, basal (mean ± SD) [Ca
2+
]i  at the start of any incubation (0 min) was 0.17 
±  0.09 ratio units (intensity), n = 82. Figure 4.7 shows the time-course changes (solid 
diamonds) in intracellular free calcium concentrations [Ca
2+
]i  expressed as fluoresences 
ratio units, in (A) 1321N1 and (B) Gos-3 cancer cell lines following incubation with 800 
µg of the crude water-soluble extract of M. charantia. The changes in [Ca
2+
]i  in 
untreated (control) 1321N1 and Gos-3 cancer cell lines (solid squares) are also shown in 
the figure for comparison. The result show that incubation of the two cancer cell lines 
with the crude water-soluble extract of M. charantia can result in significant (p < 0.05) 
time- dependent increases in [Ca
2+
]i  in  both cancer cell lines compared to control 
(untreated) cells. Maximal increase [Ca
2+
]i  was attained after 420 min of incubation. In 
control untreated cell line for each, [Ca
2+
]i    remained more or less stable in both cell 
lines after 420 mins.    
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Figure 4.7: Time-course changes in [Ca
2+
]i  expressed as fluorescence ratio units 
(intensity)  in Fura-2 AM loaded (A) 1321N1 and (B)  Gos-3 cell lines (solid diamonds) 
following incubation with 800 µg of the crude water-soluble extract of M. charantia for  
420 min. The fluorescence intensity for untreated cells (solid squares) at different time 
points are also shown for comparison. Data are mean ± SD, n = 6; (* p < 0.05) for 
treated compared to untreated cells for the time points of 120 - 420 min in  A and in B 
for time points of 240, 300, 360 and 420 min. Note gradual time-course increases in 
[Ca
2+
]i  following treatment with crude water-soluble extract of M. charantia compared 
to control.  
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Figure 4.8 shows the time-course changes [Ca
2+
]i  in (A) U87- MG  and (B)  Sk Mel 
cancer cell lines following incubation with 800 µg of the crude water-soluble extract of 
M. charantia. The changes in [Ca
2+
]i  in untreated (control) U87-MG and Sk Mel  
cancer cell lines are also shown in figure 4.8 for comparison. The data show that 
incubation of the Sk Mel cancer cell line with the crude water-soluble extract of M. 
charantia can result in significant (p < 0.05) time-dependent increases in [Ca
2+
]i  
compared to control (untreated) cells with maximal increases in [Ca
2+
]i  after 420 min 
of incubation.  In control, untreated Sk Mel cancer cell line [Ca
2+
]i  remained more or 
less stable up to 420 min. In contrast, in U87-MG cell line [Ca
2+
]i  increased slightly in 
both untreated and treated cells up to 360 min. In the control (untreated) cells, [Ca
2+
]i  
remained stable for 360 - 420 min. However, in treated U87-MG cells there was a 
small but significant (p < 0.05) increase [Ca
2+
]i  compared to untreated cells after 360 
min of incubation with the crude water-soluble extract of M. charantia. 
Figure 4.9 shows the time-course changes in [Ca
2+
]i,  in (A) Corl-23  and (B)  Weri Rb-1 
cancer cell lines (solid squares) following incubation with 800 µg of the crude water-
soluble extract of M. charantia. The changes in [Ca
2+
]i  in untreated (control) Corl-23, 
Weri Rb-1 cancer cell lines (solid triangle) are also shown in figure 4.9 for comparison. 
The data show that incubation of the two cancer cell lines with the crude water-soluble 
extract of M. charantia can result in significant (p < 0.050 time-dependent increases in 
[Ca
2+
]i  in both cancer cell lines compared  to control  (untreated) cells with maximal 
increases in [Ca
2+
]i  at 420 min. In untreated control, [Ca
2+
]i  remained more or less 
stable in both cell lines after 420 min of incubation.   
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Figure 4.8: Time-course changes in [Ca
2+
]i  expressed as fluorescence ratio units  
(intensity) in Fura -2 AM loaded (A)  U87- MG and  (B) Sk Mel cell lines (solid 
diamonds) following incubation with 800 µg crude water-soluble extract of M. 
charantia for 420 min. The fluorescence intensity for untreated cells (solid squares) at 
different time points are also shown for comparison. Data are mean ± SD, n = 6; *         
p < 0.05 for treated compared to untreated cells in both A and B. Note the gradual time-
course increases in [Ca
2+
]i  following treatment with crude water-soluble extract of M. 
charantia in Sk Mel cell line compared to control. Note also that there was only a small 
increase in [Ca
2+
]i  in U87-MG cell line following incubation with the crude water-
soluble extract of M. charantia and this was only significant  (* p < 0.05) compared to 
untreated control cells after 420 min of incubation. 
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Figure 4.9: Time-course changes in [Ca
2+
]i expressed as fluorescence ratio units 
(intensity) in Fura-2 AM loaded Corl-23 (A) and Weri Rb-1 (B) cell lines (solid 
diamonds) following incubation with 800 µg crude water-soluble extract of                  
M. charantia for 420 min. The fluorescence intensity for untreated cells (solid squares) 
at different time points are also shown for comparison. Data are mean ± SD, n = 6; * p < 
0.05 for  treated compared to untreated cells in both A and B. Note the gradual time-
course increases in [Ca
2+
]i in both cell lines following treatment with  crude water-
soluble extract of M. charantia compared to untreated control cells.  
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Figure 4.10 shows the time-course changes in [Ca
2+
]i in L6 muscle cell line (solid 
diamonds) following incubation with 800 µg of the crude water-soluble extract of        
M. charantia. The changes in [Ca
2+
]i  in untreated (control) L6 muscle cell line (solid 
squares) are also shown in figure 4.10 for comparison. The result shows that incubation 
of the L6 muscle cell line with the crude water-soluble extract of M. charantia can 
result in only a small increase in [Ca 
2+
]i  reaching maximum after 240 min of 
incubation. However, this increase in [Ca
2+
]i  was more or less the same as untreated 
control cells. Thereafter, [Ca
2+
]i   in both treated and untreated L6 cells  decreased 
gradually.  
Figure 4.11 shows the crude water-soluble extract of M. charantia evoked maximal 
increases in [Ca
2+
]i for the  six different cancer cell lines as well as L6 skeletal muscle 
cell line after 420 min of incubation. Each value taken from figures 4.7- 4.10 at 420 min 
time point is expressed as the ratio units. The results show the basal [Ca
2+
]i at 0 min, and 
increases in [Ca
2+
]i  in untreated and treated cells for a duration of 420 min. The results 
show that 800 µg crude water-soluble extract of M. charantia can evoke significant (p < 
0.05) increases in [Ca
2+
]i compared to control at 0 min as well as untreated cells over the 
same duration of incubation. In contrast, [Ca
2+
]i in L6 skeletal muscle cell line remained 
more or less the same as the untreated cells.   
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Figure 4.10: Time-course changes [Ca
2+
]I expressed as fluorescence ratio units 
(intensity) in Fura-2 AM loaded healthy L6 muscle cell line (solid diamonds) following 
incubation with 800 µg crude water-soluble extract of M. charantia for 420 min. The 
fluorescence intensity for untreated cells (solid squares) at different time points are also 
shown for comparison. Data are mean ± SD, n = 6. Note that there are no significant (* 
p > 0.05) change in [Ca
2+
]i  comparing treated with untreated cells. However, the result 
shows a small increase in [Ca 
2+
]i in both test and control L6 cells for 120-240 min. 
Thereafter [Ca
2+
]i  decreased gradually in both test and control  cells. 
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Figure 4.11: Bar charts showing maximal  increases in [Ca
2+
]i in basal control (C), 
untreated (U) cells and treated (T) cancer cell lines as well as L6 cell line following 
incubation with 800 µg crude water-soluble extract of M. charantia  for 420 min. Data 
taken from (Figures 4.7- 4.10) and they are expressed as mean mean ± SD (ratio units), 
n = 6; (* p < 0.01) for test (T) compared to control (C) [Ca
2+
]i at the start of the 
experiment (0 min) and also compared to untreated (U) cells at time point of 420 min. 
Note the large increases in [Ca
2+
]i for 1321N1, Gos-3, Corl -23 and Weri Rb-1 cell 
lines.   
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4.2.4 Cellular mechanisms of action of α,β momorcharin on L6 and cancer cell 
lines 
Since the crude water-soluble extract of M. charantia produced more or less similar 
effects on cell viability as α, β momorcharin, it was decided to investigate the 
mechanism(s) of action of α, β momorcharin on the same seven different cell lines for 
comparison. 
4.2.5 Measurement of caspase-3 and 9 activities  
Figure 4.12 shows caspase -3 activity in (A)  the  6 cancer and L6 cell lines treated with 
800 μM of the α, β momorcharin for 24 hours and (B) cell lines incubated alone with 
medium but without any α, β momorcharin for the same duration of 24 hrs. The results 
show that caspase-3 activity decreased significantly (p < 0.05) in both treated and 
untreated cell lines compared to the assay control caspase-3 activity. The decrease was 
much more pronounced in untreated cells compared to treated cells. Comparing cells 
treated with the α, β momorcharin with untreated (no α, β momorcharin) cells, the 
results show a significant (p < 0.05) increase in caspase -3 activity in the treated cells 
compared to untreated cells. It is also noteworthy, that caspase -3 activity increased 
slightly, but this was significant (p < 0.05) in L6 treated compared to untreated L6 
muscle cells. 
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Figure 4.12: Bar charts showing caspase-3 activity in the six different cancer cell lines 
(1321N1, Gos-3, U87-MG, Sk Mel, Corl- 23, Weri Rb-1) and healthy L6 muscle cell 
line (A) treated with 800 μM of the α, β momorcharin for 24 hours and (B) control 
cancer and L6 cell lines incubated alone with the media without any α,β momorcharin 
for the same duration of 24 hrs. Assay kit control caspase-3 activity is shown in the 
figure for comparison. Data are mean ± SD, n = 4 different experiments in duplicate. 
Note that caspase-3 activity increased significantly (* p < 0.05) in treated cells 
compared to untreated cells.  
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Figure 4.13 shows the percentage difference (treated – untreated cell line for each) or 
increase in caspase -3 activity in all six different cancer cell lines (1321N1, Gos-3, U87-
MG, Sk Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle cell line treated with 800 
μM of the α, β momorcharin. Caspase -3 activity in each untreated cell line was taken as 
100 %. Caspase-3 activity in each treated cell line was expressed as a percentage of 
untreated control and then substracted from the untreated control value. The results 
show that α, β momorcharin can evoke significant increases in caspase-3 activity in all 
cell line including L6. The effect of caspase-3 activity was much more pronounced in 
1321N1 and Gos-3 cell line compared to the others.  
 
 
Figure 4.14 shows caspase -9 activity in (A) the  six cancer cell lines and L6 cell line 
treated with 800 μM of the α, β momorcharin for 24 hours and (B) the same cell lines 
incubated alone with media but without any α, β momorcharin for the same duration of 
24 hrs. The results show that α, β momorcharin can elicit significant increases (p < 0.05) 
in caspase-9 activity in 1321N1, Gos-3, U87-MG, Corl -23 and Weri Rb-1 cancer cell 
lines compared to untreated cell line for each. There was no significant (p > 0.05) 
increase in caspase-9 activity in either Sk Mel and L6 healthy skeletal muscle cell line 
compared to their respective untreated cell line. 
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Figure 4.13: Bar charts showing the percentage difference (treated – untreated cell lines) 
or increase  in caspase-3 activity in six different cancer cell lines (1321N1, Gos-3, U87-
MG, Sk Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle cell line incubation with 
800 µM α, β momorcharin for 24 hrs. The values for each untreated cell was taken as 
100 %. Value from the respective treated cell was expressed as a percentage of  the 
untreated control. This value was substracted from the respective untreated control to 
give the values plotted in the figure 4.13 from each cell line. Data are taken from Figure 
4.12 and they are expresses as mean ± SD, n = 4 different experiments in duplicate.  
Note that caspase-3 activity activity increased significantly (* p < 0.05) in all cell lines 
including L6 compared to the untreated control value. 
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Figure 4.14: Bar charts showing caspase-9 activity in six different cancer cell lines 
(1321N1, Gos-3, U87- MG, Sk Mel-2, Corl- 23, Weri Rb-1) and healthy L6 muscle cell 
line following incubation with 800 µM  of α, β momorcharin for 24 hrs. The caspase-9 
activity for the untreated cell lines (no α, β momorcharin) is also shown in the figure for 
comparison. Data are mean ± SD, n = 4 different experiments in duplicate. Note that 
caspase-9 activity increased significantly (* p < 0.05) in treated compared to untreated 
cells for 1321N1, Gos-3, U87-MG, Corl-23 and Weri Rb-1 cell lines. There was no 
significant (* p > 0.05) change in caspase-9 activity in either Sk Mel or L6 cell line 
comparing to their respective control (untreated) cells. 
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Figure 4.15 shows the percentage difference (treated – untreated cell lines) or increase 
in caspase -9 activity  in all six different cancer cell lines (1321N1, Gos-3, U87-MG, Sk 
Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle cell line treated with 800 μM of 
the α, β momorcharin. The value for each untreated cell line was taken as 100 % and the 
value for the respective treated cells was expressed as percentage of the untreated cells. 
Th treated value was substracted from the untreated value and the results plotted in 
figure 4.15 as increase in caspase-9 activity above untreated control. The results show 
that α, β momorcharincan evoke significant increases in caspase-9 activity in the 6 
different cell lines. The results show that α, β momorcharin was much more effective in 
U87-MG compared to the other cells. 
 
 
Figure 4.16 shows the activity of cytochrome-c in (A) the cancer  cell lines treated with 
800 μM of the α, β momorcharin for 24 hours and (B) the same cell lines incubated with 
media alone but without any α, β momorcharin for the same duration of 24 hrs. The 
control response of cytochrome-c is also shown in the figure for comparison. The 
results show that α, β momorcharin can evoke significant (p < 0.05)  increases in 
cytochrome-c activity in all the cancer cell lines (1321N1, Gos-3, U87-MG, Sk Mel, 
Corl-23, Weri Rb-1 and L6 ) compared to either untreated cell lines or control 
cytochrome-c activity. In L6 skeletal muscle cell line, cytochrome-c activity increased 
significantly (p < 0.05) in treated (A) cells compared to untreated (B) cells but these 
values were less than the assay kit control cytochrome-c activity. 
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Figure 4.15: Bar charts showing the percentage difference (treated - untreated cell lines) 
or incerease in caspase-9 activity in six different cancer cell lines (1321N1, Gos-3, U87-
MG, Sk Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle cell line incubation with 
800 µM α, β momorcharin for 24 hrs. The value for each untreated control cell line was 
taken as 100 % and the value for the respective treated cells was expressed as a 
percentage of untreated control. The treated value was substracted from the untreated 
control value. Data are mean ± SD, n = 4 different experiments in duplicate. Note that 
caspase-9 activity increased significantly * p < 0.05 in treated compared to untreated 
cell line. Note that α, β momorcharin had little effect in L6 cell line. 
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Figure 4.16: Bar charts showing cytochrome-c activity in (A) six different cancer cell 
lines (1321N1, Gos-3, U87-MG, Sk Mel-2, Corl- 23, Weri Rb-1) and healthy L6 muscle 
cell line following incubation with 800 µM α, β momorcharin for 24 hrs. The 
cytochrome-c activity (B) for the untreated (no α, β momorcharin) cell lines is also 
shown in figure for comparison. Similarly, the background assay kit control 
cytochrome-c activity in the absence of any cells is shown in the figure. Data are mean 
± SD, n = 4 different experiments in duplicate. Note that cytochrome-c activity 
increased significantly (* p < 0.05) in all the treated cells compared to untreated cells. 
The results also show that cytochrome-c activity was maximal in Gos-3 cell line where 
as 1321N1, U87- MG, Sk Mel-2 and Weri Rb-1 contain more or less the same activity. 
However, cytochrome-c activity in L6 muscle cell line was the least compared to all the 
cancer cell lines. 
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Figure 4.17 shows the percentage difference (treated – untreated cell lines) or increase 
in cytochrome-c activity in all six different cancer cell lines (1321N1, Gos-3, U87-MG, 
Sk Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle cell line treated with 800 μM 
of α, β momorcharin. The value for each untreated cell line was taken as 100 % and the 
value for the respected treated cell line was expressed as a percentage of the untreated 
cell line. The difference between treated and untreated for each cell line is plotted in 
figure 4.17. The results show that α, β momorcharin can evoke large and significant     
(p < 0.05) increases in cytochrome-c activity in 1321N1, Gos-3, Weri Rb-1 and Corl -23 
cell line compared to the respective untreated cell lines. The results also show that α, β 
momorcharin had little effect on cytochrome – c activity in L6 skeletal muscle cell line. 
 
 
 
 
 
175 
 
 
 Figure 4.17: Bar charts showing the percentage difference (treated – untreated) or 
increase in cytochrome-c activity in six different cancer cell lines (1321N1, Gos-3, U87-
MG, Sk Mel, Corl- 23 and Weri Rb-1) and healthy L6 muscle cell line following 
incubation with 800 µM α, β momorcharin for 24 hrs. All values are expressed as a 
percentage of the respective untreated control. The data were taken from figure 4.16 and 
they are expressed mean ± SD, n = 4; (* p < 0.05) for each cell line compared to their 
respective untreated cell line. Note that α, β momorcharin had little effect on 
cytochrome – c activity in L6 skeletal muscle cell line compared to large and significant 
effects in 1321N1, Gos-3,U87-MG, and Corl -23 cell lines. 
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4.2.6 Measurement of [Ca 
2+
]i in untreated and treated cells                    
Figure 4.18 shows the time-course changes in [Ca
2+
]i expressed as fluorescence ratio 
units, in (A) 1321N1 and (B) Gos-3 cancer cell lines ( solid diamonds) following 
incubation with 800 µM of α, β momorcharin for 420 min. The changes in [Ca2+]i in 
untreated (control) 1321N1 and Gos-3 cancer cell lines (solid squares) are also shown in  
the figure for comparison. The results show that incubation of the two cancer cell lines 
with α, β momorcharin can result in significant (p < 0.05) time-dependent increases in 
[Ca
2+
]i in both cancer cell lines compared  to control (untreated) cells. Maximal 
increases in [Ca
2+
]i  was attained after 420 min of incubation. In control (untreated cell 
lines), [Ca
2+
]i remained more or less stable in both cell lines after 420 min.  The results 
also show that the increase in [Ca
2+
]i in Gos-3 cell line was much more pronounced 
following incubation with α, β momorcharin compared to 1321N1 cell line. 
Figure 4.19 shows the time-course changes [Ca
2+
]i  in expressed as  fluorescence ratio 
units (A) U87- MG  and (B) Sk Mel cancer cell lines following incubation with 800 
µM of  α, β momorcharin (solid diamonds). The changes in [Ca2+]i  in untreated 
(control) U87- MG and Sk Mel cancer cell lines are also shown in the figure for 
comparison (solid squares). The data show also that incubation of Sk Mel cell line  
with  α, β momorcharin can result in a significant  (p < 0.05) time-dependent increase 
in [Ca
2+
]i compared  to control  (untreated) cells with maximal increases in  [Ca
2+
]i  
after 420 min of incubation. In control, [Ca
2+
]i remained more or less stable after 420 
min. In contrast, with untreated U87–MG cell line basal [Ca
2+
]i  remained more or less 
the same over 420 min. However, in U87-MG cell line treated with α, β momorcharin 
[Ca
2+
]i  decreased slightly for 0 - 420 min compared to untreated control but then 
increase gradually for 360 min to 420 min when it was significant (p < 0.05) compared 
to control untreated cells. 
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Figure 4.18: Time-course changes in [Ca
2+
]i  expressed as fluorescence ratio units 
(intensity) in Fura-2 AM loaded (A) 1321N1 and (B) Gos -3 cell lines following 
incubation with 800 µM α, β momorcharin for  420 min (solid diamonds). The 
fluorescence ratio units (intensity) for untreated cells at different time points are also 
shown for comparison (solid squares). Data are mean ± SD, n = 6; (* p < 0.05) for 
treated compared to untreated cells in both A and B for time points of  60, 120, 180, 
240, 300, 360 and 420 min. Note the  time-course increases in [Ca
2+
]i  following 
treatment with α, β momorcharin compared to untreated control. Note also the larger 
increase in [Ca
2+
]i  in Gos-3 cell line (B) treated with α, β momorcharin compared to 
1321N1 cell line (A). 
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Figure 4.19: Time-course changes in [Ca
2+
]i  expressed as fluorescence ratio units 
(intensity)  in Fura -2 AM loaded (A)  U87-MG and  (B) Sk Mel cell lines (solid 
diamonds) following incubation with 800 µM α, β momorcharin for 420 min. The 
fluorescence ratio units (intensity) for untreated cells (solid squares) at different time 
points are also shown for comparison. Data are mean ± SD, n = 6; (* p < 0.05)  for 
treated compared to untreated cells in both A and B. Note the gradual  time-course 
increases in [Ca
2+
]i  following treatment with α, β momorcharin compared to control 
(untreated cells).  
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Figure 4.20 shows the time-course changes in [Ca 
2+
]i  expressed as fluorescence ratio 
units, in (A) Corl - 23 and (B)  Weri Rb-1 cancer cell lines following incubation with 
800 µM of the α, β momorcharin (solid diamonds). The changes in [Ca2+]i  in untreated 
(control) Corl-23, Weri Rb-1 cancer cell lines are also shown in figure for comparison 
(solid squares). The data show that incubation of the two cancer cell lines with α, β 
momorcharin can result in significant (p < 0.05) time-dependent increases in [Ca
2+
]i  in 
both cancer cell lines compared to control (untreated) cells with maximal increases in 
[Ca
2+
]i at 420 min. In control, [Ca
2+
]i  remained more or less stable in both cell lines after 
420 min of incubation.   
 
Figure 4.21 shows the time-course changes in intracellular free calcium [Ca
2+
]i 
expressed as fluorescence ratio units in L6 muscle cell line  following incubation with 
800 µM of the α, β momorcharin (solid diamonds). The changes in [Ca2+]i  in untreated 
(control) L6 muscle cell line are also shown in figure for comparison (solid square). The 
data show that incubation of the L6 muscle cell line with the α, β momorcharin can 
result in only a small increase in  [Ca
2+
]i reaching maximum after 420 min of incubation 
similarly to control (untreated) cells. Thereafter, [Ca
2+
]i  decreased gradually in both 
control and treated cells.  
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Figure 4.20: Time-course changes in [Ca
2+
]i  expressed as  fluorescence ratio units 
(intensity) in Fura-2 AM loaded Corl-23 (A) and Weri Rb-1 (B) cell lines following 
incubation with 800 µM α, β momorcharin for 420 min (solid diamonds). The 
fluorescence ratio units (intensity) for untreated cells at different time points are also 
shown for comparison (solid squares). Data are mean ± SD, n = 6; (* p < 0.05) for  
treated compared to untreated cells in both A and B. Note the gradual time-course 
increases in [Ca 
2+
]i  following treatment with  α, β momorcharin compared to untreated  
control cells in which [Ca 
2+
]i   remained at a steady-state basal level. 
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Figure 4.21: Time-course changes [Ca
2+
]i expressed as fluorescence ratio units in Fura -2 
AM loaded healthy L6 muscle cell line (solid diamonds) following incubation with 800 
µM α, β momorcharin for 420 min. The fluorescence ratio units (intensity) for untreated 
cells (solid squares) at different time points are also shown for comparison. Data are 
mean ± SD, n = 6. Note that there was no significant (* p > 0.05) change in [Ca
2+
]i  
comparing treated with untreated cells.  
 
 
 
 
 
 
182 
 
Figure 4.22 shows the α, β momorcharin 800 µM evoked increases in [Ca2+]i for the  six 
different cancer cell lines as well as L6 skeletal muscle cell line after 420 min of 
stimulation. Each value taken from (Figures 4.18 - 4.21) is expressed as the maximal 
ratio units at 420 min time point. The results show the basal [Ca
2+
]i at 0 min and  
maximal increases in [Ca
2+
]i  in untreated and treated cells at 420 min time point. The 
results show that 800 µM of the α, β momorcharin can evoke significant (p < 0.05) 
increases in [Ca
2+
]i compared to control at 0 min as well as untreated cells after 420 min 
of incubation. In contrast, [Ca
2+
]i in L6 skeletal muscle cell line remained more or less 
the same as the untreated cells.   
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Figure 4.22: Bar charts showing the maximal increase (T) in [Ca
2+
]i  following 
incubation of the six cancer cell lines and L6 cell line with 800 µM of the α, β 
momorcharin for 420 min. Note that all the measurements were made at the 420 min 
time point. The results also show the increase in [Ca
2+
]i  in untreated (U) cells for the 
different cell lines for 420 min as well as the basal control (C) at time 0 min just before 
treatment with α, β momorcharin. Data were taken from figures 4.18 – 4.21 and they are 
expressed as mean ± SD, n = 6. Note the large increase in [Ca
2+
]i  following stimulation 
of each cancer cell line with α, β momorcharin for 420 min. 
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4.3 Discussion  
The results presented in chapter 3 of this study have demonstrated significant anti-cancer 
effects of the crude water-soluble extract of M. charantia or the isolated and purified 
proteins, alpha, beta momorcharin of M. charantia on the six different cancer cell lines 
compared to untreated control. Anti-cancer drugs are believed to exert their „killing‟ 
effects on cells via different cellular and sub-cellular mechanisms including damages to 
the mitochondria and microtubules, inhibition of kinases or by cellular calcium over-load 
(Tam et al, 1984 ; Tsao et al, 1990; Vikrant et al, 2001; Hajnoczky et al. 2006). This 
study employed two cellular pathways via which the crude water-soluble extract of M. 
charantia and alpha, beta momorcharin may exert their anti- cancer effects on cell death, 
namely, apoptosis and cellular calcium homeostasis. 
 The results presented in this study have shown that either the crude water-soluble extract 
of M. charantia or the isolated and purified protein of M. charantia, namely alpha, beta 
momorcharin can elicit marked and significant changes in the activities of caspase-3 and 
caspase-9 and in the release of cytochrome-c in all the cell lines employed in this study 
compared to control untreated cell lines. In addition, both the crude water-soluble extract 
of M. charantia and alpha, beta momorcharin can elevate intracellular free calcium 
concentrations in all six-cancer cell lines compared to untreated control cells.  
Apoptosis is programmed cell death and it is associated with damage of cell 
mitochondria in the body to elevate such intra-cellular mediators such as caspase-3 and 
caspase-9 and the release of cytochrome-c (Bernardi et al, 1994; Chandra et al. 2002). 
In previous studies, it was shown that anti-cancer drugs exert their lethality by inducing 
apoptosis in tumour cells in vitro and in vivo targeting both the mitochondrial and death 
receptor pathways (Gati et al.1991; Makin, 2002). There are two major apoptotic 
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pathways in mammalian cells namely the receptor (extrinsic) pathway and the 
mitochondrial (intrinsic) pathway (Hajnoczky et al. 2006). The receptor-mediated 
pathway is triggered by activation of cell death receptors followed by the activation of 
caspase-8, which in turn cleaves and activates downstream caspase-3 (Ashkenazi and 
Dixit, 1998). The mitochondrial pathway is initiated by cytochrome-c release from the 
mitochondria which promotes the activation of caspase-9 through activated caspase-9 
which is responsible for the activation of cell death proteases (Ashkenazi and Dixit. 
1998; Chandra et al. 2002).  
In previous studies,  it was shown that anti-cancer drugs exert their lethality by inducing 
apoptosis in tumour cells in vitro and in vivo targeting both the mitochondrial and death 
receptor pathways (Gati et al.1991; Makin. 2002). The activity of caspase-3 was 
determined using the caspase-3 activity kit. To evaluate the activity of caspase-3, A431 
cells were treated with the 3.3 mM RIP or RIP-PEG conjugate, the cell lysates were 
respectively collected at 0, 12, 24, 36 h after exposure. The caspase activities were 
measured as fold of enzyme activity in comparison with control  (Mengen L et al, 
2009). 
The results of the present study have shown that either the crude water-soluble extract 
of M. charantia or alpha, beta momorcharin can evoke significant and time-dependent 
increases in [Ca
2+
]i  in all the six cancer cell lines employed in this study compared to 
the L6 skeletal muscle cell line. Their effect was less pronounced in U87-MG cell line 
compared to others. The question where now arises is: What is the significance of 
elevated [Ca
2+
]i in these cancer cell lines following treatment with either the crude 
water-soluble extract of M. charantia or alpha, beta momorcharin. Previous study have 
shown that sustained Ca
2+ 
elevation can act as trigger for apoptosis or cell death 
(Hajnoczky et al. 2003). In addition, Ca
2+ 
overloading in mitochondria can induce a cell 
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suicide programme by stimulating the release of apoptosis promoting factor like the 
release of cytochrome-c (Green et al. 1998; Wang and Ng 2001; Brooks et al. 2000; 
Hajnoczky et al. 2006). Cytosolic Ca
2+ 
homeostasis in resting cells is achieved by 
balancing the leak of Ca
2+ 
(entering from the outside of from the stores) by the constant 
removal of Ca
2+ 
using pumps either on the plasma membrane or on the internal stores. 
These pumps ensure that cytoplasmic [Ca
2+
]i  remains low and that the stores are loaded 
with signal Ca
2+
. In most cells, it is the internal stores (eg ER, SR, mitochondria) which 
provide most of the signal calcium (Streb et al. 1983). Furthermore, mitochondria have 
been found to play a pivotal role in Ca
2+ 
signalling (Hajnoczky et al. 2003). The cellular 
free Ca
2+ 
is an important physiological mediator and regulator in the stimulus-secreting 
coupling process in different epithelial cells (Yago et al.1999; Petersen. 1992), Many 
studies, have demonstrated mitochondrial Ca
2+ 
overload as the link between 
complement deposition and the observed changes in mitochondrial physiology and the 
triggering of programmed cell death  (PCD) (Irigoin et al. 2009).  The mitochondrial 
Ca
2+ 
overload is responsible for the increased O(2)(*-) production (Jimenez and 
Hernandez-Cruz. 2001). The rates of mitochondrial membrane potential dissipation and 
mitochondrial Ca
2+ 
uptake may determine cellular sensitivity to Ca
2+ 
toxicity under 
pathological conditions, including ischemic injury (Gogvadze et al. 2001). It has also 
been suggested that only a subpopulation of mitochondria undergoes a permeability 
transition and releases apoptogens, whereas the remaining, undamaged mitochondria 
respire normally and produce ATP (Simpson et al. 2002; Kabir et al. 1999; Jimenez and 
Hernandez-Cruz. 2001). 
Loss of Ca
2+ 
homeostasis, often in the form of cytoplasmic increases, leads to cell injury. 
Depending upon the cell type and the intensity of Ca
2+ 
toxicity, the ensuing pathology can 
be either reversible or irreversible (Gogvadze et al. 2004). Although multiple destructive 
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processes are activated by Ca
2+
, lethal outcomes are determined largely by Ca
2+
 induced 
mitochondrial permeability transition (Johansson et al. 2003; Goldstein et al. 2000). This 
form of damage is primarily dependent upon mitochondrial Ca
2+ 
accumulation, which is 
regulated by the mitochondrial membrane potential (Gogvadze et al. 2004). Together, the 
result presented in this study have demonstrated clearly that the anti-cancer effects of 
either the crude water-soluble extract of M. charantia or alpha, beta momorcharin are 
mediated via apoptosis and cellular Ca
2+ 
overloading. 
4.4 Conclusions 
 The results of this study have clearly demonstrated that either the crude water-soluble 
extract of M. charantia or the isolated and purified protein of M. charantia, namely 
alpha, beta momorcharin can evoke significant decreases in cancer cell viability (cell 
death) by exerting their anti-cancer effect on cells via damage of cell mitochondria body 
resulting in elevation in such cellular mediators as caspase-3 and caspase-9 and release 
of cytochrome-c and an elevation of intracellular free calcium concentration [Ca
2+
]i. A 
combination of all there factors may lead to Ca
2+ 
overloading in the mitochondria 
resulting in cancer cell death. However, further experiments are required to investigate 
the sub- cellular mechanisms associated with cell death including the involvement of 
kinase and gene expressions for apoptotic mediators. 
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5. General Disscusion 
This study was divided into three main categories namely 
1. Physiological investigation. 
2.  Morphological investigation and 
3. Biochemical investigation  
Emphasis in this discussion will now be focused on each investigation. 
5.1 Physiological investigations 
Firstly, the present study investigated the effect of the crude water-soluble and methanol 
soluble extracts of M. charantia and alpha, beta or alpha and beta momorcharins 
(proteins isolated and purified from M. charantia) and two commercially available anti-
cancer drugs namely, vinblastine and temozolomide (TZM) on the viability (cell death) 
of six  different cancer cell lines compared to healthy L6 skeletal muscle cell line. In 
some experiments, these agents were combined inorder to determine any possible 
potentiating or attenuating effect on the six different cancer cell lines (1321N1, Gos-3, 
U87-MG, Sk Mel, Corl -23, Weri Rb-1). The results have shown that the crude water-
soluble extract of M. charantia can evoke significant time-course and dose-dependent 
decreases in cell viability of all six different cancer cell lines. In contrast, the crude 
water-soluble extract of  M. charantia had no significant effect on the viability of the 
healthy L6 muscle cell line. Similar anti-cancer effects were obtained with alpha, beta 
momorcharin. In contrast, alpha or beta momorcharin or the crude methanol soluble 
extract of M. charantia had little or no effect on cell viability. The two commercially 
available anti-cancer drugs TMZ and vinblastine can evoke dose-dependent decreases in 
cell viability. Combining either TMZ or vinblastine with either the crude water-soluble 
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extract of  M. charantia or with alpha, beta momorcharin had only a small, but 
significant effect on cell viability compared to either alone. However, the decrease in 
cell viability during combined treatment of the different cancer cell lines was neither 
additive nor synergestic. 
Until recently, very little was known about specific anti-cancer proteins from plants. 
Most previous studies have been undertaken using peptides as anticancer agents 
(Lolitkar and Rao. 1966; Yuwai et al. 1991). The anti-cancer property of M. charantia 
has been extensively studied in experimental animals and both beneficial and 
contradictory claims have been made regarding its  effects (Bourinbaiar and Lee-Huang, 
1996). The mechanism of action of M. charantia and its effects on the complications of 
cancer have not been well established. 
In support of the current study, the beneficial anti-cancer effects of crude water-soluble 
extract of M. charantia and α, β momorcharin have been reported previously by several 
other investigators (Ganguly et al.2000; Jilka et al.1983; Singh et al.1998). A number of 
preliminary studies have shown that the crude water-soluble extracts of M. charantia 
posses anti-cancer activity against lymphoid, leukaemia, skin and prostatic cancers 
(Licastro et al.1980; Ng et al.1994; Sun et al. 2001). At present, the mechanism(s) 
involved in the crude water-soluble extract of M. charantia on cell death is not fully 
established. Several preliminary studies have been conducted using the crude water-
soluble extracts of M. charantia and in all these studies; the chemical profile(s) of M. 
charantia was not documented. Few studies have demonstrated much significant 
biological activity of M. charantia compounds such as charantin, MAP 30, momordicin, 
alpha, beta momorcharin extracted from M. charantia (Grover et al. 2004). In a in vivo 
study, the crude water-soluble extract of M. charantia was shown to inhibit tumour 
formation in mice (Catherine et al. 1983). 
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At present, the mechanism(s) of action involved in either the crude water-soluble extract 
of M. charantia or alpha, beta momorcharin on cell death has not yet been established 
(Xiong et al. 2010). However, it has been reported that alpha, beta momorcharin is a 
type-1 ribosome inactivating protein (RIP), which has a number of biological activities 
including inhibition of tumour growth. On the alternativity, either the individual alpha 
or beta momocharin has excellent cytotoxicity to tumour cells (Xiong et al. 2010). Beta 
momorcharin, was about 15-fold more active than alpha momorcharin (Yeung et 
al.1988). In contrast, the present study has shown that either alpha momorcharin or beta 
momorcharin had no significant effect on cell viability. This was a rather surprising find 
compared to the results of other reported studies (Xiong et al. 2010; Yeung et al.1988). 
5.2 Morphological investigations 
The results of the physiological investigations have shown that the crude water-soluble 
extract of M. charantia can decrease the cell viability (cell death) in six different cancer 
cell lines. In the view of these observations, it was pertinent to examine the 
morphological basis of these physiological effects. The morphological investigations on 
the effects of the crude water-soluble extract of M. charantia and alpha, beta 
momorcharin were carried out in six different cancer cell lines. The results show that 
each glioma cell line seemed to lose their normal structure following incubation with 
either the crude water-soluble extract of M. charantia or with alpha, beta momorcharin.  
Moreover, each cell line aggregated forming clumps and in some cases, they seem to 
possess a donought-like shape of clumped cells following treatment for 24 hrs. In many 
cases, the glioma cells tend to lose their neuronal-like structures, decrease in cellular 
density, condensation, fragmentation and blebbing. These abnormal structural features 
are typical of either necrosis or apoptosis. The morphological studies have  also shown 
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that the crude water-soluble extract of M. charantia or alpha, beta momorcharin had 
little or no effect on the cell viability of healthy L6 skeletal muscle cell line indicating 
that either of them does not have any adverse effect on control healthy cells. This 
interesting observation suggests that either the crude water-soluble extract of M. 
charantia or alpha, beta momorcharin can be used safely to treat cancer as well  as with 
the combination of other commarcially avaliable anti-cancer drugs.. Both the crude 
water-soluble extract of M. charantia or with alpha, beta momorcharin can induce 
marked, morphological changes in the different cancer cell lines. They can also elicit 
significant decreases in cell viability, and it was necessary to investigate the cellular 
mechanism(s) by which they may evoke cell death. 
5.3 Biochemical investigations 
The results presented in this study have demonstrated that either the crude water-soluble 
extract of M. charantia or isolated and purified protein of M. charantia, namely alpha, 
beta momorcharin can elicit marked and significant changes in the activities of caspase-
3 and caspase- 9 and release of cytochrome-c in all the cell lines employed in this study 
compared to control untreated cell lines. In addition, both the crude water-soluble 
extract of M. charantia and alpha, beta momorcharin can elevated intracellular free 
calcium concentration [Ca
2+
]i in all six cancer cell lines compared to untreated control 
cells. 
Experiments in this study examining Ca
2+ 
homeostasis in the six different cancer cell 
lines (1321N1, Gos-3, U87-MG, Sk Mel, Corl -23, Weri Rb-1) treated with either crude 
water-soluble extract of M. charantia or alpha, beta momorcharin have demonstrated 
interesting findings. The results show gradual time-dependent and significant increases 
in the [Ca
2+
]i following incubation with either crude water-soluble extract of                
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M. charantia or alpha, beta momorcharin compared to the untreated cells (control). This 
elevation in [Ca
2+
]i following stimulation of either the crude water-soluble extract of              
M. charantia or alpha, beta momorcharin may be due to several cellular processes 
outlined in figure 5.2. These results are similar to previous studies employing pancreatic 
acinar cells during stress induced condition with H202 of deplete the mitochondria of 
[Ca
2+
]i (Camello-Almaraz et al. 2002 ) 
In previous studies,  it was shown that anti-cancer drugs exert their lethality by inducing 
apoptosis in tumour cells in vitro and in vivo targeting both the mitochondrial and death 
receptor pathways (Gati et al.1991; Makin. 2002). The activity of caspase-3 was 
determined using the caspase-3 activity kit. To evaluate the activity of caspase-3, A431 
cells were treated with the 3.3 mM RIP or RIP-PEG conjugate, the cell lysates were 
respectively collected at 0, 12, 24, 36 h after exposure. The caspase activities were 
measured as fold of enzyme activity in comparison with control  (Mengen L et al, 
2009). 
 The elevation in cytochrome-c and caspase-9 activation is consistent with evidences 
showing a direct interaction between mitochondria and intracellular calcium stores (see 
figure 5.1) (Rizzuto et al. 1998; Csordas et al.1999). There is structural and functional 
evidences suggesting the presence of specific and stable interactions between 
mitochondria and intracellular Ca
2+ 
stores (e.g. mitochondrial and endoplasmic 
reticulum) which facilitate a rapid and nearly direct flux of Ca
2+ 
from endoplasmic 
reticulum to mitochondria (Hajnoczky et al. 2006; Rizzuto et al. 1998; Camello-
Almaraz et al. 2002; Filippini et al. 2003; Vay et al. 2007). These tight endoplasmic 
reticulum-mitochondria coupling may also serve to modulate Ca
2+ 
release. In addition, it 
has been suggested that mitochondria colocalize in small sub-cellular regions where 
endoplasmic reticulum and mitochondria form close contact (Vay et al. 2007). 
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Figure 5.1:  Over view of signal transduction pathways involved in apoptosis by 
intrinsic and extrinsic pathways 
(Adapted from Molecular cell biology. Harvey 5 edition, 2003) 
Figure 5.1 illustrate both intrinsic and extrinsic pathways of apoptosis. Extrinsic 
apoptosis signalling is mediated by the activation of so called “death receptors” which 
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are cell surface receptors that transmit apoptotic signals after ligation with specific 
ligands. Death receptors belong to the tumor necrosis factor receptor (TNFR) gene 
superfamily, including TNFR-1, Fas/CD95, and the TRAIL receptors DR-4 and DR-5 
(Ashkenazi, 2002). All members of the TNFR family consist of cysteine rich 
extracellular subdomains which allow them to recognize their ligands with specificity, 
resulting in the trimerization and activation of the respective death receptor (Naismith 
and Sprang, 1998). Subsequent signalling is mediated by the cytoplasmic part of the 
death receptor, which contains a conserved sequence termed the death domain (DD). 
Adapter molecules like FADD or TRADD themselves possess their own DDs by which 
they are recruited to the DDs of the activated death receptor, thereby forming the so-
called death inducing signalling complex (DISC). In addition to its DD, the adaptor 
FADD also contains a death effector domain (DED) which through homotypic DED-
DED interaction sequesters procaspase-8 to the DISC. The local concentration of 
several procaspase-8 molecules at the DISC leads to their autocatalytic activation and 
release of active caspase-8. Active caspase-8 then processes downstream effector 
caspases which subsequently cleave specific substrates resulting in cell death. Cells 
harboring the capacity to induce such direct and mainly caspase-dependent apoptosis 
pathways (Scaffidi  et al, 1998). 
The link between the caspase signalling cascade and the mitochondria is provided by 
the Bcl-2 family member Bid. Bid is cleaved by caspase-8 and in its truncated form 
(tBID) translocates to the mitochondria where it acts in concert with the proapoptotic 
Bcl-2 family members Bax and Bak to induce the release of cytochrome c and other 
mitochondrial proapoptotic factors into the cytosol (Luo et al, 1998). Cytosolic 
cytochrome c is binding to monomeric Apaf-1 which then, in a dATP-dependent 
conformational change, oligomerizes to assemble the apoptosome, a complex of wheel-
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like structure with 7-fold symmetry, that triggers the activation of the initiator 
procaspase-9 (Acehan et al, 2002). Activated caspase-9 subsequently initiates a caspase 
cascade involving downstream effector caspases such as caspase-3, caspase-7, and 
caspase-6, ultimately resulting in cell death (Slee et al, 1999). 
 As described in Figure 5.1 he intrinsic pathway is triggered by cellular stress, 
specifically mitochondrial stress caused by factors such as DNA damage and heat shock 
(Adrain et al, 2002). Upon receiving the stress signal, the proapoptotic proteins in the 
cytoplasm, BAX and BID, bind to the outer membrane of the mitochondria to signal the 
release of the internal content. The signal of BAX and BID is not enough to trigger a 
full release. BAK, another proapoptotic protein that resides within the mitochondria, is 
also needed to fully promote the release of cytochrome c and the intra-membrane 
content from the mitochondria (Hague and Paraskeva, 2004). Following the release, 
cytochrome c forms a complex in the cytoplasm with adenosine triphosphate (ATP), an 
energy molecule, and Apaf-1, an enzyme. Following its formation, the complex will 
activate caspase-9, an initiator protein. In return, the activated caspase-9 works together 
with the complex of cytochrome c, ATP and Apaf-1 to form an apoptosome, which in 
turn activates caspase-3, the effector protein that initiates degradation. Besides the 
release of cytochrome c from the intra-membrane space, the intra-membrane content 
released also contains apoptosis inducing factor (AIF) to facilitate DNA fragmentation, 
and Smac/Diablo proteins to inhibit the inhibitor of apoptosis (IAP) (Hague and 
Paraskeva, 2004; Johnstone et al, 2002) 
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Figure 5.2: A modified schematic diagram showing the possible mechanism(s) whereby 
the crude water-soluble extract of M. charantia and alpha, beta momorcharin can exert 
their effect on cancer cell death  by  Ca
2+
 homeostasis pathway.  
(www.vanderbilt.edu/viibre/Projects/images/pfi). 
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Figure 5.2: shows the model of possible role of Ca
2+
  in cancer cells leading to cell 
death. Ca
2+
 is an universal signal transduction cation in cells modulating cell growth and 
differentiation and other physiological and biochemical process in cells (Johansson et 
al. 2003). The calcium levels outside cells are 10 000 times higher than free intracellular 
Ca
2+
. However, free [Ca
2+
]i is the physiologically active form of calcium (Clapham, 
2007)). The level of free intracellular calcium ([Ca
2+
]i) is regulated and maintained as 
low (~100 nM) through the action of a number of binding proteins and ion exchange 
mechanisms. Each cell has a unique set of Ca
2+ 
signals to control its function. Ca
2+
 
signal transduction is based on rises in free cytosolic Ca
2+
 concentration. Ca
2+
 can flow 
from the extracellular space or be released from intracellular stores. The endoplasmic 
reticulum (ER) is a major site for sequestered Ca
2+
 ions. Recent studies indicate that the 
Golgi apparatus may also be a Ca
2+
 store in keratinocytes ((Bootman and Berridge, 
1995; Clapham, 2007)). Ca
2+
 is accumulated into intracellular stores by means of Ca
2+
 
pumps and released by inositol 1,4,5-trisphosphate (IP3) via IP3 receptors and by cyclic 
adenosine diphosphate ribose (cADPr) via ryanodine receptors (Berridge and Irvine. 
1989). Extracellular Ca
2+
 enters the cell through various types of plasma-membrane 
Ca
2+
 channels. Soluble proteins, such as calmodulin, contribute to the buffering of cell 
Ca
2+
, but membrane-intrinsic transporting proteins are more important. Ca
2+
 is 
transported across the plasma membrane (channel, pump, Na
+
/Ca
2+
 exchanger) and 
across the membranes of organelles (Berridge and Irvine. 1989). 
External signals arriving at the cell engage plasma membrane receptors to initiate cell-
signalling pathways (see figure 5.2). One of the results is increased intracellular calcium 
concentration. On stimulation, this level can rise globally to in excess of 1 M. This 
increase can be generated from sources both within and outside the cell (Irigoin et al. 
2009). The formation of IP3 is the focal point for two major pathways, one initiated by a 
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family of G protein-linked receptors and the other by either receptors linked by tyrosine 
kinases directly or indirectly (Carafoli, 1994). These separate receptor mechanisms are 
coupled to energy-requiring transducing mechanisms which activate phospholipase C 
(PLC) to hydrolyse the lipid precursor phosphatidylinositol 4,5-biphosphate to generate 
both DAG and IP3. The latter then binds to an IP3 receptor (IP3R) to mobilize stored 
calcium and to promote an influx of external calcium (Irigoin et al. 2009). 
Extracellular Ca
2+ 
enters the cell through plasma membrane Ca
2+
 channels and leaves 
the cell using Ca
2+
 pumps and Na
+
/Ca
2+
 exchangers. Endoplasmic reticulum (ER) is a 
major site for sequestered Ca
2+
 ions. Ca
2+
 is accumulated in intracellular stores by 
means of Ca
2+
 pumps and released by inositol 1, 4, 5- trisphosphate (IP3) via IP3 
receptors (IP3R) and by cyclic adenosine diphosphate ribose (cADPr) via ryanodine 
receptors (RyR). Store-operated calcium channels (SOCs) open in response to depletion 
of the (ER) Ca
2+
 stores. Calcium influx factor (CIF) has postulated to mediate the signal 
from IP3R to the plasma membrane store-operated calcium channels (SOCs) (Bootman 
and Lipp, 2001). 
Figure 5.2 proposed the possible mechanism(s) whereby the crude water-soluble extract 
of M. charantia and alpha, beta momorcharin may exert their effects on cancer cell 
death. It is suggested that alpha, beta momorcharin (9.7 kDa), which is a large protein, 
can activate a membrane bound receptor on the cancer cells or possible penetration of 
cell due to osmosis. Once in the cell, the protein acts on the mitochondria to bring about 
apoptosis leading to the release of cytochrome-c and enhancing the activities of caspase- 
3 and caspase-9. Damage to the mitochondria can lead to the release of Ca
2+ 
into the 
cytoplasm. It is also possible that the protein may also stimulate the influx of Ca
2+ 
from 
the extra-cellular medium and its releases from the endoplasmic reticulum.  
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The rise in [Ca
2+
]i coupled with the activities of caspase - 3 and caspase - 9 and release 
of cytochrome-c  can lead to cellular Ca
2+ 
overloading. These in turn can elicit cell 
death.  
Another possible mechanism is that activation of the membrane bound receptor with 
either the crude water-soluble extract of M. charantia and alpha, beta momorcharin        
may lead to the generation of intracellular mediators. These in turn can stimulate 
cellular apoptosis and elevate [Ca
2+
]i . Together, they can induce cell death due to 
apoptosis and Ca
2+
 overload.  
Alpha, beta momorcharin is a protein, which has been isolated from the fruit of M. 
charantia. Since the crude water-soluble extract of M. charantia can exert similar 
physiological, morphological and biological effect as the protein alpha, beta 
momorcharin, then it is possible to assume that the anti cancer effects of both are due to 
the same substance namely alpha, beta momorcharin. In addition to alpha, beta and 
alpha, beta momorcharin, it is worthwhile to examine the anticancer effects of the 
substances isolated from M. charantia including MAP-30, MRK29, alpha-momocharin, 
beta-momocharin and momordicin. 
5.4 Conclusions 
It can be concluded from this study that administration of either the crude water-soluble 
extract of M. charantia or isolated and purified protein of M. charantia, namely alpha, 
beta momorcharin can evoke significant decreases in cancer cell viability (an increase in 
cell death) without killing healthy cell line like L6 skeletal muscle cell line. These 
effects were both time and dose-dependent with maximal effect occurring after 24 hr at 
a dose of 800 µg. In contrast, either the crude methanol-soluble extract of M. charantia 
or alpha or beta momorcharin had little effect on cancer cell viability. Either 
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temozolomide or vinblastine, two commercially available anti-cancer drugs, can also 
elicit dose-dependent decreases in cancer cell viability. Anticancer drugs interfere with 
the growth of tumor cells, eventually causing their death. However, because these drugs 
are so powerful, they may also affect the growth of normal body cells, causing many 
side effects, some of which may be serious. Anticancer drugs are sometimes given 
together with other medicines. When using a combination of medicines either 
temozolomide or vinblastine with either the crude water-soluble extract of M. charantia 
or alpha, beta momorcharin had effect on the viability of each cell line compared to the 
effect of either alone. It is important to understand the advantages of using combination 
of temozolomide or vinblastine with either the crude water-soluble extract of M. 
charantia or alpha, beta momorcharin may have very less  side effects when compare to 
individual anti-cancer drugs. It is concluded that M. charantia possesses anti-cancer 
properties since it can induce cell death.  
The results of this study have also demonstrated that either the crude water-soluble 
extract of M. charantia or isolated and purified protein of M. charantia, namely alpha, 
beta momorcharin can increase the activities of caspase-3 and caspase - 9, the release of 
cytochrome-c and an elevation in intracellular free calcium concentrations. Together, 
the result suggest that either the crude water-soluble extract of M. charantia or alpha, 
beta momorcharin can exert their effect on cell death possible via an apoptotic 
mechanism involving  Ca
2+
 overloading. Further experiments are required to determine 
the direct relationship between apoptosis and Ca
2+
 overload during cell death, 
measuring a number of kinases, which may be involved in the mechanism. 
The results obtained from this study have enhanced our knowledge on the possible 
mechanism(s) of the anti-cancer effects of the crude water-soluble extract of M. 
charantia and alpha, beta momorcharin. However, further experiments are required to 
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investigate the sub-cellular mechanisms associated to cell death including the 
involvement of kinases and gene expressions for apoptotic mediators. 
Scope of future work 
The studies in this thesis open up many possibilities for further investigations. 
Proposed goals of future research in to bitter gourd are: 
Although M. charantia has been studied in non-randomized, controlled trials only, it is 
considered to be one of the most promising supplements with anti-cancer properties. 
To better understand the mechanism of action in killing the cancer cells. 
To test various M. charantia types from different environments and different growing 
sites for differences in their anti-cancer activity. 
To perform long term and better randomized, controlled trials to assess the clinical 
efficacy and safety and the optimum dosage. 
The reduction in size of the cancer cells has been due to necrosis or in fact apoptosis 
rather than just cellular atrophy. Since there are markers of these phenomena, one could 
examine these in order to gain knowledge about the nature of cellular atrophy. 
It would be possible to do cancer cell based- cytokine with ELISA, RT-PCR, Western 
blotting measurements in order to examine which are associated with atrophy are 
induced.  
To measure the protein kinases enzymes which are capable of transferring the γ 
phosphate group from ATP to serine, threonine or tyrosine residue in specific substrate 
proteins. Protein kinase are important targets for drug development 
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